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Abstract  
The heart does not regenerate new tissue when myocardium dies following acute 
myocardial infarction. We have undertaken an iterative process to develop a prototype patch that 
will replace infarcted tissue and induce myocardial regeneration to improve heart function. The 
result is a composite scaffold design composed of an endocardial patch to provide mechanical 
stability and an injectable filler material to provide a regenerative scaffold environment. This 
project provides a vital first step towards a final solution for myocardial regeneration. 
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Executive Summary 
Myocardial infarction is one of the leading killers of men and women in the United 
States. 565,000 new cases and 300,000 recurrent cases occur annually, and complications 
following myocardial infarction can lead to progressive heart failure and ventricular aneurysm 
[1]. The treatments currently used for secondary care of myocardial infarction are aimed solely at 
preventing reinfarction and improving survival. The goal of this project was to progress toward a 
treatment for myocardial infarction that will not only decrease recurrence and mortality, but will 
restore heart function by regenerating new myocardium to replace the dead tissue.  
Ventricular restoration is an approach for secondary treatment of myocardial infarction 
that involves excising the infarct and replacing it with a cardiac patch to restore the heart to a 
more efficient shape. Current commercially available patches are passive; they do not contribute 
to the work of the heart or assist in regeneration. We propose the design of a new myocardial 
patch for ventricular restoration that will induce regeneration and improve long-term heart 
function. To this end, we have undertaken an iterative design process to develop the required 
characteristics of such a patch. A basic design was developed that is composed of an endocardial 
patch to provide mechanical stability, and an injectable filler material that will induce myocardial 
regeneration. The material chosen for the patch must withstand the forces associated with 
ventricular contraction and suturing during surgery. The filler material is designed to incorporate 
growth factors and exhibits material properties conductive to the migration and differentiation of 
bone marrow cells into new myocardium.  
Different materials were evaluated using a quantitative evaluation matrix, and the highest 
scoring alternatives were chosen for preliminary testing. For the patch component, bovine 
pericardium-derived collagen matrix (Veritas, Synovis Innovations) and urinary bladder matrix 
(UBM, ACell Inc.) were assessed for suture retention and uniaxial tension properties. Results 
revealed that Veritas and UBM were able to hold sutures effectively under clinical conditions, as 
well as having appropriate strength and elongation properties for this application. UBM was 
shown to have significantly greater elongation over Veritas and Polyester, making it a closer 
match to native myocardium. For the filler material, fibrin gel was selected, and experiments 
were conducted to characterize cell migration and proliferation in the gel.  A variety of fibrin 
formulations were tested at fibrinogen concentrations of 3, 5, and 9 mg/ml. Results showed no 
significant migration of cells in any of these fibrinogen concentrations after 9 days. The viability 
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assays revealed the all three formulations of gel demonstrated hMSC viability, with the 9 mg/ml 
concentration achieving significant population increase after only 7 days, as well as the greatest 
overall evidence of cell viability.  
We conclude that both Veritas and UBM materials are suitable for cardiac patch 
applications, and that future studies should include more detailed characterization, as well as in 
vivo studies in animal models. Fibrin gel was shown to promote viability of hMSCs, however, no 
migration was observed. This leads us to recommend that future research focus on increasing the 
ability of bone marrow cells to migrate from the body into the scaffold through the use of growth 
factors to recruit native bone marrow cells. The outcome of this project is the final design and 
characterization of selected materials for a patch for ventricular restoration. This is an important 
first step toward the ultimate goal of achieving regeneration of myocardium and improved heart 
function for post-infarct patients in a clinical setting. 
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Chapter 1: Introduction 
Coronary heart disease is the leading cause of death in the United States [1]. Heart 
disease can take many forms, the most severe of which is myocardial infarction, also known as 
heart attack. American men and women experience 565,000 new cases and 300,000 recurrent 
cases of myocardial infarction annually [1], making treatment for myocardial infarction a 
significant sector of the healthcare industry. 
Myocardial infarction occurs when a coronary artery that supplies blood to the heart 
becomes blocked, making it unable to adequately perfuse the myocardium. Without the 
necessary oxygen or nutrients to survive, myocytes enter a state known as ischemia and may 
soon begin to die [2]. The death of myocytes creates an infarcted region within the myocardium 
that impedes heart function due to its inability to contract. Over time this infarcted area thins and 
elongates, causing the heart to take on a more spherical shape to compensate [3]. This leads to a 
decrease in cardiac output, which in turn leads to an overall decrease in the health and quality of 
life of the patient [4]. A wide variety of treatments have been developed in an attempt to address 
myocardial infarction and remodel the heart back to its healthy, elliptical shape. The most direct 
approach involves cutting out the infarcted region of myocardium and replacing it with a patch. 
Using this patch, the surgeon is able to restore the original geometry of the heart, thus improving 
cardiac output [5]. 
The heart patches currently available for clinical use in the United States are made either 
of treated bovine pericardium, the synthetic polymer polyethylene terephthalate (PET), or 
expanded polytetrafluoroethylene (ePTFE). Bovine pericardium is treated to remove cells and 
crosslinked with a chemical such as glutaraldehyde to alter its mechanical properties [6 , 7]. 
Minimal cellular infiltration into genepin fixed bovine pericardium along with a thick layer of 
fibrous tissue was observed four weeks after implantation in rat models by Wei et al. [8]. 
Although these materials are adequate for restoring ventricular geometry and maintaining 
ventricular pressure, these studies demonstrate that they result in the development of a region of 
acellular scar tissue instead of a region of viable muscle cells. The presence of myocardial 
muscle cells has been found to be related to the work performed by patch implant regions [9]. 
We therefore hypothesize that if the section of infarcted myocardium were to be replaced with 
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healthy contractile tissue, the function of the heart could be greatly improved. The new 
myocardium would contribute to the workload of the heart since the non-contractile region 
would be replaced with new, beating heart tissue. 
The goal of this project is to design and develop a clinically applicable scaffold to replace 
full-thickness infarctions. The scaffold must be safe for the patient and have structural and 
mechanical properties similar to healthy myocardium, leading to restoration of an efficient 
ventricular shape. The scaffold must also be clinically applicable by being easy to implant using 
existing surgical techniques, customizable in shape, and cost effective to produce. Scaffold 
implantation should result in immediate heart remodeling followed by regeneration of contractile 
myocardium to improve heart function. The scaffold will provide temporary biomechanical and 
biochemical support for cells to grow until they are able to construct new extra cellular matrix. 
The scaffold will stimulate angiogenesis and as it is replaced by contractile myocardium fed by a 
neovascular network. 
This basic design consists of two components: an endocardial patch sutured to the 
endocardial region of the ventricular wall, followed by a filler material placed above the 
endocardial patch filling and sealing off the wall thickness. The endocardial patch provides 
mechanical support to hold heart pressure and can be used for cardiac remodeling similar to 
current patches until new regenerated tissue can function mechanically. The filler material 
provides a provisional matrix for controlled myocardial regeneration and angiogenesis which is 
an improvement over the formation of uncontrolled scar tissue in the current patches [6].  
The ability of the scaffold to meet its functional requirements were analyzed by putting it 
through a series of tests. Mechanically, it must hold the pressure inside the left ventricle, 
withstand tensile forces experienced during wall contraction, retain mechanical properties under 
fatigue conditions, and comply with the stretch ratio of heart muscle. To this end, the materials 
chosen for the device were subjected to uniaxial tensile testing, measuring tensile strength and 
stretch under normal loading conditions of the heart. To test the interaction of the scaffold with 
sutures, the materials also underwent testing to characterize their suture retention capabilities. 
Suturability is another concern that will be tested by measuring the force required to puncture the 
scaffold with a suturing needle. To assess the regenerative capability of the filler material, we 
focused on assessing the cellular migration and viability properties of a variety of different filler 
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formulations. We used human mesenchymal stem cells (hMSCs) to model a cellular therapy 
intended to regenerate myocardium. hMSC migration into the filler scaffold material was 
measured over a period of 9 days. The ability of hMSCs to proliferate in the scaffold was also 
measured using an MTS viability assay.  
The results of this project indicated that that both Veritas and UBM materials are suitable 
for cardiac patch applications, and that future studies should include more detailed 
characterization, as well as in vivo studies in animal models. Both materials demonstrated 
appropriate strength properties in order to withstand the stresses in the wall of the heart. 
Elongation of both materials also fell within the desired range, although UBM had a significantly 
greater rate of elongation, making it a closer match to native myocardium. Suturability tests of 
both materials also passed specification. Fibrin gel was shown to promote viability of hMSCs, 
however, no migration was observed. The strong viability data suggests that fibrin gel will serve 
as a good myocardial scaffold material of the migration of cells into the material can be increase 
through further research. The outcome of this project is the final design and characterization of 
selected materials for a patch for ventricular restoration. This is an important first step toward the 
ultimate goal of achieving regeneration of myocardium and improved heart function for post-
infarct patients in a clinical setting. Future research may include in vivo testing of materials and 
the overall device design in applicable animal models. 
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Chapter 2: Background 
This chapter describes the deterioration of a healthy heart to an infarcted heart and the 
major effects that this has on overall heart function. Traditional treatments such as medications 
and surgical interventions are explained with special emphasis on the use of cardiac patches and 
ventricular restoration. In addition, new approaches involving the regeneration of myocardium 
using biomaterial scaffolds and growth factor therapies is examined. 
2.1 The Healthy Heart 
The heart is the center of the circulation system and distributes blood throughout the 
body. The function of the heart is vital to supply oxygen and nutrients to, and remove waste 
products from the body via the blood in order to maintain the balance that is necessary to sustain 
life [3]. It beats an average of 100,000 times and pumps 2,000 gallons of blood throughout the 
vascular system on a daily basis. A healthy heart is of the utmost importance to support day to 
day life [10]. 
Strong muscular contractions in the left ventricle pump blood out of the heart and into the 
circulatory system. These muscular contractions are produced by the muscle tissue that makes up 
the walls of the ventricle [11]. Healthy heart muscle wall is composed of three layers as seen in 
Figure 1: two collagenous membranes, the endocardium and epicardium, on either side of a 
muscular sheet, the myocardium.  
 
Figure 1: Schematic of Myocardium 
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The outer and inner layers are networks of type I and type III collagen and elastin, with 
the endocardium being populated by endothelial cells [12]. The myocardium is the layer of 
functional beating muscle that consists of fibroblasts and highly oriented myocyte muscle fibers 
in a matrix of collagen. Myocytes in this functional tissue layer also facilitate conduction of the 
electrical signals needed to initiate contractile movement in order to pump blood out of the 
ventricles [11]. Electrical conduction occurs with the help of intercalated discs that join the cells 
together. Gap junctions in these intercalated discs allow the action potential to travel through the 
membranes of the myocytes, thus facilitating signal propagation and a synchronized contractile 
pulse [13]. 
The coronary circulation system provides blood flow through the myocardium, 
nourishing the myocytes as they work to pump blood throughout the rest of the body. When 
blood flow to the myocardium is interrupted, the muscle becomes starved of oxygen and cells 
enter a serious and potentially fatal pathway, diagramed in Figure 2. This sets the stage for 
ischemic heart conditions and can lead to myocardial infarction. 
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Figure 2: Pathway and Effects of Myocardial Infarction 
2.2 From Ischemia to Myocardial Infarction 
Coronary heart disease is one condition that can interrupt the flow of blood to the 
myocardium [14]. This loss of blood flow is called ischemia and can lead to cell death if the 
myocardium is starved of oxygen for too long [2]. The three common ways that ischemia occurs 
are through atherosclerosis, embolism, and an artery spasm [14]. Once blood flow to the 
myocardium is severely restricted there are immediate physiological and metabolic changes that 
occur within seconds, as depicted in Figure 3 [14, 15]. Eight seconds after occlusion ATP 
production in the myocardium switches from an aerobic mechanism to an anaerobic mechanism. 
This happens as a result of oxygen and glucose deficiency in the tissue and causes the production 
of ATP to fall rapidly. Since the myocytes have less ATP to use for energy, the muscle begins to 
lose its ability to contract. After approximately 30 seconds the supply of creatine phosphate, 
which is used as an energy reserve for ATP production, is 90% depleted. As anaerobic glycolysis 
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continues, hydrogen ions accumulate as a byproduct and after 10 minutes the intracellular pH of 
the myocytes decreases by about one pH unit [14]. This causes osmotic flooding of water into 
the myocytes. Edema occurs as the heart tissue continues to swell, and by 20-30 minutes 
following blockage, irreversible damage and cell death occurs in the myocardium. Within weeks 
to months scar formation takes place as fibroblasts infiltrate the infarct area and deposit fibrous 
collagen. Macrophages, monocytes, and neutrophils migrate to the scarred area as part of the 
inflammatory response and matrix metalloproteinases (MMPs) released from the neutrophils 
causes further infarct expansion and myocyte collagen degradation [16].  
 
 
Figure 3: Timeline: Artery Occlusion to Scar Formation 
 
The region of infarcted tissue in the heart muscle has two main effects; electrical function 
is disturbed and cardiac output is reduced [3, 17]. The infarction, now scar tissue, becomes a 
region of unproductive myocardium that can block the normal electrical conduction pathways of 
the heart. Depending on the location of the infarct, the function of the sinoatrial node, 
atrioventricular node, or the His bundle branches can be compromised due to tissue damage, 
resulting in an altered and unnatural heart rhythm [17]. This arrhythmia typically causes the heart 
to either beat slower than normal (bradyarrhythmia), leading to fatigue and cardiac arrest, or 
faster than normal (tachyarrhythmia), causing pain and discomfort [18]. 
Aside from arrhythmias, the unproductive region of myocardium also causes structural 
rearrangements. Slippage between myocyte bundles decreases the number of cells in the 
ventricular wall [19] causing the ventricle to slowly remodel itself as the infarcted myocardium 
thins and elongates due to the high ventricular pressure on the wall. This affects the overall shape 
of the heart, changing it from an elliptical shape to a more spherical shape [3]. Thinning of the 
infarcted region continues, triggering the unaffected myocytes to compensate by undergoing 
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7.2 to 6.2 
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INFARCTION 
20-30 min 
Irreversible damage 
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hypertrophy in the attempt to increase healthy muscle mass [3]. This ventricular remodeling 
causes cardiac output parameters such as ejection fraction and stroke volume to change because 
they are directly dependant on the size and muscle strength of the ventricle [4]. The ejection 
fraction, the fraction of blood within the ventricle that is ejected with each stroke, declines with 
infarct size, but compensatory responses work to maintain normal stroke volume. As a result of 
the extra pressure and volume generated by these compensatory responses, stresses in the 
ventricular walls increase. Without treatment this can lead to serious complications such as 
aneurysm and ventricular rupture [4]. 
2.3 Cardiac Patches in the Clinical Environment 
Following a myocardial infarction, the first step toward improving health is to reperfuse 
the blocked coronary artery, restoring blood flow to the infarcted region. This primary treatment 
must be administered as soon as possible in order to minimize ischemic death of the 
myocardium. The longer the myocardium is deprived of blood flow, the more serious the damage 
will become [20]. Typically, medications are the first attempt to dissolve the clot. Surgical 
treatments may be necessary if medications do not accomplish the desired outcome, or if the 
infarction has progressed long enough that it has inflicted serious damage to the myocardium. In 
conditions where the development of an aneurysm is a primary concern, surgical intervention is 
necessary to remove the weak, infarcted region and remodel the ventricle. Ventricular 
remodeling involves removing the infarcted region of the ventricle and reshaping the heart from 
a spherical shape, to a more efficient elliptical shape [21]. This can be done using either direct 
linear closure or endocardial patch plasty.  
Direct linear closure is a procedure by which the infarcted section of the ventricle is 
removed, and the remaining heart tissue is sutured together [5]. This procedure provides a 
method for restoring the size and shape of the infarcted heart however, sometimes there is not 
enough myocardial tissue to restore the ventricle to the correct dimensions [5]. The Dor 
procedure, also known as endoventricular patch plasty, has been used since 1984. This is an 
alternate surgical technique that removes the infarcted myocardium and restores heart structure 
using a patch that is sutured into the opening as seen in Figure 4 [22]. In this procedure the heart 
is completely arrested and coronary revascularization is performed, normally by using the 
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internal left mammary artery [22]. Then an incision is made in the center of the infarcted area 
and any thrombi that are present are removed and the infarcted scar is cut out. A balloon is 
inflated inside the left ventricle and a suture is used to tighten the ventricle to the shape of the 
balloon. Once the suture it tightened, a patch is sutured in the remaining gap in the myocardium. 
The use of a patch ensures the restoration of ventricular volume and prevents further ventricular 
distortion [5, 22]. 
 
Figure 4: Dacron patch being sewn into the heart (Courtesy of G.R. Gaudette) 
Synthetic patches available for clinical use in endocardial patch plasty in the United 
States are made of polyethylene terephthalate (PET) and polytetrafluoroethylene (PTFE). A 
summary of the clinically available patches approved for use in the United States is presented in 
Table 1. The technology to form these polymers into fibers was developed in 1939 by DuPont, 
Inc. and are commercially known as Dacron and Teflon respectively. When these materials are 
used in cardiovascular patches the fibers can be arranged into either velour, knitted, or woven 
configurations depending on the desired porosity [23]. Due to the high porosity of the knitted 
form, the material must be coated with a sealant such as collagen or albumin in order to prevent 
bleeding through the patch. Coatings are also sometimes used to improve the suture retention 
strength and help to induce endothelialization. One example, the Gore-Tex® Acuseal 
Cardiovascular Patch, is a composite material made of expanded PTFE with a middle layer of an 
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elastomeric fluoropolymer. Use of this patch has been shown to significantly reduce suture-hole 
bleeding compared to other products [24]. 
In addition to these synthetic materials, an extracellular matrix derived from biological 
membrane is also commonly used [6]. This membrane, bovine pericardium, is treated to remove 
cells and cross-linked with chemicals such as gluteraldehyde to strengthen the mechanical 
properties [7].  
Although these materials are adequate for restoring ventricular geometry and maintaining 
ventricular pressure, they do not address the basic issue of regenerating myocardial tissue that 
has been lost. The wide-spread use of these materials is largely due to the fact that they are 
relatively inert and that they do not degrade over time, thus making the interaction between the 
material and its biological surroundings very predictable [23]. The result is the development of a 
region of acellular scar tissue instead of a region of viable myocardium that can contribute to the 
work of the heart. 
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Table 1: Commercially available heart patches 
MATERIAL PRODUCT FEATURES 
Gore-Tex® ACUSEAL 
cardiovascular patch (Gore 
Medical Products, Inc.) 
Significant reduction in suture hole 
bleeding Expanded Polytetra-
fluoroethylene 
(ePTFE) Cardiovascular Patch (Bard 
Peripheral Vascular, Inc.) 
Multi-directionally oriented node-
fiber structure accommodates cellular 
ingrowth 
DeBakey® cardiovascular fabrics 
(Bard Peripheral Vascular, Inc.) 
Wide range of configurations from 
which the surgeon can select for each 
individual case 
Hemashield Double Velour 
Fabrics (Boston Scientific, Inc.) 
Collagen impregnation provides  
blood tight seal and optimal tissue 
ingrowth 
Polyethylene 
terephthalate (PET) 
HemaPatch® Knitted 
(DataScope, Inc.) 
Coated with cross-linked type I 
bovine collagen 
PeriGuard® (Synovis Surgical, 
Inc.) 
Improved suturability and handling 
over synthetic patches 
Glutaraldehyde treated 
bovine pericardium SJM Pericardial Patch with 
EnCap® technology (St. Jude 
Medical, Inc.) 
Proprietary coating minimizes 
calcification and promotes 
endothelial covering 
 
2.4 Research in Myocardial Regeneration 
 In the field of cardiac tissue engineering the topic of cardiac patches is being researched 
extensively. The current trend in this research is to take a biomaterial scaffold, seed it with 
cardiac cells and implant it in the heart. With these experiments researchers are trying to 
determine if a scaffold can be used to induce regeneration of contractile myocardium that will 
replace the infarcted region of the heart and contribute to its overall workload. A summary of 
some of this research can be found in Table 2.  
One important point to highlight is that myocardial regeneration has become a highly 
controversial topic because of recent research that contradicts long-held beliefs about properties 
of myocardium. For years the accepted dogma has been that ventricular myocytes are terminally 
differentiated cells and are unable to divide in the adult heart. This stipulates that the heart is 
only capable of growing through myocyte hypertrophy [25]. Researchers who support this point 
of view cite as evidence the fact that the heart does not repair itself after infarction [25].  
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Recently, other researchers have found evidence that contradicts the long-believed 
dogma. Studies in animal and human hearts have shown that myocytes express growth-related 
genes immediately after infarction [26]. These myocytes are found in the infarct border zone 
where they have access to a sufficient blood supply. They also exhibited a 3 to 4 fold higher 
activity level one week after infarction [26]. The origin of these replicating myocytes is 
unknown, but it is suggested that they may come from a pool of resident cardiac stem cells or 
from circulating hematopoietic stem cells that have migrated to the heart through the blood [26]. 
It is important to note however, that because this natural replication and regeneration is restricted 
to areas where the replicating cells have access to a blood supply, the infarcted region is never 
functionally regenerated [25]. The scaffolds being researched are being designed to create a 
conducive environment in the infarct region so that regeneration, whether it occurs naturally or 
not, can take place in the infarct zone.  
2.4.1 Use of Scaffolds in Myocardial Regeneration 
Porcine urinary bladder matrix (UBM) is currently being researched as a direct 
replacement for the non degradable patches used clinically today. Robinson et al. [6] implanted a 
4 layer UBM patch in the left ventricles of porcine models and after 3 weeks found that it had 
resorbed and been replaced by tissue growth. This tissue tested positive for alpha smooth muscle 
actin myofibroblasts and cardiomyocyte specific filament proteins. This suggests the possibility 
of regeneration of the myocardial tissue. However, the authors are unsure of the origin of the 
cells that make up this new tissue.  
Park et al. [27] tested three scaffolds against a series of goals that would help create 
functional cardiac tissue: the scaffold must be highly porous to facilitate mass transport, 
hydrophilic to enhance cell attachment, structurally stable to hold mechanical loads, degradable 
to be biocompatible, and elastic to comply with contraction. A PLGA/collagen type 1 composite, 
a collagen sponge, and a PLGA sponge were seeded with cells isolated from the left ventricle of 
neonatal rats and cultured for eight days in bioreactors. The perfused environment of the 
bioreactor improved the maintenance of a high and spatially uniform cell density. Both the 
composite and collagen sponge had localized contractions and synchronous contractions in 
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response to electrical stimuli after 1 to 2 weeks. Also, the composite had the highest presence of 
connexin-43 gap junction protein in the scaffold.  
Alginate gels and sponges are natural materials that are used extensively in cartilage 
regeneration therapy. Leor et al. [28] seeded alginate sponges with cells isolated from the 
ventricles of embryonic rat hearts and attached them to the epicardium of rat ventricles for nine 
weeks. After removal the authors found that both the seeded scaffold and the unseeded control 
were partially degraded, the cells were uniformly distributed throughout the scaffold, and the 
scaffold was covered with connective tissue and neovascularization. There was evidence of 
differentiation into mature myocardial fibers, gap junctions, and parallel arrangement of 
myofibers.  
Gelatin sponges are also being researched as potential cardiac scaffolds. Li et al. [29] seeded 
three dimensional Gelfoam sponges with fetal rat cardiomyocytes and investigated in vitro cell 
growth and in vivo interactions. In vitro cell growth was able to occur, increase, and the cells 
survived in culture for two months. In vivo, it was found that the sponges partially dissolved 
after five weeks of being implanted subcutaneously. The cells organized themselves into a 
pattern resembling normal cardiac tissue and medium sized blood vessels formed indicating 
significant angiogenesis from the muscle into the graft. Spontaneous regular contractions were 
observed but there was no overall improvement in heart function. Also this sponge was found to 
be too thrombogenic for direct contact with blood so its use in the heart would be limited to non 
endocardial applications.  
Fibrin glue is a routinely used surgical adhesive and sealant that can also be used as a 
scaffold to support myocardial regeneration. Christman et al. [30] seeded fibrin glue with 
skeletal myoblasts, and injected it into the infarcted area of left ventricles of rats. Initial cell 
culture testing demonstrated that myoblasts were capable of surviving in fibrin glue for seven 
days in culture. After five weeks in vivo the myoblast density had increased and the cells were 
found at the infarct border zone and within the infarct scar. Overall the size of the infarct had 
been reduced to about 20% and there was evidence of new blood vessel formation in the scar 
area.  
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Table 2: Summary of materials being researched for cardiac repair applications 
Material Experimental 
Model 
Advantages Disadvantages Reference 
UBM 4 layer, implanted as 
full thickness wall 
patch in left 
ventricle of pigs 
• Promoted myofibroblast 
recruitment 
• Supports cell proliferation 
• Degradable 
• Retains matrix elements 
• Regeneration has been 
observed 
• Questionable 
mechanical 
properties 
• Not currently used 
in humans 
[6] 
 
Collagen 
Sponge 
neonatal rat heart 
cells suspended in 
Matrigel were 
seeded onto 
Ultrafoam sponges 
and cultured 
• Main protein of ECM 
• Biocompatible 
• Enhance properties by 
crosslinking 
• Naturally degraded by 
MMPs 
• Excellent for cell attachment 
and proliferation 
• Elastic modulus conducive 
to supporting contractile 
myocytes 
• Poor mechanical 
properties 
• Lack of structural 
stability 
• Large degree of 
swelling 
• Thrombogenic 
 
[27] 
 
Tissue 
Fleece 
neonatal rat 
cardiomyocytes 
seeded into Tissue 
Fleece, electrically 
stimulated for 
contraction force 
measurements 
• Currently used for tissue 
grafts in Europe 
• Significant elasticity 
• Compliant 
• potentially 
thrombogenic 
 
[31] 
 
Alginate 
Gel/Sponge 
fetal rat cardiac cells 
grown within 
alginate scaffolds to 
form multi-cellular 
contracting 
aggregates, 
implanted over 
myocardial scar on 
left ventricle of rats 
• hydrophilic 
• easily wetted 
• highly porous structure 
• transparent 
• soft consistency 
• integrates with adjacent 
tissue 
• extensive neovascularization 
with cell seeding 
• degradable 
• easy to handle 
• injectable 
• no cell adhesion 
sites 
• crosslinking agent 
typically Ca, could 
be toxic to heart 
tissue 
[28] 
 
Fibrin Glue rat skeletal 
myoblasts in fibrin 
glue were injected 
into wall of infarcted 
left ventricle in rats 
• readily available 
• can be augmented easily 
with growth factors 
• injectable 
• use in heart with 
mesenchymal stem cells 
• contains RGD binding sites 
• clotting risk 
• scar formation 
potential 
[30] 
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Polyanaline H9c2 cardiac 
myoblasts cultured 
on conductive 
polyanaline substrate 
• electrically conductive 
• highly studied polymer 
• biocompatible – no effect on 
cell proliferation, 
morphology 
• non degradable 
• effect of matrix 
electroactivity has 
not been 
determined for 
cardiac cells 
[8] 
 
Gelatin 
Sponge 
Cardiomyocyte- 
enriched cell 
inoculum from fetal 
rat ventricular 
muscle seeded into 
Gelfoam and 
implanted into 
subcutaneous tissue 
of rat leg or over 
myocardial scar in 
rat heart 
• Biodegradable 
• Growth in three dimensions 
• Blood vessel growth 
• Supports contraction of 
myocytes 
• Thrombogenic 
• Too porous 
[29] 
 
2.4.2 Stem Cells in Myocardial Regeneration 
The heart is generally thought to have no endogenous ability to regenerate new 
myocardium after suffering a myocardial infarction. There is some controversy as to whether this 
always the case [32], but if the heart does have any endogenous regenerative ability, the 
mechanism is poorly understood. Accordingly, many studies that have sought to regenerate 
myocardium have done so by attempting to transplant cells into the heart, or to recruit them from 
other sources within the body and induce them to differentiate into cardiac myocytes [33].  
Because of the ability of stem cells to differentiate into many different types of cells, 
there is hope that some types of stems cells have the ability to differentiate into myocytes [34]. 
This sparked a number of studies that sought to transplant various types of stem cells into the 
heart. Notably, the BOOST and TOP-AMI clinical trials showed increased ejection fraction in 
patients that received stem cells [35, 36]. Other studies have called into question the mechanism 
through which this occurs and whether the cells are actually differentiating into myocytes [33]. It 
has been hypothesized that the improvement due to injection of these cells results from passive 
mechanical support, but that true regeneration required the electrical coupling of cells through 
gap junctions in order to support synchronous contraction [37]. 
Some of the most promising studies involve the use of bone marrow cells or bone marrow-
derived stem cells. Bone marrow aspirate contains heterogeneous populations of many different 
cell types which can be separated to obtain an assortment of progenitor cells, such as 
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mesenchymal stem cells and multipotent adult progenitor cells [36, 38]. Studies involving these 
types of cells, such as one done by Orlic et al., have found evidence of myocardial regeneration 
following injection of bone marrow-derived cells [39]. A recent study by Potapova, et al. [40] 
showed that bone marrow-derived mesenchymal stem cells were capable of producing cardiac 
lineage markers under in vitro conditions. Implanting these cells on UBM scaffolds into full-
thickness defects in canine hearts resulted in increased regional stroke work, evidence of 
functional regeneration. 
2.4.3 Use of Growth Factors in Myocardial Regeneration 
One approach to myocardial regeneration that has garnered much publicity and 
controversy is the use of growth factors such as granulocyte colony-stimulating factor (G-CSF). 
This is used to mobilize autologous bone marrow cells within the patient which may regenerate 
myocardial heart tissue, as discussed above. G-CSF is a cytokine growth factor that is commonly 
used as an adjuvant to mobilize neutrophils from bone marrow in patients with abnormally low 
neutrophil levels, such as those undergoing certain types of cancer treatment [41]. Orlic et al. 
[42] conducted a study in which bone marrow cells mobilized with G-CSF and stem cell factor 
(SCF) were injected into the border regions of infarction in mice, followed by intravascular 
administration of G-CSF and SCF. The treated mice showed a significant degree of tissue 
regeneration and improved cardiac function. Several other studies have also demonstrated 
promising results for the use of G-CSF mobilized cells in cardiac applications [43-45], however 
some studies have shown limited evidence of any regenerative activity [43]. Thus far, G-CSF 
treatments aimed at myocardial regeneration have involved either systemic administration of G-
CSF, or injection of cells the had been mobilized with G-CSF directly into the myocardium, but 
G-CSF itself has not been administered locally to the heart.  
The precise mechanism by which G-CSF improves cardiac function remains unknown 
and controversial. When G-CSF is delivered systemically, it is hypothesized that cardiac 
regeneration occurs through mobilization of stem cells from the bone marrow. These bone 
marrow-derived stem cells have a high affinity for the injured tissue in the myocardial infarction. 
Thus it is hypothesized that the mobilized stem cells circulate to the site of the infarction, where 
they migrate into the tissue and differentiate into myocytes [46]. However, at least one 
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conflicting study has demonstrated that prevention of cardiac remodeling by G-CSF occurs 
because G-CSF protects still-viable cardiomyocytes instead of recruiting stem cells [47]. It is 
known that G-CSF mobilized mesenchymal stem cells have a high affinity for fibrin, and fibrin 
microbeads have been used to isolate mesenchymal stem cells from G-CSF mobilized bone 
marrow cells [48]. 
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Chapter 3: Project Approach 
After a comprehensive literature review of published works, we focus on developing the 
present device, a scaffold for regenerating myocardium. Before launching into the design process 
we wish to further define our project by identifying the project hypothesis and enumerating the 
overall assumptions and goals.  
3.1 Project Hypothesis 
Conventional approaches to treatment of myocardial infarction, as described above, are 
aimed primarily at preventing any future deterioration of the heart. However, there is currently 
no method of treatment that seeks to actively heal the myocardium and restore heart function that 
has been lost. Conventional treatments do nothing to regenerate dead myocardium and grow 
new, functional heart muscle tissue. We hypothesize that identifying materials with the 
appropriate mechanical and regenerative properties will enable the formation of a composite 
scaffold to replace the currently used patches. This approach would supplant the practice of 
replacing infarcted tissue with a synthetic patch during endoventricular patch plasty and 
ventricular restoration. The regenerative scaffold must fulfill the primary function of a synthetic 
patch by providing mechanical support to the ventricle wall in addition to its regenerative 
capability.  
3.2 Project Assumptions 
For any engineering project it is important to explicitly set forth the assumptions that will 
be made in order to carry out the project. These assumptions give a basis for simplifying the 
complex problem of heart disease and myocardial infarction to a problem that is within the scope 
of a senior design project. The primary assumptions that have been made in order to carry out the 
present project are as follows: 
• Regeneration of myocardium following myocardial infarction will lead to 
improved heart function. 
• Bone marrow derived stem cells migrate to the infarcted region and play a 
beneficial role in myocardial regeneration. 
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• In vitro cell growth can be used to model myocardial regeneration. 
Although the validity of these assumptions are subject to debate and controversy, for the 
purpose of this project, we are working toward fulfilling goals that will lead to myocardial 
regeneration and improved cardiac function only under these assumptions. Verification of the 
validity of these assumptions is beyond the scope of this project.  
3.3 Project Goals 
As previously identified, the purpose of this project was to create a scaffold that will 
induce myocardial regeneration in the infarcted heart. The specific goals of this project are to:  
• Develop a conceptual design and prototype composite scaffold that is clinically 
applicable and cost effective for myocardial regeneration 
• Select appropriate candidate materials with the mechanical and regenerative 
properties to replace a section of ventricular myocardium 
• Characterize mechanical properties of candidate materials 
• Characterize the ability of candidate materials to promote stem cell migration 
and viability 
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Chapter 4: Design 
At the beginning of this project the design team received the following initial client 
statement:  
 
“Design and develop a clinically applicable scaffold for cardiac applications that will 
induce cell migration essential in angiogenesis and myocardial regeneration.” 
 
In order to develop this statement into a feasible design, we followed an iterative 
engineering design process. First, the primary stakeholders of the design process were identified. 
Based on input from these stakeholders, the objectives, functions, constraints, and specifications 
of the design were developed in order to clearly state what the design must do and what 
limitations it must be designed within. Finally, a detailed revised client statement was developed, 
which incorporated all the major attributes of the design process and provided a basis for 
developing design alternatives. 
4.1 Stakeholders 
The stakeholders were categorized as designers, clients, and users as shown in Figure 5. 
 
Figure 5: Project Stakeholders 
 
 21 
The main stakeholders in this project are the project advisors, George Pins and Glenn 
Gaudette, and the design team. It is these individuals that will be defining the immediate 
objectives and functions of the design of the scaffold so that it satisfies the project requirements 
as well as establish a strong base as an initial step in a complex design project.  
The primary users of this scaffold will be cardiac surgeons. Through talking with Dr. 
Nicola Francalancia (Appendix A: Interview with Dr. Nicola Francalancia), a cardiac surgeon, 
we discovered that the main concerns of these stakeholders are the survival and long term 
clinical improvement of their patients. Surgeons are interested in a short and simple surgery in 
order to minimize complications and are generally more interested in the clinical outcomes than 
the mechanism by which they occur. The ultimate test of the feasibility of the scaffold designed 
in this project will be to convince cardiac surgeons that it is superior enough to replace currently 
used treatments.  
One group of clients that must be considered in the design process are cardiologists. 
When a patient first exhibits signs of heart failure, they are often referred to a cardiologist by 
their primary care physician. The cardiologist then prescribes a treatment for the patient which 
can range from medication to surgical intervention. Because cardiologists determine the 
treatment for the vast majority of the patients with myocardial infarctions, their opinion of any 
new treatment will be very important. If cardiologists can be convinced that this approach to 
myocardial regeneration will result in significant cardiac functional improvement, then the 
clinical acceptance of this design approach will be greatly enhanced.  
Another important client group consists of those who represent the business interests 
involved in producing this scaffold and developing it into a marketable product. Without an 
efficient, profitable means for producing this product and making it clinically available, it will 
never be able to reach the patients that it is designed to help. The businesses and investors that 
would be involved in this process are thus keenly concerned with the ease with which the 
product can be made clinically available. Easing the product-to-market transition cuts costs and 
allows for less time and money to be spent in development and regulatory approval. These 
stakeholders are also concerned with issues such as manufacturing, storing, and packaging that 
are not major issues in a research lab and can be easily overlooked. It is important to carefully 
consider how design decisions made in this project will affect such issues in the future. 
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Closely tied to the business interests are regulatory considerations. Medical devices that 
enter the market in the United States are closely regulated by the Food and Drug Administration 
(FDA). Manufacturers must demonstrate that their product does not introduce harmful materials 
into the human body. The level of stringency with which the FDA examines devices increases 
with their complexity and obtaining FDA approval can become large percentage of the overall 
cost of product development. 
4.2 Objectives, Functions, and Constraints 
Based on consultations with the stakeholders of this design project and a review of the 
relevant literature, we generated design objectives to define the parameters of our device. The 
parent and sub level objectives are listed below: 
 
OBJECTIVES 
1) Be safe for the patient 
• Have reliable mechanical properties 
• Have predictable biomaterial-tissue responses 
2) Be clinically applicable 
• Be practical for use in surgery 
• Be marketable 
• Be easy to produce 
3) Have similar properties to healthy myocardium 
• Be contractile 
• Be regenerative 
 
Regardless of how good the concept behind a medical device is, it will never be used in 
the clinic if it is not safe for the patient. In being safe for the patient the scaffold must have 
reliable mechanical properties so that it is consistently functional once implanted in the heart. 
Reliable mechanical properties are important because the implanted scaffold will have to 
withstand systolic ventricular pressure, and cannot fail mechanically under various cyclic loads 
and tensions related to the contraction and relaxation of the beating heart. It also needs to have 
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predictable biomaterials-tissue responses so that it does not induce any immune or 
biocompatibility response in the body. Since the scaffold will be directly in contact with the 
ventricular blood flow, not only will it have to be biocompatible, but it will also have to be 
hemocompatible so as not to induce thrombus and embolus formation.  
 The next major objective involves the clinical applicability of the design. To this end, a 
critical component of this objective to be practical for use in surgery. Surgeons will be the 
primary users of this device and they are more likely to accept a new device if it involves limited 
variation from procedures that they already perform. The application of the scaffold should 
therefore conform to currently used surgical procedures. Marketability is another important 
aspect of being clinically applicable. This patch needs to be marketable with respect to cost and 
other business interests so that health care providers are drawn to purchase and use it. Finally, the 
ease of production of the patch will also play a role in how it is incorporated into the clinical 
field since it must be easily manufactured in order to make it out into the clinical environment.  
 The last objective stipulates that we must engineer the scaffold to have similar properties 
to healthy myocardium. Since it will be incorporated in the heart, the scaffold must reflect the 
properties of the native tissue in order to create a suitable environment for regeneration of 
contractile myocardium. In order to be similar to the native myocardium, the scaffold must be 
compliant enough to allow for contraction of new myocytes and to avoid compliance mismatch 
with the native myocardium. 
Subsequent to the development of main-level and sub-level objectives, an objectives tree 
was formed in order to map out the relationship of the objectives relative to each other and to 
pave the way for the development of functions and constraints. Before we identified the desired 
functions of the scaffold, the objectives were weighted in order to better understand their relative 
importance in the design process. The our project advisor stakeholders and the design team 
completed pairwise comparison charts to rate the importance of each objective (Appendix B: 
Pairwise Comparison Charts). The input from the different stakeholders was weighted in 
accordance with each stakeholder’s relevant expertise in the subject of cardiac tissue 
regeneration and function. Dr. Glenn Gaudette’s responses were given the highest weight at 50% 
because of his expertise and current research in cardiac patches, Dr. George Pins’ responses were 
weighted at 30% since he is our primary expert for the biomaterials and tissue engineering 
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aspects of the project, and the design team’s responses were weighted at 20% based on the 
research conducted by the team for this project. The pairwise comparison charts were analyzed 
and the respective weight of each stakeholder’s opinion was applied to create the weighted 
objectives tree that is shown in Figure 6. The first number represents the weight with respect to 
the parent objective while the second number represents weight with respect to other objectives 
on the same level.  
 
Clinically 
Applicable
0.289 | 0.289
Safe for Patient
0.444 | 0 .444
Regenerative
0.603 | 0 .161
Contractile
0.397 | 0.106
Marketable
0.280 | 0.081
Practical for use 
in Surgery
0.609 | 0.176
Cardiac Scaffold
1.0 | 1.0
Easy to Produce
0.111 | 0.032
Predictable 
Biomaterial-Tissue 
Response
0.464 | 0 .206
Reliable 
Mechanical 
Properties
0.536 | 0 .238
Similar Properties 
to Healthy 
Myocardium
0 .267 | 0.267
 
Figure 6: Weighted Objectives Tree  
 These weighted objectives created a preferential order for our design priorities. This 
order is as follows:  
• Patient safety 
• Clinical applicability 
• Exhibition of properties similar to native myocardium 
Using this information, several functions and constraints were identified that help to 
further define our design and reflect the weighted objectives shown above. The following list 
summarizes the primary functions, in order of importance, that the scaffold must perform in 
order to meet the established objectives.  
FUNCTIONS 
• Hold heart pressure 
• Regenerate contractile myocardium 
• Provide a perfused environment 
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• Facilitate surgical simplicity 
 
Since this scaffold will replace the infarcted myocardium, it must withstand the pressure 
and forces that occur within the ventricular myocardium. This is essential to prevent catastrophic 
failure of the device. What sets our patch design apart from current clinically used endocardial 
patches is that it must also have the ability to regenerate contractile myocardium. Our hypothesis 
states that new myocardium will improve cardiac function, so this would require the patch to 
induce and support the growth of myocytes. In order to regenerate new myocardial tissue, it is 
important for the patch to have a perfused environment for the transport of cells, nutrients, gases 
and waste products. These are the main functions that support our hypothesis as stated in the 
project approach. Furthermore, surgeons will use this scaffold as a patch in endoventricular patch 
plasty, therefore it must be able to maintain and restore the shape of the heart during these 
procedures.  
Along with the primary functions of our design, we developed a series of constraints to 
restricted our design space. These constraints were as follows: 
 
CONSTRAINTS 
• Must be biocompatible 
o Must be composed of nontoxic material 
o Must have nontoxic degradation products 
• Cannot induce thrombus or embolus formation on endocardial surface 
• Cannot cause arrhythmias 
• Non-load bearing components must be degradable 
• Must be cost effective for both producers and the consumers 
o Cannot cost more than the project budget of $624 
• Must be finished by April 2007 
 
These constraints were made in order to filter out undesirable design alternatives later on 
in the design process. Briefly, the scaffold must be biocompatible so as not to induce an 
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undesirable inflammatory response. Besides being biocompatible, the scaffold must also be 
blood compatible. The endocardial region of the scaffold is in direct contact with the blood, 
which requires strictly nonthrombogenic and nonembologenic properties. The scaffold also 
cannot cause arrhythmias that would be detrimental to the function of a healthy heart. Since the 
scaffold is intended to induce myocardial regeneration and is designed to be a provisional tissue 
replacement until new tissue is formed, it must be biodegradable to allow new tissue ingrowth 
[28]. Finally, the design must be within the budget of the design team, and must be completed by 
April 2007. 
4.3 Specifications 
Once the objectives and functions of the project were clearly defined, design 
specifications were developed to detail the specific engineering criteria that the device must 
meet. These design specifications were developed in accordance with the functions and dictate 
methods which can be used to assess the scaffolds ability to perform its functions. The 
specifications are given in Table 3 through Table 6. These tables summarize each individual 
specification and an appropriate testing method. The details of each testing method are described 
in the Methodology chapter.  
Table 3: Specifications - Hold Heart Pressure 
Specification Description 
Strength/Strain 
The scaffold must be able to withstand a tensile force of 1.37 N/mm with 
corresponding strain between 5 and 15%[49-51] 
Suture Retention The scaffold must resist suture pullout under a force of 2.74 N/Suture 
Fatigue Strength 
The scaffold should have a failure strength that is not statistically different 
before and after cyclic loading of 276 cycles/minute for 100,000 cycles at 
1.37 N/mm [49, 50] 
 
 The above specifications focused on the mechanical strength of the scaffold in order to 
hold heart pressure. All calculations include a safety factor of 5 since failure in these parameters 
would cause catastrophic failure of the device and probably loss of life. The ventricular pressure, 
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from a patient with abnormally high ventricular pressure [50], was used to calculate the average 
wall tension on the ventricle, and was normalized as tensile resistance by dividing by the 
ventricle wall thickness (Appendix C: Strength/Strain Protocol Calculations). The suture 
retention force per suture was calculated to ensure the sutures would not tear out of the material 
after implantation in the heart (Appendix D). Fatigue strength is critical for the scaffold as it is 
subjected to cyclic loading caused by the beating of the heart. The scaffold must retain its tensile 
strength following cyclic loading that mimics an accelerated heart rate. 
Table 4 shows the specifications that the device must meet in order to regenerate 
contractile myocardium. 
Table 4: Specifications - Regenerate Contractile Myocardium 
Specification Description 
Viability 
Human mesenchymal stem cells (hMSCs) seeded on a scaffold 
should maintain viability as shown by increasing in cell number 
by 100% within 6 days [52] 
Migration 
hMSCs seeded in fibrin gel should show statistically significant 
migration laterally into the scaffold within 9 days [53-56] 
 
 As explained earlier, our hypothesis involves mobilizing bone marrow stem cells and 
inducing them to differentiate into contractile myocytes. Mobilization of these cells first involves 
migration into the scaffold from the surrounding area. Once the cells are in the scaffold they 
must proliferate in order to fully populate the scaffold. Human mesenchymal stem cells (hMSCs) 
are commercially available and are of bone marrow origin, thus the specifications are designed to 
test their ability to migrate and proliferate in the scaffold.  
Table 5 shows the specifications that the device must meet in order to provide a perfused 
environment. 
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Table 5: Specifications - Provide a Perfused Environment 
Specification Description 
Viability 
Human vascular endothelial cells (hVECs) seeded on a 
scaffold should maintain vaibilty as shown by increasing in 
cell number by 100% within 48 hours [57] 
Migration 
hVECs seeded in fibrin gel should show statistically 
significant migration laterally into the scaffold within 9 days 
[53-56] 
 
A perfused environment, as mentioned earlier, is critical for transport of cells and 
nutrients. These specifications are aimed at predicting angiogenic behavior in vivo that will 
provide a perfused environment for the scaffold material. 
To facilitate use in surgery, the patch should be easy to handle and work with as shown in 
Table 6. Suturability is a critical factor during an open heart surgery as the surgeon must be able 
to suture the scaffold quickly and easily. A suture insertion force of 5N was identified as a 
currently acceptable insertion force in clinically used materials (see Appendix E: Suture Insertion 
Force Calculation).  
Table 6: Specifications - Facilitate Surgical Complicity 
Specification Measurement 
Force required to penetrate the scaffold with a needle 
should be less than 5N [58] 
Puncture test 
 
4.4 Revised Client Statement 
 The objectives, functions, constraints, and specifications developed above define a much 
clearer picture of the design space in which the scaffold is to be created. With a more defined 
idea of the goals of our project, the client statement is revised as follows: 
 
Design and develop a clinically applicable scaffold for cardiac applications that will induce cell 
migration essential in angiogenesis and myocardial regeneration to replace full-thickness 
infarctions in heart attack victims. Materials for the scaffold must be evaluated for patient safety 
by being able to withstand a tensile force of 1.37 N/mm and retain sutures at a force of 2.74 
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N/suture. Implantation of the scaffold should result in immediate heart remodeling in order to 
improve ventricular efficiency, followed by regeneration of contractile myocardium. Materials 
must be evaluated for their regenerative ability by promoting viability and migration of 
mesenchymal stem cells. The scaffold must be clinically applicable by being easy to implant 
using existing surgical techniques, customizable in shape, and having a suture penetration force 
of less than 5 N. The scaffold must also degrade in proportion to new tissue growth.  
4.5 Developing Design Alternatives 
This section describes the techniques used to develop various design alternatives, a basic 
overall design, and evaluation of the materials used for the basic design. The process began by 
identifying various means to fulfill the functions, then combining the compatible means into 
design alternatives. A basic overall design was selected, followed by the evaluation of different 
possible materials. Finally, a preliminary design was proposed in order to begin testing.  
4.5.1 Morphological Chart and Evaluation Matrices 
 The morphological chart, shown in Table 7, lists all the functions along with the possible 
means to carry out each function that were produced by brainstorming (Appendix F: Design 
Alternatives) 
Design alternatives were formed using combinations of the above means. Only 
alternatives that were rational and feasible were considered in evaluation. The following list 
details a number of the possible alternatives formed from these means: 
• Whole wall thickness, growth factors, porous 
• Whole wall thickness, seeded, porous 
• Sew endocardial edges together, injectable gel 
• Endocardial patch, growth factors, injectable gel 
• Endocardial patch, seeded, injectable gel 
• Endocardial patch, growth factors, void 
• Endocardial patch, seeded, void 
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Table 7: Morphological Chart 
FUNCTIONS MEANS 
Hold heart 
pressure 
Whole, wall 
thickness, 
scaffold is one 
strong piece 
Sew 
endocardial 
edges together 
Endocardial 
patch 
   
Regenerate 
contractile 
myocardium 
Growth factors 
for myocyte 
migration and 
proliferation 
Material 
properties for 
myocyte 
migration and 
proliferation 
Scaffold 
seeded with 
mesenchymal 
stem cells 
Growth 
factors for 
MSC 
migration 
and 
proliferation 
Material 
properties for 
MSC 
migration and 
proliferation 
 
Provide a 
perfused 
environment 
Injectable gel 
that promotes 
angiogenesis 
from 
surrounding 
tissue 
Leached out 
channels for 
oriented 
angiogenesis 
Leave void 
Porous 
material for 
angiogenesis 
Concentration 
gradient in 
scaffold to 
direct mass 
transport 
Attach a 
blood 
vessel to 
scaffold 
Facilitate 
surgical 
simplicity 
Etched 
directional 
lines 
Rough surface 
on one side 
Colored 
markings 
   
 
These alternatives were organized into a numerical evaluation matrix and weighted 
according to how well they fulfilled the constraints and objectives. A list of detailed metrics can 
be seen in Appendix G: Metrics and Matrices for Evaluation of Design Alternatives. Each 
objective was broken down and defined on a scale of 0-2, 0 being the least favorable and 2 being 
the most favorable in fulfilling the objective. For example, the objective ‘predictable biomaterial-
tissue responses’ was given a score of 2 if the design had very high potential for controlling the 
response of the tissue to the implanted scaffold, and a score of 0 was given if the design did not 
plan for any control over tissue response.  
After these metrics were established, an evaluation matrix was made to evaluate each 
candidate design. An excerpt of this table can be seen in Table 8. 
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Table 8: Evaluation Matrix to Evaluate Design Alternatives 
                  
        Design 
 
 
Objectives  
& Constraints 
Weight Design 1  Design 2 Design 3 
C: Constraint 1 Y/N    
O: Objective 1 (0.238)    
Total Score     
 
The top row lists the various candidate designs, and the left column lists the design 
objectives (O) and constraints (C). The second column shows the objective weights that were 
established earlier from the weighted objectives tree. The designs were evaluated by scoring 
them against the metrics (0, 1, or 2) and writing the corresponding metric for each material along 
the row. After doing this, each metric was multiplied by its corresponding objective weight and 
the final score for the design was obtained by adding the weighted metric score for each 
objective. The maximum score any design could get was 2, which would mean that it met all 
stated objectives.  
The top design candidates can be seen in Table 9. The full list of evaluated designs and 
total scores, along with a description of each design and justification of scoring can be found in 
Appendix G: Metrics and Matrices for Evaluation of Design Alternatives.  
 
Table 9: Evaluation of Design Alternatives 
Design Alternatives 
Total 
Score 
Endocardial patch, growth 
factors, injectable gel 
1.414 
Endocardial patch, seeded, 
injectable gel 
1.125 
Whole wall thickness, 
seeded, porous 
1.110 
Whole wall thickness, 
growth factors, porous 
1.062 
Sew endocardial edges 
together, injectable gel 
0.984 
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For holding heart pressure, an endocardial patch is ideal because it is an established 
surgical repair method. The whole wall thickness design was rated lower because it would make 
it difficult to reach the suture line, and direct linear closure was eliminated because it would not 
provide any volume for myocardial regeneration to take place nor would it allow for restoration 
of the original shape of the heart.  
Regeneration of contractile myocardium using adult myocytes was decided against 
because of the difficulty involved in their isolation and in vitro culture. Seeding a scaffold with 
cells prior to implantation is advantageous in that the damaged region is replaced with an already 
developed tissue structure. However, the geometry of seeded scaffolds is limited by the thickness 
through which oxygen and nutrients can diffuse to support the cells. This limitation in thickness 
is not compatible with the thicknesses of myocardium that must be regenerated, and thus seeded 
scaffolds were rated lower in the different alternatives. Growth factors are also a powerful 
method for inducing the migration and proliferation of cells, however their use may be limited by 
their high cost.  
For providing a perfused environment, an injectable gel is ideal due to its ease of 
implantation and use in other clinical applications. For facilitating surgical simplicity, all the 
means were considered because they all would aid the surgeons in identifying and using the 
patch. 
4.5.2 Basic Design 
Based on the evaluations above, a basic design was developed in accordance with the 
design alternative that scored the highest. This basic design consists of two components: an 
endocardial patch sutured to the endocardial region of the ventricular wall, and a filler material 
that would be placed above the endocardial patch filling the wall thickness. Figure 7 shows an 
illustration of a cross section of the myocardium in which the infarcted region would be removed 
and replaced by this composite scaffold.  
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Figure 7: Illustration of the Basic Patch Design 
The endocardial patch provides mechanical support to hold heart pressure and can be 
used for cardiac remodeling similar to current patches. The filler material provides a provisional 
matrix for controlled myocardial regeneration and angiogenesis. Another feature of this design is 
the incorporation of growth factors such as G-CSF. We have hypothesized that G-CSF has a 
similar chemotactic affect on bone marrow-derived mesenchymal stem cells as on 
polymorphonuclear leukocytes so we plan to incorporate G-CSF into a scaffold filler material for 
myocardial regeneration. In this way we hypothesize that stem cells will be mobilized from the 
bone marrow, and migrate into the filler material due to both a high affinity for fibrin and the 
chemotactic affect of G-CSF. These stem cells will then be able to proliferate and differentiate 
into myocytes to form new, functional heart tissue.  
 This device has several advantages associated with it, one of the most important of which 
is that it replaces the full thickness of the removed myocardial region. The filler material is 
designed to promote the re-growth of new myocardium, which is an improvement over the 
formation of uncontrolled scar tissue in the current patches. In addition, this device would be 
acellular which would make it relatively easy to manufacture and be in accordance with FDA 
regulations. The endocardial patch would be the pressure bearing component. Furthermore, the 
whole patch can be designed to be bioresorbable and would be completely replaced by new 
tissue. 
4.5.3 Evaluating Candidate Materials for Basic Design  
After the basic design composite scaffold design was established, several candidate 
materials for each component were evaluated against the design objectives using another set of 
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metrics. An explanation of these metrics can be seen in Appendix H. Each objective was broken 
down and defined with relevance to material selection on a scale of 0-2, 0 being the least 
favorable and 2 being the most favorable in fulfilling the objective. For example, the objective 
‘predictable biomaterial-tissue interactions’ was given a score of 2 if the material had literature 
references indicating an absence of fibrotic response to the material, and a score of 0 was given if 
the material had a past history of extensive fibrotic response when used in cardiac applications.  
After these metrics were established, an evaluation matrix was made to evaluate each 
candidate material for the endocardial patch and filler. An example of this table can be seen in 
Table 10.  
Table 10: Evaluation Matrix to Evaluate Candidate Materials 
Objectives 
!  
Reliable 
mechanical 
properties 
Predictable 
biomaterial-
tissue 
interactions  
Practical 
for use 
in 
surgery 
Regenerative Contractile Marketable 
Easy to 
produce 
Total 
Score 
Objective 
Weights 
!  
0.238 0.206 0.176 0.161 0.106 0.081 0.032  
Patch 1 2 0 1 0 0 2 2 0.878 
Filler 1 - 1 1 1 2 1 0 0.836 
 
 The left column lists the various candidate materials, and the top row lists the design 
objectives. The second row shows the objective weights that were established earlier from the 
weighted objectives tree. The materials were evaluated by scoring them against the metrics (0, 1, 
or 2) and writing the corresponding metric for each material along the row. After doing this, each 
metric was multiplied by its corresponding objective weight and the final score for the material 
was obtained by adding the weighted metric score for each objective. The maximum score any 
material could get was 2, which would mean that it met all stated objectives.  
The top candidates for endocardial patch materials and filler materials can be seen in 
Table 11 and Table 12. The full list of evaluated material and total scores, along with a 
description of each material and justification of scoring can be found in Appendix H. 
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Table 11: Evaluation of Patch Materials 
Patch Material 
Total 
Score 
UBM 1.531 
Veritas 1.531 
 Trimethylene Carbomate 
(TMC) – D,L-Lactide 
(DLLA) copolymer 
1.338 
Tissue Fleece 1.081 
 Poly(glycolide-co-
caprolactone) (PGCL) 
copolymer 
1 
Dacron 0.878 
ePTFE 0.878 
Cross linked Bovine 
Pericardium 
0.878 
 
Table 12: Evaluation of Filler Materials 
Filler Material 
Total 
Score 
Fibrin Glue 1.524 
Alginate Gel 1.492 
Platelet Rich Plasma 1.46 
Gelatin Sponge 
(Gelfoam) 
1.348 
Collagen Sponge 
(Ultrafoam) 
1.316 
Alginate Sponge 1.104 
Collagen Hydrogel 1.036  
 
4.6 Proposed Final Design 
Based on the results of the evaluation matrices for the endocardial patch and filler 
material, porcine urinary bladder matrix (UBM) and Veritas were chosen as test materials for the 
endocardial patch, and fibrin glue was chosen as the filler material. Another material, collagen 
membrane, was also selected for testing as one of the candidate materials based on the 
suggestion of Dr. George Pins since these are currently being developed in his lab. These films 
are made by cross linking a thin layer of collagen solution on a plastic stencil. The cross linking 
method used for fabricating the collagen membranes for this project was by using carbodiimide 
(EDC) as the cross linking agent. EDC cross linking was used to fabricate the collagen 
membranes because the membranes had favorable elastic modulus, swelling ratio and fibroblast 
migration rates [59]. The collagen membranes are stored as thin brittle sheets that become 
flexible and viscoelastic when hydrated with saline solution. As part of the project, the collagen 
membranes would be characterized to determine if they have sufficient strength and strain 
properties for their use as an endocardial patch.  
Urinary bladder matrix, as explained in section 2.4.1, is a lyophilized extracellular matrix 
taken from a porcine urinary bladder. Figure 8 shows the characteristic features of the 4 layer 
UBM material. The solid markings on the material are due to the processing of the material as 
the 4 layers are lyophilized to form a thicker material. Figure 9 shows the single layer UBM. The 
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collagen fibers are oriented in different directions which increases the strength of this biological 
material. It is currently used in veterinary applications like tissue remodeling and regeneration 
after wounds [6]. 
 
Figure 8: Four layer lyophilized UBM (5X) 
 
Figure 9: Single layer UBM (5X) 
 
Veritas is currently under investigation by Dr. Gaudette for use in cardiac applications. 
Veritas is a non crosslinked bovine pericardium that is used in pelvic reconstruction surgeries. 
Because of the nature of these surgeries, repair materials used must have similar mechanical 
requirements as compared to the conditions in the heart [60]. It is also advantageous for use in 
these surgeries because it integrates into the surrounding tissue and supports new tissue growth. 
Other qualities include exceptional tensile strength, biocompatibility, suture retention, and 
angiogenic responses [61]. Figure 10 shows the structure of the Veritas collagen membrane. 
Similar to UBM the collagen fibers are multidirectionally oriented which increases the strength 
and suture retention [62].   
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Figure 10: Veritas Collagen Matrix (5X) 
 
The final endocardial patch material that was tested is a woven fabric (Hemashield, 
Boston Scientific Corp.). This material will serve as the high end control since it is the standard 
for cardiac patches. Figure 11 shows the woven pattern of a typical Dacron patch material. The 
fibers are weaved orthogonally and form a strong structure. 
 
Figure 11: Dacron woven material (5X) 
Figure 12 and Figure 13 show the woven polyester vascular graft which was the synthetic 
material actually used during testing. The structure of the woven polyester vascular graft is very 
similar to the structure of the Dacron material shown in Figure 11. The inner view of the vascular 
graft shows a much smoother weave as compared to the outer view. Also, the woven structure of 
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the vascular graft is much looser in order to allow for increased flexibility and longitudinal 
stretch. 
 
Figure 12: Woven polyester graft, inner view (5X) 
 
Figure 13: Woven polyester graft, outer view (5X) 
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Chapter 5: Methodology 
This chapter discusses the preliminary testing methods that are used to determine which 
endocardial patch materials would be appropriate to use. The production of the filler material as 
well as the testing methods used to characterize both the filler and patch materials will also be 
discussed. A diagram of the overall testing plan can be seen in Figure 14.  
 
Figure 14: Overall Testing Plan 
5.1 Preliminary Testing of Endocardial Patch 
The preliminary testing phase was designed to eliminate those materials which had been 
identified for possible use as the structural component of our device but which may not meet the 
specifications that were established. The two specifications used to screen materials in this phase 
are as follows: 
• The ability of the material to hold the required load while exhibiting the appropriate 
stretch. 
• The suture retention strength of the material. 
 
These specifications were chosen as the focus of preliminary testing because inadequate 
performance in either of these categories would result in catastrophic failure of the device. The 
details of the testing methods for each of these tests are described in the following sections. Four 
materials were tested in this phase, UBM, Veritas, collagen membranes, and woven polyester 
vascular graft as a high end control.  
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5.1.1 Strength/Strain 
The strength of the material was measured uniaxially using an Instron In-Spec 2200 
Benchtop Portable materials testing machine controlled by LabView 7.1. A detailed testing 
protocol can be found in Appendix I: Strength Strain Testing Protocols. Uniaxial testing does not 
completely quantify the strength of the material since the heart wall experiences multiaxial 
loading however it is a comparatively simple method that yields data sufficient for an initial 
screening of materials.  
The samples were cut to into the dog bone shape specified by ASTM Standard 
Designation E8M-04 (Appendix J: Drawings of Dog Bone and Suturability Base). Markers were 
placed at the center of each sample for image analysis and each sample was secured to the upper 
and lower grips as seen in Figure 15. The grips were advanced at a strain rate of 0.20/s to mimic 
one heart beat at average heart rate. The test was run until failure or until the maximum 
capabilities of the Instron were reached.  
 
Figure 15: Strength Strain Sample 
 
Raw data was obtained in the form of force in grams and extension in millimeters. Force 
is converted to Newtons using a factor of 0.0098 N/g. Crosshead strain was calculated by 
dividing the extension by the original gauge length. Since the samples are cut into a dog bone 
shape, an analysis of local strain was also performed in order to establish its relationship to the 
crosshead strain. Local strain of the sample was measured by acquiring images of two markers 
placed vertically on the central portion of the sample. Images are taken 0.5s apart throughout the 
Visual markers 
Grip 
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duration of the test. The relative displacement of the markers was then analyzed using ImageJ 
(National Institutes of Health) (Appendix K: ImageJ Strain Measurement). The relationship 
between crosshead strain and local strain was established by plotting the two against each other 
and creating a line of best fit. The equation of this line was then used to convert crosshead strain, 
as given in the raw data, to give a better approximation of local strain.  
5.1.2 Suture Retention  
The suture retention test was performed based on the methods described in American 
National Standards Institute standard VP20-1994, which addresses cardiovascular implants and 
vascular prostheses. The detailed testing protocol can be found in Appendix L: Suture Retention 
Testing Protocols. Each material was cut into 2 x 1cm samples and placed in the bottom grip of 
an Instron In-Spec 2200 Benchtop Portable materials testing machine. A 6-0 prolene suture, 
which is commonly used in cardiac surgery, was threaded through the center of the sample at a 
2mm bite depth according to the standard, see Figure 16. The remainder of the suture was 
secured to the upper grip which was advanced at a crosshead speed of 2mm/s (0.05/s strain rate). 
The test was allowed to run until either material failure or suture failure, or until the maximum 
capabilities of the Instron were reached.  
 
Figure 16: Suture Retention Sample 
 
Raw data was obtained in the form of force in grams and extension in millimeters. Force 
was converted to Newtons using a factor of 0.0098 N/g. The failure of the sample was assessed 
by measuring force at failure and visually inspecting for signs of tearing at the suture insertion 
6-0 prolene 
suture 
UBM 
material 
 
Grip 
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point. Materials that did not show signs of failure at specification were considered to have 
acceptable suture retention strength. 
5.2 Characterization Testing of Endocardial Patch 
Once preliminary testing has established which materials have acceptable critical 
properties to be used as the structural component of our design, further testing was performed to 
more fully characterize our endocardial patch. These tests examined the following specifications:  
• The ability of the material to hold the required load while exhibiting the appropriate 
stretch (repeated from preliminary testing at larger sample size) 
• The suture retention strength of the material (repeated from preliminary testing at 
larger sample size) 
• The force required to puncture the material with a suturing needle 
5.2.1 Strength/Strain 
This test was performed using the same protocol as section 5.1.1. One minor change was 
made to ensure the samples would not slide out from between the grips. Sandpaper was used to 
create a tougher surface on the grip faces to more securely anchor the patch materials as seen in 
Figure 17. 
 
Figure 17: Sandpaper Lined Grip Face 
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5.2.2 Suture Retention 
This test was performed using the same protocol as described in section 5.1.2. One 
change was made to ensure the loose ends of the suture would not slide out of the grips. The 
suture was knotted in a square knot around a ring, as seen in Figure 18, so that slippage would be 
eliminated. Sandpaper was also used on the lower grip to prevent the sample from slipping out. 
 
Figure 18: Ring for Suture Retention Test 
5.2.3 Suturability 
Suturability testing measures the force required to puncture the patch with a suturing 
needle, see detailed protocol in Appendix M: Suturability Testing Protocol. Samples were placed 
over a custom made base to support the material during testing as seen in Figure 19 and Figure 
20. A suturing needle is placed in the top grip of the Instron testing machine and was advanced 
downwards at a rate of 2mm/s. Force data was acquired until the suture needle penetrated the 
sample as determined by a sharp decrease in the measured force along with visual inspection. 
The maximum force recorded before this sharp decrease is recorded as the patch penetration 
force.  
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Figure 19: Suturability Base Top View 
 
Figure 20: Suturability Base Side View 
.  
5.3 Cell Culture 
The migration and proliferation experiments in the following sections were performed 
using human mesenchymal stem cells (hMSCs; Cambrex). Cells between passages 9 and 12 were 
cultured in Dulbecco's Modified Eagle's Medium (DMEM; Invitrogen) supplemented with 10% 
fetal bovine serum (Invitrogen) and 1% penicillin/streptomycin (Invitrogen). The cells were 
incubated in T75 tissue culture treated flasks (Falcon) at 5% CO2 and 37° C and the media was 
replaced every 3-4 days. To detach the cells from the tissue culture flasks, 5mL of 0.25% trypsin 
(Invitrogen) was added for approximately 5 minutes or until the cells were visibly detached. The 
proteolytic action of the trypsin was stopped by adding 5mL of DMEM and thoroughly rinsing 
the surface of the flask with this solution to ensure that all cells were dislodged. The cell 
suspension was then transferred to a 15mL conical tube and centrifuged for 5 minutes at 1000 
rpm. The supernatant was decanted and the cell pellet was resuspended in DMEM. To determine 
the number of cells, 10µL of the cell suspension was added to 50µL trypan blue (Invitrogen) and 
40µL phosphate buffered saline solution and the number of viable cells was counted using a 
hemocytometer. Additional DMEM was added to the cell suspension to achieve the desired 
concentration of cells. 
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5.4 Production and Testing of Filler Material 
Fibrin, the material that we have chosen to use as our filler material, can exist in many 
different forms and has a wide range of properties based on the methods of production. In order 
to develop the optimal form of fibrin with the properties best suited for the regeneration of 
myocardium, we are producing fibrin using several different methods. Each method will be 
evaluated based on the migration and proliferation of cells in the material as defined by our 
specifications. 
5.4.1 Manufacturing of Fibrin Glue 
The method for producing fibrin gel was based primarily on methods used by Tuan et al. 
[63] and Silver et al. [64]. Fibrinogen from bovine plasma ~60% protein (~95% clottable) and 
thrombin lyophilized powder from bovine thrombin, 40-300 NIH units/mg were purchased from 
Sigma-Aldrich. Anhydrous calcium chloride was acquired from Sigma-Aldrich. FibriJect fibrin 
adhesive applicators were generously donated by Micromedics, Inc. Step-by-step protocols can 
be found in Appendix N. 
Thrombin was resuspended in a 9:1 solution of HEPES buffered saline (HBS) and H2O to 
a concentration of 40 U/ml and sterilized by passing through a 0.22 !m syringe filter. Thrombin 
was stored at -20ºC until use. Upon use, the thrombin was warmed and mixed 1:1 with a sterile 
40 mM CaCl2 solution to yield the final concentrations of 20 U/ml thrombin and 20 mM CaCl2 
in HBS. The thrombin concentration was chosen because low thrombin concentrations produce 
gels with thicker fibrin strands and larger pores than higher thrombin concentrations [65]. This is 
desirable to encourage cell migration through the gel. Lower thrombin concentrations also 
contribute to an increased ultimate tensile stress and stiffness [66]. A final concentration of 20 
U/ml is still active enough to provide a relatively rapid gelling time [64]. The 20 mM CaCl2 
serves to catalyze the fibrin polymerization reaction. 
Fibrinogen was resuspended in HBS with a pH of 7.4 at a fibrinogen concentration of 30 
mg/ml. The solution was prefiltered by passing through a 0.45 !m syringe filter to remove large 
particulates, followed by a 0.22 !m tissue culture vacuum filter. Fibrinogen was stored at -20ºC 
until use; final dilutions of fibrinogen were diluted using HBS. The final fibrinogen/fibrin 
concentrations that were tested were 3, 5, and 9 mg/ml. 3 mg/ml was chosen because it is close 
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the normal physiological concentration of fibrinogen in the plasma [67]. Brown et al. [68] also 
found that a fibrinogen concentration of 3 mg/ml allowed fibroblasts to migrate optimally. Ho et 
al. [52]found that a fibrin concentration of 5 mg/ml provided maximal proliferation of 
mesenchymal stem cells in a 3D clot formation, while a separate study by Benaïd et al. [69] 
found that proliferation of seeded mesenchymal stem cells was optimized at 9mg/ml. Although 
these two studies did not take migration into account, proliferation of mesenchymal stem cells is 
also vital to the success of this project. 
Due to the limitations of this project we were unable to obtain the synthetic peptides or 
other resources necessary to conjugate heparin to a fibrin matrix. We were also unable to obtain 
G-CSF due to budget constraints for our project. 
5.4.2 Migration 
A migration assay was performed based on the methods described by Clark et al. [70]. 
The migration of fibroblasts from normal dermal tissue into a clot region was modeled by 
seeding fibroblasts into a collagen gel to represent the dermis and surrounding it with an 
unseeded fibrin gel to represent the clot. The cells were not stained and the assay was designed to 
be non-terminal to allow limited resources to be used for as many samples as possible. This 
method was adapted for our uses to model the migration of cells from the bloodstream into the 
fibrin gel implant. The fibrinogen concentration of the seeded gel was the same as the lowest 
concentration used to measure migration, and close to the physiological concentration in human 
blood [67] at 3 mg/ml fibrinogen. An unseeded fibrin gel was used to model our regenerative 
filler material. The concentration of this gel was varied in order to find an optimized 
concentration. In this adapted scenario, rather than measuring cell migration from one material to 
a different material, migration was measured between different concentrations of the same 
material.  
hMSCs were chosen to model to mobilized bone marrow cells for the migration assay. 
Please refer to Appendix O: Migration Testing Protocols for the complete protocol. Both 
Greiling et al. [71] and Clark et al. [70] seeded collagen scaffolds with cells at a concentration of 
106 cells/ml, therefore the same concentration was used for our assay. Another important 
consideration is the thickness of the sample, since this affects the perfusion of oxygen and 
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nutrients, the amount of material required, and the ease with which the sample can be imaged. 
Greiling et al. [71] used 0.6 ml samples that were approximately 2.4 mm thick when they were 
first formed. Although these dimensions are for the gel before it contracted, they provide a good 
approximation of what thicknesses are appropriate and we will therefore use them for our 
procedure. Refer to Appendix P: Calculations for Migration Assay. 
To form the inner and outer gels, 8 mm circles were scored in the bottom of standard 16 
mm diameter 12-well tissue culture plates using a etching tool and a circular template. The plate 
was then thoroughly washed in 70% ethanol and sterile H2O to remove any plastic particles. The 
fibrinogen solution and thrombin solution were each loaded into one syringe of a FibriJect fibrin 
adhesive applicator (Micromedics). An equal volume of each solution was then dispensed 
simultaneously through the blending applicator tip. A total of 800 !l mixed fibrinogen/thrombin 
solution was dispensed into the outer ring of the well. The outer ring of fibrin was allowed to 
polymerize, and 300 !l of the seeded solution was dispensed into the inner ring.  
The samples were analyzed by measuring the distance from the boundary between the 
seeded and unseeded gels to the farthest cell at 5 randomly selected locations. A limitation of this 
approach is that it is not an accurate measure of the actual migration of the cells since it is not 
possible to determine if the cells in the unseeded gel migrated from the seeded gel or if they are 
the result of the proliferation of cells which previously migrated into the unseeded region. A 
more accurate way to express this data would be as the spreading of cells from the seeded gel 
into the unseeded gel. Although an assay which strictly measures migration would be preferred 
from an experimental point of view, cell spreading will be sufficient for our purposes because we 
are interested in characterizing the ability of cells to populate the implanted gel. 
Samples were analyzed using light microscopy with a Nikon Eclipse TS100 inverted 
microscope at 10X magnification. Four images of each gel were acquired at each time point 
using a RT Color Spot camera system and Spot imaging software (Diagnostic Instruments, Inc.). 
The locations for the images were randomly chosen and were independent at each time point. 
The focal depth for all analyzed images was set at 184 !m above the score mark for each well. 
The distance in pixels from the external edge of the score mark to the centroid of the farthest cell 
in each image was measured using ImageJ software. This distance was then converted to 
micrometers using a scale determined by observing a micrometer at the same magnification. 
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5.4.3 MTS Assay: Viability 
The MTS assay (CellTiter 96® AQueous One Solution Reagent; Promega) is a 
colorimetric method based on the reduction of a tetrazolium compound into a purple formazen 
dye by mitochondria. The concentration of this dye is thus directly proportional to the total 
metabolic activity of the cells. The manufacturer’s protocol specifies that MTS solution be added 
directly to the cell culture media of each sample at a ratio of 1:5 and incubated for 1-4 hours 
before reading the absorbance at 490nm.  
To determine the incubation time that would be best suited to these experiments, 15,000 
hMSCs were placed in 8 wells of a 96-well plate and cultured for 3 hours to ensure that they 
were confluent. Short incubation times increase the ease with which the experiment can be 
performed, and thus 1 and 2 hour incubations were compared. MTS solution was added to all of 
the wells, and the absorbencies of four of the wells were recorded after 1 hour and the 
absorbencies of the other four wells were measured after 2 hours. A qualitative assessment of the 
absorbencies at both time points was made to determine whether the increase in absorbance 
signal at a longer incubation time was appreciable enough to warrant its use.  
To develop a conversion between absorbance and cell number a standard curve was 
created by seeding hMSCs into a 96-well plate at a range of different concentrations as shown in 
Table 13. Three wells of each concentration were made. After a 3 hour incubation in media, 
20µL of MTS solution was added and the samples were incubated for 2 hours before recording 
the absorbance at 490nm.  
The absorbance for each concentration was reported as the mean ± standard deviation of 
the three wells. The absorbance values were plotted against the known cell number and fit to a 
linear equation to determine a general relationship which would allow a conversion between 
absorbance and cell number. 
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Table 13: Range of concentrations used for standard curve 
Plate Well Concentration (cells/mL) Cells/well (0.1mL) 
A 500,000 50,000 
B 375,000 37,500 
C 250,000 25,000 
D 187,500 18,750 
E 125,000 12,500 
F 62,500 6,250 
G 31,250 3,125 
H 0 0 
 
Fibrin gels were formed as described previously by placing 25!L of thrombin solution in 
the appropriate wells of a 96-well plate. Twenty-five microliters of fibrinogen solution were then 
added and pipetted up and down several times to ensure that the two solutions were completely 
mixed. Seeded fibrin gels containing 15,000 hMSCs were formed as well as gels containing no 
cells. The final fibrinogen concentrations of 3 mg/mL, 5 mg/mL, and 9 mg/mL were 
investigated. The gels were allowed to solidify for 2 hours before adding media. The day 0 gels 
were incubated in media for 1 hour before adding MTS solution and incubating for 2 hours. One 
hundred microliters was then transferred from each well into a new 96-well plate and the 
absorbance was recorded at 490nm.  
Veritas and UBM were seeded with hMSCs by placing a 30µL drop containing 15,000 
cells onto the center of 1cm x 1cm samples in a 24 well plate. Positive control wells containing 
only hMSCs were also made. The samples were placed in the incubator for 2 hours to allow the 
cells to attach before adding 300µL of DMEM. After an additional 1 hour incubation, 60µL of 
MTS solution was added directly to the media. The samples were incubated in the MTS solution 
for 2 hours before transferring 100µL of solution from each sample to a 96-well plate and 
recording the absorbance at 490nm.  
Correction for background absorbance was performed by recording the absorbance at 
each time point in control wells containing only culture medium or samples with no cells. 
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Corrected absorbance was determined by subtracting the average background absorbance of each 
material from the absorbance recorded for each experimental data point. Absorbencies were 
reported as the mean ± standard deviation of the corrected absorbencies and converted to cell 
number using the standard curve. 
5.5 Statistical Analysis 
Statistical difference between groups was analyzed using ANOVA with a Bonferroni post 
hoc correction (SPSS). Significance was established for p < 0.05. 
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Chapter 6: Results and Analysis 
This chapter describes the outcomes of the procedures outlined in the Methodology 
chapter.  
6.1 Endocardial Patch Preliminary Testing 
The results and analysis of the preliminary testing provide an initial screen of materials to 
assess whether or not each material meets or fails the critical specifications. Those materials that 
pass this round of testing will continue to Characterization Testing where they will be further 
tested against the remainder of the specifications.  
6.1.1 Suture Retention 
The collagen membranes were eliminated from testing due to their qualitatively fragile 
properties. Placing a suture through the membrane caused it to immediately tear and the 
membranes fell apart into multiple pieces upon cutting them out of their support frames. Based 
on these results it can be concluded that the collagen membranes, in their present state, would not 
act as a good cardiac patch and thus were not tested any further. 
The ability of the Veritas, UBM, and Hemashield to retain a suture under force is shown 
in Figure 21. All three materials passed the specification force of 2.74 N as shown by the solid 
specification line. Table 14 summarizes the maximum force and modulus for each material. Two 
UBM samples were tested, however, due to a software error data from only one sample was 
available for preliminary analysis. 
 Table 14: Suture Retention Results 
 
 
 
 
 
*data is presented as mean + stdev, data available from only one UBM sample  
 
  Maximum Force (N) Modulus (N/mm) Mode of Failure 
Specification 2.76 - - 
Veritas 4.58+0.54 0.61+0.12 
all samples: suture 
slipped from grip 
UBM* 4.05 0.34 
all samples: material 
slipped from grip 
Hemashield 4.53+0.29 0.55+0.04 
all samples: suture 
slipped from grip 
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Figure 21: Suture Retention Preliminary Data 
 
The maximum force in Table 14 shows a convergence of all materials at a force between 
4 and 5 N. This is due to a defect in the testing method. The loose ends of the suture were 
secured in the top grip in testing setup as seen in Figure 22. During testing the suture ends began 
to slide out from between the grip between 4 and 5N, therefore no sample experienced more 
force than this. Once the suture began to slip, the force fluctuated around this range. Even with 
this defect, the preliminary data showed that all three materials passed the specification since the 
material retained the suture beyond the specification line even while the suture was slipping from 
the top grip. The procedure was altered for characterization testing to ensure that the true suture 
retention strength of the materials can be measured.  
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Figure 22: Gripping of Suture in Preliminary Testing 
 
The moduli in Table 14 represent the slopes of the graph of each material between 2mm 
and 8mm extension. Since the stretching of the suture accounts for most of the strain that was 
observed, these moduli are fairly similar to each other. Any difference that exists is due to the 
small amount of material that is stretching as the suture applies force to it. The elastic modulus 
calculated for UBM is lower than that of Hemashield and Veritas. This is likely due to there 
being only one UBM sample, thus preventing a truly representative sampling, and that this 
material slid out of the lower grip during testing as opposed to having the sutures slide from the 
top grip.  
6.1.2 Strength/Strain 
Figure 23 depicts the force versus strain data for each material in the strength/strain 
preliminary test. Crosshead strain was normalized to local strain using image analysis (Appendix 
Q: Transformation of Strength/Strain Preliminary Data). Table 15 summarizes the important 
parameters, including the ultimate tensile strength and strain at the specification force.  
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Figure 23: Strength Strain Preliminary Results 
 
Table 15: Summary – Strength/Strain Preliminary 
Material 
Maximum 
Force (N) 
Strain at Specification 
Force (%) 
Specification 4.11 5 to 15 
UBM 7.98+1.30 12+3 
Veritas 12.7+1.6 5+2 
Hemashield 18.6+7.4 10+3 
 
All materials passed the force specification of 4.11 N and are generally within the stretch 
specification range (5 to 15%). The Veritas, in blue, is very close to the low end of the 
specification range but it will be kept for further testing since one of the samples was within the 
range.  
6.2 Endocardial Patch Characterization Testing 
The results obtained from the characterization testing of each material will allow us to 
obtain a more thorough understanding of how the material will respond in the cardiac 
environment. This testing covers the following three tests: 
• Suture retention 
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• Uniaxial strength and strain 
• Suturability 
6.2.1 Suture Retention 
The suture retention of all materials is summarized in Table 16 and Figure 24. The test 
method was successfully modified from the preliminary methodology in that all samples 
experienced either material failure or failure of the suture. All materials again passed the force 
specification of 4.11 N as expected, however the failure strength is not statistically different 
based on analysis of variance (Appendix R: Suture Retention Statistical Analysis).  
 
Table 16: Summary - Suture Retention Characterization 
Material Max Force (N) Mode of Failure 
Specification 2.76 - 
UBM 7.47+1.48 
2 samples: suture broke, 1 
sample: material failure 
Veritas 6.12+0.94 all samples material failure 
Hemashield 7.69+0.69 all samples suture broke 
 
 
 
Figure 24: Suture Retention Characterization 
6.2.2 Strength/Strain 
Figure 25 depicts the force versus strain data for each material in the strength/strain 
characterization test. The solid lines show an average linear fit of all samples of each type of 
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material (n=6 for UBM and Veritas, n=3 for woven fabric). Crosshead strain was normalized to 
local strain using image analysis (Appendix S: Transformation of Strength/Strain 
Characterization Data). Table 17 summarizes the important parameters, including the ultimate 
tensile strength and strain at the specification force. 
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Figure 25: Strength Strain Characterization 
 
Table 17: Summary – Strength Strain Characterization 
Material 
Maximum 
Force (N) 
Strain at Specification 
Force (%) 
Specification 4.11  5 to 15 
UBM 7.7+0.7 11.0+1.8 
Veritas 10.5+0.7 6.5+0.3 
Hemashield 37.7+4.1 6.4+0.7 
 
All materials passed the force specification of 4.11 N as expected and are within the 
stretch specification range (5 to 15%). Statistically, there is no difference between the strain at 
specification for Veritas and Hemashield as determined by ANOVA with a Bonferroni post-hoc 
test (Appendix S: Transformation of Strength/Strain Characterization Data).  
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6.2.3 Suturability 
The maximum recorded force needed to insert the suture needle in the patch materials is 
summarized in Table 18. The force needed to insert the suture needle into the patch materials 
was established as the maximum recorded force until the needle completely passed through the 
patch material. The maximum force required to insert the suture needle in the patch materials 
was lower than 5N for each patch material.  
Table 18: Summary - Suturability 
Material Maximum Force (N) 
Specification 5 
UBM 0.95+0.08 
Veritas 0.71+0.23 
Hemashield 0.76+0.14 
 
6.3 Filler Material 
 The results obtained from the testing of each formulation of fibrin gel was intended to 
test the suitability of fibrin gel as a filler in the composite scaffold design. We also wished to 
optimize the formulation of the fibrin gel for this application by testing gels containing several 
different fibrinogen concentrations. 
6.3.1 Migration 
Initially we planned to run preliminary assays to optimize a fibrinogen concentration for 
hMSC and endothelial cell migration and proliferation. Following this, we planned to conduct 
studies using different concentrations of G-CSF in the fibrin gels. However, we were unable to 
obtain G-CSF for the project due to budgetary constraints. Media for culturing endothelial cells 
was ordered but did not arrive in time to be utilized in this project.  
The initial hMSC migration assay was intended to provide only preliminary data and was 
conducted with a sample size of three. The results of this migration assay are shown in Figure 26 
and are expressed as the average distance +/- the standard error of means (SEM) of the farthest 
cell from the score mark at various time points. An experiment was run with time points taken at 
days 1, 3, 6, and 9. This assay showed no significant migration of cells at the time points 
observed for any of the fibrinogen concentrations tested (ANOVA, p > 0.05). A full 
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characterization assay was begun with sample size of five (data not shown), however bacterial 
contamination was observed after one day and the experiment was terminated. In the initial 
experiment (Figure 26), measurements were not taken at day 0, leaving the possibility that cells 
were migrating between day 0 and day 1, but not after day 1. To test this possibility, a third 
experiment was initiated with sample size of five to measure migration distance starting at day 0. 
A fibrinogen concentration of 5 mg/ml was used since this concentration showed the greatest 
distances in the initial experiment. Figure 27 shows the measured distance of hMSCs from the 
score mark in fibrin gel at a fibrinogen concentration of 5 mg/ml at days 0 and 1. On day 1 of 
this experiment contamination was observed once again, likely fungal in nature, however we 
were still able to obtain measurements from unaffected areas and uncontaminated wells for day 
1. The results revealed no significant migration between days 0 and 1 (p < 0.05). At this point, 
the decision was made not to pursue the hMSC migration experiments any further. 
 
Figure 26: hMSC distance from score mark in fibrin gel at days 1-9 
 
Figure 27: hMSC distance from 
score mark in fibrin gel at days 0-1 
6.3.2 MTS Assay 
 This section validates the use of the MTS assay in this study, reports the results obtained, 
and discusses their significance. Figure 28 compares the absorbance from wells containing 
hMSCs at 1 and 2 hours. The absorbance for the hMSCs increases 60% from 0.928 ± 0.043 at 1 
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hour to 1.488 ± 0.130 at 2 hours. Because of this substantial increase in absorbance, an MTS 
solution incubation time of 2 hours will be used.  
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Figure 28: Optimization of Incubation Time (n = 4) 
 
 The absorbencies from wells containing known numbers of hMSCs are plotted in Figure 
29. This curve is one representative of the standard curves which are created for each new 
experiment which was performed. The equation of the trend line which is fit to the data points 
was used to calculate the number of cells corresponding to each recorded absorbance.  
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Figure 29: Standard Curve (n = 3) 
 
Figure 30 shows the number of cells estimated from the absorbencies recorded at 0, 1 and 
4 days. Data is presented as mean ± SD. 
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Figure 30: Cell viability (n = 3) 
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A representation of this data as the percent increase in number of viable cells from the 
number measured at day 0 is given in Figure 31. Data is presented as mean ± SD and the (*) 
indicates significant statistical difference between Day 1 and Day 4. This figure shows that both 
Veritas and UBM had a statistically significant increase in the number of viable cells at Day 4.  
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Figure 31: Increase in number of viable cells (n=3) 
 
The statistically significant differences between the materials are indicated in Table 19. 
 
Table 19: Comparison of percent increase in number of viable cells  
 Day 1 Day 4 
 
3
m
g
/m
L
 
5
m
g
/m
L
 
9
m
g
/m
L
 
U
B
M
 
V
er
ita
s 
P
la
stic 
3
m
g
/m
L
 
5
m
g
/m
L
 
9
m
g
/m
L
 
U
B
M
 
V
er
ita
s 
P
la
stic 
3mg/mL ···   *  * ···    *  
5mg/mL  ···  * *   ···   *  
9mg/mL   ··· *  *   ···  *  
UBM    ··· *     ··· *  
Veritas     ··· *     ··· * 
Plastic      ···      ··· 
* 
* 
 62 
 
The results from a further experiment which examined the number of viable cells in fibrin 
gels over a time period of two weeks are shown in Figure 32. Data is presented as mean ± SD. 
 
0
10000
20000
30000
40000
50000
60000
3 mg/mL 5 mg/mL 9 mg/mL Plastic
C
e
ll
 N
u
m
b
e
r
Day 0
Day 1
Day 4
Day 7
Day 14
 
Figure 32: Cell viability in fibrin gels (n = 4) 
 
 A representation of this data as the percent increase in number of viable cells from the 
number measured at day 0 is given in Figure 33. All materials exhibited a statistically significant 
increase in number of viable cells at Day 7. The fibrin gels containing 9mg/mL of fibrinogen 
also had a statistically significant increase at Day 4. Data is presented as mean ± SD and the (*) 
indicates significant statistical difference from previous time point. 
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Figure 33: Increase in number of viable cells in fibrin gels (n = 4) 
 
Table 20 shows the statistically significant differences between the materials at each of 
the time points.  
 
Table 20: Comparison of percent increase in number of viable cells  
  Day 1 Day 4 Day 7 Day 14 
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Chapter 7: Discussion 
This chapter serves to interpret results of both the endocardial patch testing and filler 
material testing. The analysis of both of these components will aid in assembling the best 
possible composite scaffold with appropriate properties for myocardial regeneration. 
7.1 Endocardial Patch 
The mechanical testing performed in this project begins to characterize each of the 
candidate materials to quantitatively assess their ability to serve as the patch component of a 
composite scaffold.  
No statistical difference existed between the suture retention failure strengths of any of 
the three materials tested. Photographs of a sample of UBM and Veritas from this test are shown 
in Figure 34A-F. Images A and D were taken at the specification force, B and E were taken at 
failure, and C and F are detailed views of the sample after failure. These two materials exhibited 
different mechanisms of failure. The suture created a large hole in the UBM until either the 
suture or the UBM broke. Veritas, however, conformed to the suture until maximum force, at 
which the suture simple rips out of the material. Figure 34E shows that at failure, parts of the 
Veritas still cling to the suture even after the suture has pulled out of its original insertion point.  
Since the UBM plastically deforms to create large holes, it is important to understand at what 
point this begins to happen. It is not readily apparent from the pictures that were taken whether 
or not there is any hole present at the specification force. Therefore a more through assessment 
would be necessary before implantation in patients, especially since there have been incidents of 
single layer UBM failing in the heart in animal studies [6].  
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Figure 34: Suture Retention Modes of Failure: UBM and Veritas 
The strength/strain characterization test confirmed the results of the preliminary testing in 
that all of the materials met the predefined specifications. There are differences in the two data 
sets, but this can be attributed to improved testing methods during characterization testing as 
opposed to preliminary testing. There was no slipping of the material between the grips when 
they were lined with sandpaper and the gage length of the sample was more accurately measured. 
The Hemashield samples did not fail, which matched our expected results since this is a very 
strong woven material. However, the results did not show the level of stiffness that was expected 
of a woven synthetic heart patch. One possible explanation for this is that the specific 
Hemashield material that was tested was designed to be a vascular graft.  
Veritas demonstrated a strain response that fell completely within the specification, but 
on the lower end of the range. It was also not statistically different from the high end control 
Hemashield. In order for the endocardial patch component of this design to improve upon 
existing endocardial patches, the material should be more compliant than current synthetic 
materials. UBM was statistically different from both Veritas and Hemashield with 11% stretch at 
the specification force. However, the question still remains whether or not strain at the 
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specification force, as measured in this test, will translate to the correct material properties in 
vivo. The specification force incorporates a safety factor of 5, a higher force than a typical 
endocardial patch would experience during loading in the heart. Further testing would have to be 
conducted to understand the properties of this material at realistic contractile forces.  
The suturability results demonstrated that all the patch materials, UBM, Veritas and 
Hemashield, had needle insertion forces significantly lower than the set specification of 5N 
(Appendix T). The order of magnitude of the measured insertion forces was very small and the 
force measurements made during this experiment had a low signal-to-noise ratio because the 
load cell was not sensitive enough to accurately measure the required forces. This force 
measurement noise can be seen in Figure 35. This data cannot be used to accurately describe the 
actual needle puncture force but it does demonstrate that all materials passed the specification.  
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Figure 35: Suturability Data 
 
7.2 Filler Material 
The results of the migration assay showed a remarkable uniformity of distance 
measurements within each fibrinogen concentration, but high baseline variability between 
different concentrations. One possible explanation for this is that the concentration of fibrinogen 
affected the viscosity of the fibrinogen solution as it was injected into the well, thus altering the 
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manner in which the gels initially formed and the resulting conformation within the well. 
However, this would lead one to expect that the 3 mg/ml sample would be the least viscous, and 
would therefore flow the farthest outside of the score mark. This is not what was observed 
experimentally, as the 5 mg/ml samples generated the greatest baseline distance from the score 
mark to the farthest cell. At this point we are unsure of the exact cause of this baseline 
variability. The results from the third experiment (Figure 27) were inconsistent with the high 
distance response observed at 5 mg/ml fibrinogen in the initial assay. This is likely due to the 
complexity of the procedure.  
The data obtained from the MTS viability assay show that cells remain viable in fibrin 
gels for up to 14 days and is consistent with previous studies [72]. The lack of increase in cell 
number between days 7 and 14 in the 9 mg/ml sample is not surprising and is consistent with the 
behavior of hMSCs grown on tissue culture plastic which normally reach confluency in 7-10 
days. At day 0 the number of cells in the fibrin gels measured by the MTS assay was 
significantly less than the actual number of cells placed in the material. This difference in 
number of viable cells was not observed on the tissue culture plastic and might be brought about 
by an initial lack of adherence of the cells in the fibrin gels. Another possible cause for this 
might be that the fibrin gel itself interferes with the diffusion of the MTS solution and the 
formazen dye that it is converted into. Normally the cells are directly in contact with the media 
and MTS solution, therefore when it is converted into formazen dye, the dye is again directly 
transferred into the media. However, when the cells are in fibrin gels, the MTS solution must go 
through the fibrin gel before contacting the cells. So then the formazen dye must also go through 
the fibrin gel to get back out to the media where it can be detected. This may be responsible for 
the decrease in formzen dye in the media rather than the lack of viable cells. However, the cells 
in the fibrin gels subsequently had a significant increase in cell number with final counts over 6 
times that of the initial cell number. In contrast, the final cell number for hMSCs on plastic was 
about twice that of the initial cell number. Despite the fact that the increase in cell number was 
greater for the fibrin gels than for the plastic, the overall number of viable cells on plastic was 
higher at all time points. The parameter of most interest to us in this project was not the overall 
number of cells present in the material but the rate of increase in cell number over time. Thus 
fibrin gel was considered to have a superior cell response compared to tissue culture plastic since 
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the increase in number of viable cells was greater.  
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Chapter 8: Conclusions 
Based on the testing and analysis outlined in the previous chapters, several conclusion 
can be formed that summarize our efforts towards the design of a composite cardiac scaffold.  
Both Veritas and UBM have appropriate suture retention, strength/strain, and suturability 
properties for cardiac patch applications as defined by our specifications. The only significant 
differences between the materials exist in their strain properties. This is an important quality of 
an endocardial patch material and merits further examination to determine if both materials are 
indeed appropriate for the environment of the heart.  
From the data shown in Figure 26 and Figure 27, we conclude that hMSCs do not migrate 
in fibrin gel alone at fibrinogen concentrations of 3-9 mg/ml. This suggests that fibrin gel may 
not be an ideal scaffold filler material for this design, and that other materials should be tested in 
order to compare the results with those from the fibrin gel. Another approach would be to add 
growth factors to the fibrin gel in an effort to increase migration. It must also be considered 
whether hMSCs are a good model for the mobilized bone marrow cells that we hope to produce 
under actual in vivo conditions. It is possible that clinical results could differ significantly from 
our observations using this limited model for cellular migration. 
Fibrin gels with any of the fibrinogen concentration tested here are well suited to support 
the viability of mesenchymal stem cells. This finding supports their use for the filler material 
application to promote viability of bone marrow cells. Given the strong viability data, but the 
absence of any evidence of migration, one possible approach would be to test the fibrin gel 
material as a carrier for cells to be seeded onto the surgical site. Instead of having to migrate into 
the gel, the cells would be able to proliferate inside, utilizing the high cell-binding affinity of 
fibrin gel. 
 Overall this testing has proven the initial capabilities of the selected materials. A 
significant amount of testing remains to be completed before full clinical applications can be 
realized, however this characterization presented here serves as a very important initial step 
towards the design of a composite cardiac scaffold. 
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Chapter 9: Recommendations 
The work presented here describes just the beginning of the characterization of a heart 
patch that takes a vital first step towards regeneration of myocardium. There are many areas that 
can be further investigated in order to continue the development of this design so that it can 
completely fulfill its functionality and make a difference for patients suffering from myocardial 
infarction.  
The results from testing the endocardial patch materials demonstrated that Veritas® and 
UBM had sufficient strength to hold heart pressure and stretched within the strain specifications. 
However, the tensile testing done in this project was limited to uniaxial testing. In order to ensure 
that the patch material has sufficient strength and strain properties when implanted in the heart, it 
is essential to perform multi-axial testing. This type of testing would ensure that the patch 
material is able to withstand the many different orientations of forces applied to it. Suggested 
multi-axial test methods include biaxial tensile testing and burst testing. It would also be 
advisable to perform fatigue testing to confirm the ability of the material to withstand the 
repetitive contractions it would experience once implanted in the heart.  
The results of the migration assays revealed no significant migration of hMSCs in fibrin 
gel. The next step in this area would be add G-CSF to the fibrin gels and see if migration is 
affected in any way. Past studies have shown that G-CSF acts as a chemotactic agent for human 
polymorphonuclear leukocytes [73] and have suggested the same for neutrophils 
specifically[74], however, to our knowledge no studies have examined the chemotactic effect of 
G-CSF on bone marrow or mesenchymal stem cells. It should be noted that one study has shown 
that G-CSF has been implicated in increased risk of ischemia for patients who suffer from 
coronary artery disease [75]. Future research may also seek to examine the possibility of seeding 
the fibrin gel with bone marrow or mesenchymal stem cells, or testing other candidate materials 
for applications in a composite scaffold. 
Seeing as this is a composite scaffold, it is also be important to study the interactions 
between the patch and filler component of this device. Degradation studies would estimate how 
long the patch and filler are able to stay at the site of implantation, as well as test if any toxic 
byproducts are released. Tests should also be done to characterize the ability of the filler material 
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to adhere to the patch material. Mechanical tensile testing would characterize the strength and 
strain in the composite and ensure that the filler material does not adversely effect mechanical 
properties of the patch material, such are reducing its elongation capacity.  
The ultimate test to demonstrate the efficacy of this design would be in vivo testing of the 
combined patch and filler device. In vivo testing could be done on an animal model such as a rat, 
by excising a full thickness portion of the ventricle wall and replacing it with the composite 
device. The patch would first be sutured similar to current patches, and the filler would be 
injected on top of the patch to fill the full thickness of the myocardium. Upon explantation after 
at least eight weeks, the patch and heart should be examined for several different characteristics. 
Angiogenesis, the formation of new blood vessels, is essential to new tissue growth, so the patch 
should be stained to measure the microvessel density and observe the presence of new blood 
vessels [28, 30]. Degradation of the device components should be analyzed macroscopically to 
see how much degradation occurs over the time of implantation, with special attention paid to 
degradation as it relates to the mechanical stability of the implant [28]. Scar tissue formation 
should also be analyzed macroscopically for abscess formation, fibrotic encapsulation, and 
calcification, all of which would be detrimental to the development of new heart tissue [6]. 
Thrombus formation could also be detected by examining the endoventricular side of the patch 
for blood clots. The presence of blood clots would indicate the need to further investigate the 
blood compatibility of the materials [6]. Finally, the inflammatory response can be measured by 
staining for the presence of inflammatory cells such as macrophages, lymphocytes, and 
fibroblasts [28, 30].  
Upon the successful evaluation of this device in rats, it could then be implanted in larger 
animal models such as a dog or pig heart, as these more closely mimic the human heart. This 
study would concentrate on two main outcomes: regional contractility and the presence of 
myocytes. Regional work is an important assessment because it measures whether or not the 
implanted patch is contributing to the work of the heart during contraction. This can be measured 
by placing markers on the patch and analyzing the change in area of the patch region as 
compared to the native myocardium [9]. Finally, staining for the presence of myocytes indicates 
how the patch is inducing regeneration of the myocardium. By staining with Connexin-43, the 
gap junctions of the myocytes will be visible and their orientation and presence in the device can 
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be analyzed. 
Overall, the results from the patch and filler material characterization in this project were 
a crucial stepping stone towards the development of a new composite cardiac scaffold. While 
research done in this project is not a complete validation for using this composite scaffold in a 
clinical setting, it provides a strong foundation for future development of a therapy for 
ventricular restoration and myocardial regeneration.  
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Appendix A: Interview with Dr. Nicola Francalancia 
1. Cardiothoracic surgeon, PSU, JHU, 1997 
a. Research and surgery, sternum project 
2. our project background 
a. patch for aneurysm excision surgery – actually help regenerate myocardium 
3. aneurysm is a small piece of what cardiology field is 
4. under what circumstances would you cut hole 
a. ventricular aneurysm: unusual thin 
b. HF more common 
c. Look for some treatments for HF 
i. Ventricular restoration – failing in all other ways 
ii. Cutting out doesn’t always work 
iii. Need to correct geometry to get anything to work 
iv. Cut out and replace and need to maintain new geometry 
1. Dacron patch – endoventricular patch and then reconstruct the 
outside 
d. Patch inside, close outside, remodel 
5. overall reluctance: big jump from value op to cutting ventricle 
a. time and risk 
b. heart failure is still a medically treated disease 
6. mechanical, modeling, vasculature, myocardial regeneration  
a. ladder 
7. ventricular restoration 
a. infarcted – hypokinetic, a kinetic 
b. will replace areas no with no aneurysm, just infarct 
c. viable tissue – new blood flow supply, doesn’t work, recovers hibernating 
myocardium 
d. patch inside to maintain inner volume 
e. suture to endocardial surface 
i. prolene sutures 
ii. cut patch 
f. free wall rupture, pericardium contained 
g. aneurysm – old, easy to suture to 
h. key is getting geometry back 
i. Baptiste – not specific to diskinetic region 
i. Muscle weakening – whole heart – cut out a lot and put it back together 
ii. Reduce the whole thing 
j. Denton Cooley – Jarvic 
k. Endoventricular patch – Dor 
8. Decision to cut out infarct 
a. Patient with heart failure – amiable to improving function then will 
b. Will go in only to cut out an infarct – ventricular restoration 
9. suturing – cut off blood supply to where it is attached 
a. strangulation: edge not going to do too well, want to distribute tension 
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b. want it to be connected 
c. glues – not always reliable for pressure for bonding 
i. glue contacting blood going to brain = not good 
ii. use glue in patients with clotting problems, glue holds 
iii. or for things not in direct contact with the blood stream 
10. electrical connections 
a. aneurysm surgery: arrhythmia management 
b. arrhythmia: border zone, electrophysiology, get rid of this section that is causing 
arrhythmia 
c. infarct over conductive 
11. patch procedure suturing 
a. hold – how patch? 
b. Cut out oval shape, patch – Dacron, sew all the way, " cm from edge sutures 
pulling 
c. Felt pieces cover next hold 
12. patch 
a. Hemashield – Dacron 
b. albumin – less porous 
13. Dacron: easy to use, super important to be able to cut, sew, bend 
a. Strength 
b. Biocompatibility 
c. Blood compatibility: endothelialize 
14. bovine pericardium 
a. packaged in rectangular sheets, cut it how you want 
b. easy to work with 
c. small pieces to stick on 
d. not flexible but more handelability 
i. no crunching or cracking 
ii. hold sutures 
e. Dacron better – right kind of spring to it 
i. Pericardium: use when need something small 
1. 2 surfaces, shiny on one side 
15. cells – acceptance 
a. if it fills some need, better than it can 
b. hurdles 
i. biomaterial: FDA stuff 
ii. extraneous cells on something – active blood stream and growing 
iii. carcinogenic worries 
c. if it is useable and has demonstrated advantages 
i. improved ventricular function 
ii. have to show survival benefit – randomized clinically controlled trials 
iii. better than just plain without cells 
16. growth factors 
a. show that it makes a difference 
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i. blood vessels or is that worse/better than fixing geometry 
17. suture: how close together 
 
18. produce patch with monitoring 
a. don’t have a lot of applicability: studying natural history of patch – research 
b. no used In people 
c. markers 
d. follow patient with conventional methods – echocardiogram 
i. don’t distort MRI 
ii. can see which walls are moving and which aren’t 
iii. not high priority to see where you put it 
19. redo operations more complicated 
20. most important thing is functional results – want something that will be there 
21. region is electrically isolated, can come in over the top layer of tissue that was place back 
a. doesn’t have to conduct 
22. contraction 
a. biopatch that would beat – clinically no more desirable 
b. talking about having something beating, making it better through geometry not 
making spot beat again 
c. beating not priority but interesting for down the line applications 
23. secondary – incorporates into vascular tissue well 
a. put patient on blood thinners, worry of clotting 
24. next factors: use related, does it work with currently used remodeling tools 
25. deploy patch without surgery 
26. mitral valve regurgitation – when heart enlarging 
27. porosity – not very porous so doesn’t bleed through 
a. matters when not covering the other side with tissue because it can’t leak into the 
pericardium 
28. features over currently used 
a. various thickness and flexibility 
b. posterior have to lift heart 
c. easier way than suturing – method of attachment involving less surgery 
29. Dalin Tang FEM patch size 
a. Large parts without contraction making the rest of the heart work harder 
30. .ctsnet.org modified endoventricular 
a. Ventricular restoration: donato, Marisa 
b. Menicanti 
c. Show on eco that ventricular geometry is beginning to distort 
31. myocardial regeneration would have to be attributing to functional improvement 
a. regenerate muscle mass – help out 
b. regrown but still have decreased ventricular function long term: regenerate heart 
tissue to keep shape 
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Appendix B: Pairwise Comparison Charts 
Table 21: Pairwise Comparison Chart - Pooled 
Goals Marketable 
Easy to 
Produce 
Practical 
for Use 
in 
Surgery Contractile Regenerative 
Reliable 
Mechanical 
Properties 
Predictable 
Biomaterial-
Tissue 
Interactions Score 
Score 
+ 1 
(Score 
+ 
1)/40.1 
Marketable •••• 1.3 0.25 0.4 0.3 0 0 2.25 3.25 0.08 
Easy to 
Produce 0.3 •••• 0 0 0 0 0 0.3 1.3 0.03 
Practical for 
Use in 
Surgery 1.35 1.6 •••• 1.25 1.25 0.25 0.35 6.05 7.05 0.18 
Contractile 1.2 1.6 0.35 •••• 0.1 0 0 3.25 4.25 0.11 
Regenerative 1.3 1.6 0.35 1.5 •••• 0.1 0.6 5.45 6.45 0.16 
Reliable 
Mechanical 
Properties 1.6 1.6 0.85 1.6 1.5 •••• 1.4 8.55 9.55 0.24 
Predictable 
Biomaterial-
Tissue 
Interactions 1.6 1.6 1.25 1.4 1 0.4 •••• 7.25 8.25 0.21 
                  40.1 1 
 
 
Table 22: Pairwise Comparison Chart - Professor Gaudette 
Goals Marketable 
Easy to 
Produce 
Practical 
for Use 
in 
Surgery Contractile Regenerative 
Reliable 
Mechanical 
Properties 
Predictable 
Biomaterial-
Tissue 
Interactions Score 
Score 
+ 1 
(Score 
+ 
1)/28 
Marketable •••• 1 0 0 0 0 0 1 2 0.07 
Easy to 
Produce 0 •••• 0 0 0 0 0 0 1 0.04 
Practical for 
Use in 
Surgery 1 1 •••• 0.5 0.5 0.5 0.5 4 5 0.18 
Contractile 1 1 0.5 •••• 0 0 0 2.5 3.5 0.13 
Regenerative 1 1 0.5 1 •••• 0 0.5 4 5 0.18 
Reliable 
Mechanical 
Properties 1 1 0.5 1 1 •••• 1 5.5 6.5 0.23 
Predictable 
Biomaterial-
Tissue 
Interactions 1 1 0.5 1 0.5 0 •••• 4 5 0.18 
                  28 1 
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Table 23: Pairwise Comparison Chart - Professor Pins 
Goals Marketable 
Easy to 
Produce 
Practical 
for Use 
in 
Surgery Contractile Regenerative 
Reliable 
Mechanical 
Properties 
Predictable 
Biomaterial-
Tissue 
Interactions Score 
Score 
+ 1 
(Score 
+ 
1)/27 
Marketable •••• 1 0.5 0 0 0 0 1.5 2.5 0.09 
Easy to 
Produce 0 •••• 0 0 0 0 0 0 1 0.04 
Practical for 
Use in 
Surgery 0.5 1 •••• 1 1 0 0 3.5 4.5 0.17 
Contractile 1 1 0 •••• 0 0 0 2 3 0.11 
Regenerative 1 1 0 1 •••• 0 0.5 3.5 4.5 0.17 
Reliable 
Mechanical 
Properties 1 1 0 1 1 •••• 1 5 6 0.22 
Predictable 
Biomaterial-
Tissue 
Interactions 1 1 1 1 0.5 0 •••• 4.5 5.5 0.20 
                  27 1 
 
 
Table 24: Pairwise Comparison Chart - Design Team 
Goals Marketable 
Easy to 
Produce 
Practical 
for Use 
in 
Surgery Contractile Regenerative 
Reliable 
Mechanical 
Properties 
Predictable 
Biomaterial-
Tissue 
Interactions Score 
Score 
+ 1 
(Score 
+ 
1)/90 
Marketable •••• 2.5 0.5 2 1.5 0 0 6.5 7.5 0.08 
Easy to 
Produce 1.5 •••• 0 0 0 0 0 1.5 2.5 0.03 
Practical for 
Use in 
Surgery 3.5 4 •••• 3.5 3.5 0 0.5 15 16 0.18 
Contractile 2 4 0.5 •••• 0.5 0 0 7 8 0.09 
Regenerative 2.5 4 0.5 3.5 •••• 0.5 1 12 13 0.14 
Reliable 
Mechanical 
Properties 4 4 3 4 3.5 •••• 3 21.5 22.5 0.25 
Predictable 
Biomaterial-
Tissue 
Interactions 4 4 3.5 3 3 2 •••• 19.5 20.5 0.23 
                  90 1 
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Appendix C: Strength/Strain Protocol Calculations 
 
 
 
Figure 36: Strip of Heart Wall Showing Meridional Forces 
 
Source for cardiac data and dimensions: [50] 
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Appendix D: Suture Retention Protocol Calculations 
 
 Source for cardiac data and dimensions: [50] 
Source for distance between sutures: [76] 
 
( )( )( ) N/Suture 737.25m/suture 002.0m 017.0kPa 1.16                                
SFlhF suture,per  Force
m/suture 002.0mm/suture 2l suture,between  distance Estimated
5(SF)factor Safety 
mm 17h pressure,icular left ventrhigh  with patientsfor   thickness wallAverage
 
kPa 16.1   pressure,icular left ventrhigh  with patientsin  stress  wallMeridional
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=!!!=
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Crosshead speed: between 50 and 150 mm/min 
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Appendix E: Suture Insertion Force Calculation 
Source: [58] 
 
  
Force from DeBakey woven fabric = 510 grams
Assuming gravitional acceleration = 9.81 m/s2
Peneration force = mass! acceleration = 0.510 kg ! 9.81 m/s2 = 5 N
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Appendix F: Design Alternatives 
Design Alternative 1 
 
Figure 37: Design Alternative 1 
 
Components: 
 
• Endocardial Patch: 
o An endocardial patch sutured to the endocardial region, and is degraded once the 
differentiated myocytes can form a strong matrix to hold heart pressure.  
• Middle Squirtable Layers: 
o Hydrogel layer for angiogenesis induced from surrounding tissue 
o Middle layers is another hydrogel layer embedded with growth factors (G-CSF) 
for stem cell differentiation into myocytes 
o This layer should also degrade as new tissue id formed 
• Epicardial Patch: 
o Placed to hold the gel layers in place 
o Can be substituted with any left over Epicardial tissue 
Pros: 
• Stratified layers analogous to native tissue 
• Degrades to leave only natural tissue 
Cons: 
• Complex architecture 
• May be difficult to apply in surgery 
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Design Alternative 2 
 
Figure 38: Design Alternative 2 
 
Components: 
• Endocardial Patch: 
o An endocardial patch sutured to the endocardial region to hold heart pressure and 
remodel the shape of the ventricle. Its elastic modulus is similar to the 
myocardium to allow for flexibility. 
• Porous Filler: 
o Full thickness porous material miller to allow for angiogenesis and stem cell 
migration and differentiation. Pore size about 100um for stem cell and endothelial 
proliferation and migration 
• Epicardial closure: 
o The scaffold can then be closed up using the left over epicardium 
Pros: 
• Scaffold is able to fully interface with surrounding tissue 
• Many highly characterized scaffold materials to choose from 
Cons: 
• Shape of three-dimensional scaffold is not easily customized during operation 
• Compliance mismatch may cause motion of the scaffold within the ventricular wall and 
tissue damage
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Design Alternative 3 
 
Figure 39: Design Alternative 3 
 
Similar to Design Alternative 2, but instead of a porous filler, there can be an injectable 
hydrogel. This would allow for better spread of filled material in the void. The hydrogel can be 
made of fibrin glue and can incorporate growth factors for stem cell differentiation into 
myocytes. 
 
Pros: 
• Hydrogels are customizable to suit the purpose 
• Can include RDG binding domains, growth factors, etc. in the gel 
• Injectable design makes it easy to implant during surgery 
Cons: 
• Adhesion strength of the material may be limited
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Design Alternative 4 
 
Figure 40: Design Alternative 4 
 
Components: 
• UBM Endocardial Patch: 
o UBM patch sutured in for holding heart pressure and structural remodeling 
• Injectable Filler: 
o Injectable polymer hydrogel with growth factors and cell adhesion cites.  
o Degradable 
• UBM Epicardial Patch: 
o UBM patch sutured in for closing up the injectable gel filler. 
Pros: 
• Synthetic materials are easier and cheaper to mass produce 
• Complex polymer design 
• Injectable design makes it easy to implant during surgery 
Cons: 
• Synthetic materials do not have as high an affinity for cell ingrowth 
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• Design Alternative 5 
 
Figure 41: Design Alternative 5 
 
Please refer to figure for detailed explanation 
Pros: 
• Natural materials have natural cell-binding domain 
Cons: 
• Many growth factors complicates design, increases expense, and complicated passage 
through the FDA 
• Complex scaffold design may be difficult to manufacture 
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Design Alternative 6 
 
Figure 42: Design Alternative 6 
 
Components: 
• Endocardial Patch 
o Holds heart pressure and aids in remodeling 
o Epicardial side of the patch has material and chemical properties needed to attract 
stem cells and differentiate them into myocytes 
• Blood-filled space 
o The void over the endocardial patch is filled with blood 
o Epicardium is sewed over to close the void 
Pros: 
• Simple implantation procedure same as currently used techniques 
• One-piece design 
Cons: 
• Does not control the environment throughout the full thickness of the myocardium 
• Clot may lead to scar tissue formation 
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Appendix G: Metrics and Matrices for Evaluation of Design 
Alternatives 
 
This appendix details the evaluation of the design alternatives. Constraints and objectives 
from Section 4.2 that were applicable to the design of the scaffold are explained below in the 
context of metrics. The metrics create a scaling system to evaluate design alternatives and choose 
which one best fulfills our design criteria.  
 
Constraints 
 
Constraint: No thrombus or embolus formation 
Basis for Comparison: Ability of the design in general to be compatible with blood. Presence of 
crevices or opportunities to form blood clots would be evaluated as not meeting this constraint.  
Metric: Y (yes) or N (no) 
 
Objective: Cost effective 
Basis for Comparison: Will the design be in a reasonable cost range to produce and use? 
Incorporation of expensive techniques or complicated assembly would be evaluated as not 
meeting this constraint.  
Metric: Y (yes) or N (no) 
 
 
Main Objective: Similar Properties to Healthy Myocardium 
 
Objective: Contractile 
Basis for Comparison: Ability of the design to be conducive to redeveloping an area of 
contractile myocardium 
Metric: 0 for no ability, 1 for provides some ability, 2 for definite ability 
 
Objective: Regenerative 
Basis for Comparison: Ability of design to support new tissue growth into the replaced region 
Metric: 0 for no ability, 1 for provides some ability, 2 for definite ability 
 
 
Main Objective: Clinically Applicable 
 
Objective: Marketable 
Basis for Comparison: Ability of the design to be attractive for marketing  
Metric: 0 for no ability, 1 for provides some ability, 2 for definite ability 
 
Objective: Easy to Produce 
Basis for Comparison: Ability of the design to be easily manufactured, packaged, and stored.  
Metric: 0 for no ability, 1 for provides some ability, 2 for definite ability 
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Objective: Practical for Use in Surgery 
Basis for Comparison: Ability of the design to be easily used in current surgical procedures  
Metric: 0 for no ability, 1 for provides some ability, 2 for definite ability 
 
Main Objective: Safe for Patient 
 
Objective: Reliable Mechanical Properties 
Basis for Comparison: Ability of the design to provide the necessary mechanical stability to the 
heart  
Metric: 0 for no ability, 1 for provides some ability, 2 for definite ability 
 
Objective: Predictable Biomaterial-Tissue Interactions 
Basis for Comparison: Ability of the design to control the growth of new tissue in the 
implanted region  
Metric: 0 for no ability, 1 for provides some ability, 2 for definite ability 
 
 
 
 
Table 25: Evaluation Matrix for Design Alternatives Part 1 
                  
        Design 
 
 
Objectives  
& Constraints 
Weight 
Endocardial 
patch, growth 
factors, 
injectable gel 
Endocardial 
patch, seeded, 
injectable gel 
Endocardial 
patch, growth 
factors, void 
Endocardial 
patch, seeded, 
void 
C: No thrombus 
or embolus 
formation 
Y/N Y Y N N 
C: Cost 
effective 
Y/N Y Y - - 
O: Reliable 
mechanical 
properties 
(0.238) 2(0.238)=0.476 2(0.238)= 0.476 - - 
O: Predictable 
biomaterial-
tissue responses 
(0.206) 1(0.206)=0.206 1(0.206)=0.206 - - 
O: Practical for 
use in surgery 
(0.176) 2(0.176)=0.352 1(0.176)=0.176 - - 
O: Regenerative (0.161) 1(0.161)=0.161 1(0.161)=0.161 - - 
O: Contractile (0.106) 1(0.106)=0.106 1(0.106)=0.106 - - 
O: Marketable (0.081) 1(0.081)=0.081 0(0.081)=0 - - 
O: Easy to 
produce 
(0.032) 1(0.032)=0.032 0(0.032)=0 - - 
Total 2 1.414 1.125 - - 
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Table 26: Evaluation Matrix for Design Alternatives Part 2 
                  
        Design 
 
 
Objectives  
& Constraints 
Weight 
Whole wall 
thickness, growth 
factors, porous  
Whole wall 
thickness, seeded, 
porous 
Sew endocardial edges 
together, injectable gel 
C: No thrombus 
or embolus 
formation 
Y/N Y Y Y 
C: Cost 
effective 
Y/N Y Y Y 
O: Reliable 
mechanical 
properties 
(0.238) 2(0.238)=0.476 2(0.238)=0.476 2(0.238)= 0.476 
O: Predictable 
biomaterial-
tissue responses 
(0.206) 1(0.206)=0.206 1(0.206)=0.206 1(0.206)= 0.206 
O: Practical for 
use in surgery 
(0.176) 0(0.176)=0 0(0.176)=0 0(0.176)=0 
O: Regenerative (0.161) 1(0.161)=0.161 2(0.161)=0.322 1(0.161)=0.161 
O: Contractile (0.106) 1(0.106)=0.106 1(0.106)=0.106 0(0.106)=0 
O: Marketable (0.081) 1(0.081)=0.081 0(0.081)=0 1(0.081)=0.081 
O: Easy to 
produce 
(0.032) 1(0.032)=0.032 0(0.032)=0 2(0.032)=0.060 
Total 2 1.062 1.110 0.984 
 
Justification of Scores 
Design: Whole wall thickness, growth factors, porous 
• No thrombus or embolus formation 
o (Y): fills excised area 
• Cost effective 
o (Y): reasonable enough to produce, incorporation of growth factors would be 
expensive 
• Reliable mechanical properties 
o (2): provides a whole wall thickness plug, will be stable to hold pressure of heart 
• Predictable biomaterial-tissue responses 
o (1): know generally what growth factors should do, but not entirely sure if they will 
perform as needed 
• Practical for use in surgery 
o (0): will need to design procedure in order to implant since it is a full thickness 
scaffold instead of a patch that can be sutured to the endocardium 
• Regenerative  
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o (1): porous to allow some cell ingrowth and growth factors should attract cells for 
new tissue formation 
• Contractile 
o (1): porous spaces would allow cells to grow and contract within scaffold, whole 
scaffold would have to degrade to get entire region contracting 
• Marketable 
o (1): attractive as single piece scaffold, unknowns of growth factors may detract from 
this 
• Easy to produce 
o (1): easy as a single piece, material would have to be made porous or come porous, 
procedure needed for incorporating the growth factors 
 
Design: Whole wall thickness, seeded, porous 
• No thrombus or embolus formation 
o (Y): fills excised area 
• Cost effective 
o (Y): reasonable enough to produce, incorporation of cells may be expensive and 
difficult 
• Reliable mechanical properties 
o (2): provides a whole wall thickness plug, will be stable to hold pressure of heart 
• Predictable biomaterial-tissue responses 
o (1): know generally what seeded cells should do, but not entirely sure if they will 
perform as needed 
• Practical for use in surgery 
o (0): will need to design procedure in order to implant since it is a full thickness 
scaffold instead of a patch that can be sutured to the endocardium 
• Regenerative  
o (2): as long as scaffold supports cell viability there will be new tissue growth since 
cells are seeded throughout the scaffold 
• Contractile 
o (1): porous spaces would allow cells to grow and contract within scaffold, whole 
scaffold would have to degrade to get entire region contracting 
• Marketable 
o (0): attractive as single piece scaffold, seeding cells at time of implantation and 
unknowns about how cells would react could detract from this 
• Easy to produce 
o (0): easy as a single piece, material would have to be made porous or come porous, 
would have to find a way to store it with cells seeded or seed the cells at the time of 
implantation 
 
Design: Sew endocardial edges together, injectable gel 
• No thrombus or embolus formation 
o (Y): suturing eliminates gaps in area 
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• Cost effective 
o (Y): injectable gel easy to produce and apply 
• Reliable mechanical properties 
o (2): walls of heart muscle are being sewn back together, heart wall is already strong 
enough to support pressure 
• Predictable biomaterial-tissue responses 
o (1): injectable gel will provide some control over new tissue growth but may not be 
enough 
• Practical for use in surgery 
o (0): not always enough muscle tissue to sew heart back together in the right shape, gel 
will not be strong enough to cover open gaps 
• Regenerative  
o (1): gel can provide environment for regeneration but is not controlling exactly what 
new tissue is growing 
• Contractile 
o (0): suturing heart muscle will still leave some dead space that will not contract with 
any new tissue formed 
• Marketable 
o (1): injectable gel is easy to sell, but procedure is not always applicable to everyone 
because of the need of a certain amount of heart tissue 
• Easy to produce 
o (2): injectable gel would be relatively easy to produce and store 
 
Design: Endocardial patch, growth factors, injectable gel 
• No thrombus or embolus formation 
o (Y): fills excised area 
• Cost effective 
o (Y): reasonable enough to produce a gel and a patch, incorporation of growth factors 
would be expensive 
• Reliable mechanical properties 
o (2): provides an endocardial patch similar to existing procedures, will be stable to 
hold pressure of heart 
• Predictable biomaterial-tissue responses 
o (1): know generally what growth factors should do, but not entirely sure if they will 
perform as needed 
• Practical for use in surgery 
o (2): suturing endocardial patch in is already a surgical procedure, injecting gel 
afterwards is a simple addition 
• Regenerative  
o (1): gel with growth factors should attract cells for new tissue formation and provide 
conducive environment 
• Contractile 
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o (1): space in gel would allow cells to grow and contract within scaffold, patch may 
have to degrade to get entire region contracting 
• Marketable 
o (1): attractive as already established surgical procedure and ease of gel injection, 
unknowns of growth factors may detract from this 
• Easy to produce 
o (1): production of different pieces (gel and patch) make production less complex, 
growth factors can be incorporated into gel 
 
Design: Endocardial patch, seeded, injectable gel 
• No thrombus or embolus formation 
o (Y): fills excised area 
• Cost effective 
o (Y): reasonable enough to produce a gel and a patch, incorporation of seeded cells 
may be difficult and expensive 
• Reliable mechanical properties 
o (2): provides an endocardial patch similar to existing procedures, will be stable to 
hold pressure of heart 
• Predictable biomaterial-tissue responses 
o (1): know generally what seeded should do, but not entirely sure if they will perform 
as needed 
• Practical for use in surgery 
o (1): suturing endocardial patch in is already a surgical procedure, injecting gel 
afterwards is a simple addition, but having seeded cells in the gel may make things 
more complex than just growth factors 
• Regenerative  
o (1): gel with seeded cells should be conducive new tissue formation and the gel 
provides stable environment 
• Contractile 
o (1): space in gel would allow cells to grow and contract within scaffold, patch may 
have to degrade to get entire region contracting 
• Marketable 
o (0): attractive as already established surgical procedure and ease of gel injection, 
seeding cells at time of implantation and unknowns about how cells would react 
could detract from this 
• Easy to produce 
o (0): production of different pieces (gel and patch) make production less complex, 
would have to find a way to store gel with cells seeded or seed the cells at the time of 
implantation 
 
Design: Endocardial patch, growth factors, void 
• No thrombus or embolus formation 
o (N): leaves unfilled area behind patch for clot formation and unknown regeneration 
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Design: Endocardial patch, seeded, void 
• No thrombus or embolus formation 
o (N): leaves unfilled area behind patch for clot formation and unknown regeneration 
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Appendix H: Metrics and Matrices for Evaluation of Materials 
The metrics formed in the previous appendix for design evaluation were further defined 
to be quantitatively specific to evaluate different types of materials. The scales for ranking each 
objective are described below.  
 
Main Objective: Similar Properties to Healthy Myocardium 
Objective: Contractile 
Basis for Comparison: Ranking the stiffness of the material on a scale of 0 (worst) to 2 (best) in 
comparison with the stiffness of the healthy myocardium 
Metric: 0 for stiffness greater than 280 kPa (stiffness of heart wall at the end of systole), 1 for 
stiffness between 60 kPa (stiffness of heart wall at the start of systole) and 280 kPa (stiffness of 
heart wall the end of systole), 2 for stiffness less than 60 kPa (stiffness of heart wall at the start 
of systole). 
 
Objective: Regenerative 
Basis for Comparison: Ranking the adherence, migration and proliferation of stem cells on the 
scaffold on a scale of 0 (worst) to 2 (best) 
Metric: 0 is stem cells adhere to the material, 1 if stem cells adhere and migrate in the material, 
2 if stem cells adhere, migrate and proliferate in the material 
 
Main Objective: Clinically Applicable 
Objective: Marketable 
Basis for Comparison: Ranking the cost and FDA compliance scale of 0 (worst) to 2 (best)  
Metric: 0 for cost greater that $10000, 1 for cost less that $10000 and use of FDA unapproved 
materials, 2 for cost less that $10000 and use of FDA approved materials 
 
Objective: Easy to Produce 
Basis for Comparison: Ranking the manufacturability on a scale of 0 (worst) to 2 (best)  
Metric: 0 for un-established reproducibility of material (eg. creating a new polymer 
configuration), 1 for established manufacturing techniques with available resources, 2 for use of 
off the shelf materials 
 
Objective: Practical for Use in Surgery 
Basis for Comparison: Ranking the complexity of surgery on scale of 0 (worst) to 2 (best)  
Metric: 0 for need for new surgical technique, 1 for moderate complexity and time for surgery 
(i.e. scaffold must be cut into desirable shape and sutured), 2 for minimal complexity and time 
for surgery (i.e. Injectable material) 
 
Main Objective: Safe for Patient 
Objective: Reliable Mechanical Properties 
Basis for Comparison: Ranking the ability of patch material to withstand a high ventricular 
pressure on scale of 0 (worst) to 2 (best)  
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Metric: 0 for inability to withstand tensile resistance of 1.37 N/mm, 1 for ability to withstand 
tensile resistance of 1.37 N/mm but not under cyclic conditions, 2 for ability to withstand tensile 
resistance of 1.37 N/mm under cyclic conditions 
 
Objective: Predictable Biomaterial-Tissue Response 
Basis for Comparison: Ranking the ability of material to resist a fibrotic tissue development on 
scale of 0 (worst) to 2 (best)  
Metric: 0 for extensive fibrotic tissue development, 1 moderate fibrotic tissue development, 2 
for negligible fibrotic tissue development 
Table 27: Metrics Scoring for Patch Materials 
                  
         Objectives 
 
Patch  
Materials 
Reliable 
Mechanical 
Properties 
Predictable 
Biomaterial-
tissue 
Response 
Practical 
for use 
in 
Surgery 
Regenerative Contractile Marketable 
Easy to 
Produce 
Total 
Score 
 (0.238) (0.206) (0.176) (0.161) (0.106) (0.081) (0.032) 2 
UBM 2 2 1 2 0 1 2 1.531 
Veritas 2 2 1 2  1 2 1.531 
Trimethylene 
carbonate 
(TMC) - DLLA 
copolymers 
2 2 1 1 0 1 1 1.338 
Tissue Fleece 0 2 1 1 1 2 2 1.081 
Poly(glycolide-
co-
caprolactone) 
(PGCL) 
1 1 1 1 1 1 1 1 
Electrospun 
natural 
polymers 
0 2 1 2 0 1 0 0.991 
Dacron 2 0 1 0 0 2 2 0.878 
ePTFE 2 0 1 0 0 2 2 0.878 
Bovine 
Pericardium 
(crosslinked) 
2 0 1 0 0 2 2 0.878 
polymer poly-4-
hydroxybutyrate 
(P4HB) 
0 1 1 1 2 1 0 0.836 
E-caprolactone-
co-L-lactide 
reinforced with 
knitted poly-L-
lactide fabric 
(PCLA) 
0 1 1 1 0 1 1 0.656 
Polyaniline   1 2 0 1 0 0.579 
Alginate/PEO 
electrospun 
0  1  0 1 1 0.289 
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Table 28: Metrics Scoring for Filler Materials 
                  
         Objectives 
 
Patch  
Materials 
Reliable 
Mechanical 
Properties 
Predictable 
Biomaterial-
tissue 
Response 
Practical 
for use 
in 
Surgery 
Regenerative Contractile Marketable 
Easy to 
Produce 
Total 
Score 
 (0.238) (0.206) (0.176) (0.161) (0.106) (0.081) (0.032) 2 
Fibrin Glue 0 2 2 2 2 2 2 1.524 
Alginate Gel 0 2 2 2 2 2 1 1.492 
Injectable 
Collagen 
Scaffold 
0 2 2 2 2 2 1 1.492 
Fibrin Blend 0 2 2 2 2 2 1 1.492 
Platelet Rich 
Plasma 
0 2 2 2 2 2 0 1.46 
Gelatin Sponge 
(Gelfoam) 
0 2 1 2 2 2 2 1.348 
Collagen 
Sponge 
0 2 1 2 2 2 1 1.316 
Alginate Sponge 0 2 1 2 0 2 1 1.104 
Collagen 
Sponge 
(Ultrafoam) 
0 1 1 2 1 2 2 1.036 
Collagen Gel 
(hydrogel) 
0 1 1 2 1 2 2 1.036 
 
Justification of Metrics by Material 
DACRON 
• Reliable Mechanical Properties 
o (2):  Its suitable mechanical properties can be inferred from the fact that it is 
currently used 
• Predictable Biomaterials-Tissue Response 
o (0): Dacron exhibits fibrosis [9] 
• Practical for Use in Surgery 
o (1): Dacron is sold as large sheets that can be cut 
• Regenerative 
o (0):  No cardiomyocytes observed on implanted Dacron patches [9] 
• Contractile 
o (0): vascular graft materials ~ 690 stiffer than normal canine myocardium [77] 
• Marketable 
o (2): Currently used  
• Easy to Produce 
o (2): Already established product 
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ePTFE 
• Reliable Mechanical Properties 
o (2): Its suitable mechanical properties can be inferred from the fact that it is 
currently used 
• Predictable Biomaterials-Tissue Response 
o (0) ePTFE exhibited extensive fibrotic encapsulation after being implanted for 3 
months [6] 
• Practical for Use in Surgery 
o (1): Sold as large sheets that can be cut 
• Regenerative 
o (0):  No striated cardiac cells observed on implanted ePTFE patches [6] 
• Contractile 
o (0): Vascular graft materials ~ 690 stiffer than normal canine myocardium [77] 
• Marketable 
o (2): Currently used  
• Easy to Produce 
o (0): Already established product 
 
Bovine Pericardium (crosslinked) 
• Reliable Mechanical Properties 
o (2): Its suitable mechanical properties can be inferred from the fact that it is 
currently used 
• Predictable Biomaterials-Tissue Response 
o (0): A thick layer of fibrous tissue was attached to bovine pericardium patches 4 
weeks after implantation [78] 
• Practical for Use in Surgery 
o (1): Bovine Pericardium can be made to any shape 
• Regenerative 
o (0) No mesothelial cells found on patch 12 weeks after implantation [78] 
• Contractile 
o (0): Tensile modulus of glutaraldehyde crosslinked bovine pericardium was 0.51 
+/-0.09 MPa at a load of 20 kPa (low modulus region) and 3.8 +/- 0.8 MPa under 
150 kPa (high modulus region) [79] 
o Stiffness of glutaraldehyde fixed bovine pericardium in preferred direction and 
cross direction were 3.27+/-0.25 MPa and 1.31+/-0.18 MPa respectively [80] 
• Marketable 
o (2): Currently used  
• Easy to Produce 
o (2): Already established product 
 
UBM 
• Reliable Mechanical Properties 
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o (2): Maximum force was 1.79 N/mm (tensile strength of 0.3-0.4 MPa) [81, 82]. 
Tensile strength was ~2 MPa [83] 
• Predictable Biomaterials-Tissue Response 
o (2): Tissue replacing UBM patch in canine heart showed had “healing scar” [6] 
• Practical for Use in Surgery 
o (1): UBM comes as a sheet that must be cut 
• Regenerative 
o (2): Cardiomyocytes account for ~30% of remodeled tissue after 8 weeks in vitro 
[84] 
• Contractile 
o (0): Estimated stiffness was 450 kPa [82] 
• Marketable 
o (0): UBM is not approved by the FDA for use in cardiac patch applications (it is 
approved for other uses though) 
• Easy to Produce 
o (2): UBM is a commercially available material 
 
Polyanaline 
• Reliable Mechanical Properties 
o (0): Polyurethane/polyaniline blend had tensile strength of 2.5 MPa (Abbati et al., 
J Appl Sci 2003;89:2516-1521) 
• Predictable Biomaterials-Tissue Response 
o (0): Tissue excised from implant region had similar histological characteristics to 
healthy tissue away from implant site [85] 
• Practical for Use in Surgery 
o (1): Can be electrospun into fibers [8] 
• Regenerative 
o (2): Adhesion and proliferation of cardiac myoblasts was similar to that observed 
on tissue culture polystyrene [8] 
• Contractile 
o (0): Stiffness of electrospun scaffolds made of 45:55 blend of polyanaline: gelatin 
was 1384 +/- 105 MPa [8]. Polyurethane/polyaniline copolymer had stiffness of 4 
MPa [86] 
• Marketable 
o (1): Polyanaline is not approved by the FDA for implantation in humans 
• Easy to Produce 
o (0): Can be electrospun, formed into a gel, or formed into other morphologies 
 
Veritas® collagen matrix 
• Reliable Mechanical Properties 
o (0): Currently used for lung, gastric, and thoracic surgeries which have similar 
mechanical environments to the ventricle [87] 
• Predictable Biomaterials-Tissue Response 
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o (2): Number of acute/inflammatory cells was small [88] 
• Practical for Use in Surgery 
o (1): Derived from bovine pericardium 
• Regenerative 
o (2): Significant host cell infiltration of the implant was observed [88] 
• Contractile 
o (0): No information available 
• Marketable 
o (1): Approved by the FDA for lung, gastric, thoracic surgeries but not for cardiac 
applications 
• Easy to Produce 
o (2): Veritas is a commercially available material 
 
Electrospun natural polymers 
• Reliable Mechanical Properties 
o (0): Mechanical properties are controlled by copolymerizing with synthetic 
polymers 
• Predictable Biomaterials-Tissue Response 
o (2): Natural materials mimic native extracellular matrix 
• Practical for Use in Surgery 
o (1): Can be electrospun or formed into gel 
• Regenerative 
o (2): Natural materials mimic native extracellular matrix 
• Contractile 
o (0): Mechanical properties are controlled by copolymerizing with synthetic 
polymers 
• Marketable 
o (1): Natural polymers not approved by FDA for cardiac use. Electrospinning is an 
economical manufacturing process [89]. 
• Easy to Produce 
o (0): materials must be copolymerized and electrospun or formed into gel 
 
Trimethylene Carbonate (TMC) – D,L-Lacitide (DLLA) copolymer 
• Reliable Mechanical Properties 
o (2): TMC-DLLA blends had a tensile strength from 10-50 MPa [90] 
• Predictable Biomaterial-Tissue Response 
o (1): All samples showed endothelial cell migration and proliferation on the 
surface [90] 
• Practical for Use in Surgery 
o (1): Polymer is prepared as thin sheets that have to be cut for optimized shape 
[90] 
• Regenerative 
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o (0): Only published studies were done with myocytes that, however, did 
proliferate and migrate [90] 
• Contractile 
o (0): Elastic modulus was in the range of 5-2000 MPa [90] 
• Marketable 
o (1): TMC is unapproved by the FDA and is a relatively new material for research 
in cardiac applications [90] 
• Easy to Produce 
o (1): This is not an off the shelf material, but has well established manufacturing 
techniques [90] 
 
Tissue Fleece 
• Reliable Mechanical Properties 
o (1): Tissue Fleece had a tensile strength similar to native heart muscle, unsure 
about actual numbers [31] 
• Predictable Biomaterial-Tissue Response 
o (2): All samples were able to successfully culture contractile myocytes [31] 
• Practical for Use in Surgery 
o (1): Tissue Fleece needs to be cut into appropriate shape before application [31] 
• Regenerative 
o (0): Only published studies were done with myocytes that, however, did 
proliferate, migrate and contract [31] 
• Contractile 
o (1): The stress strain curve was very similar (almost identical) to native rat 
myocardium. However, this was with myocyte seeded and cultured tissue fleece 
samples. [31] 
• Marketable 
o (1): TMC is approved by the FDA and is currently used in surgical applications 
[31] 
• Easy to Produce 
o (2): Tissue Fleece can be bought off the shelf [31] 
 
Poly(glycolide-co-caprolactone) (PGCL) 
• Reliable Mechanical Properties 
o (1): PGCL polymer had about 100% recovery in cyclic loading, with yield 
strength of about 0.2 MPa [91] 
• Predictable Biomaterial-Tissue Response 
o (1): Showed no adverse tissue response when seeded with smooth muscle cells in 
vitro [91] 
• Practical for Use in Surgery 
o (1): Polymer is prepared as thin sheets that have to be cut for optimized shape 
[91] 
• Regenerative 
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o (0): Only published studies were done with smooth muscle cells that did 
proliferate and migrate [92] 
• Contractile 
o (1): Elastic modulus was in the range of 100 kPa [91] 
• Marketable 
o (1): PGCL is unapproved by the FDA but has been used for research in cardiac 
applications [91] 
• Easy to Produce 
o (1): This is not an off the shelf material, but has well established manufacturing 
techniques [91] 
 
Fibrin Glue 
• Predictable biomaterial – tissue Response 
o (2): no inflammation or fibrosis occurred when fibrin glue was injecting into 
infarction regions of rat hearts [30, 93].   
• Practical for Use in Surgery 
o (2): fibrin glue is an injectable material with a long history of clinical application 
[94].   
• Regenerative 
o (2): has been shown to improve cell transplant survival, reduce infarct expansion, 
and improve heart function [30, 93].   
• Contractile 
o (2): modulus of elasticity is approximately 14.6-27.5 kPa depending on fibrinogen 
concentration [95].   
• Marketable 
o (2): fibrin glues are already FDA approved for use in humans [30, 93].   
• Easy to Produce 
o (2): readily available off-the shelf product [30, 93, 96].  
 
Fibrin Blend 
Was merged with fibrin glue 
 
 
Injectable Collagen Scaffold 
• Predicatable biomaterial-tissue Response 
o ( 2): uncrosslinked collagen integrated into native tissue, while crosslinked 
collagen material induce encapsulation and scar formation [97]    
• Practical for Use in Surgery 
o (2): it is injectable and has been used for surgery extensively in the past [96].   
• Regenerative 
o (2): seeded human heart cells have proliferated on a collagen matrices in a past 
study [53].   
• Contractile 
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o (2): it is a soft, injectable gel [96].   
• Marketable 
o (2): it is a currently approved biomaterial for clinical use [96].   
• Easy to produce 
o (1): we would have to produce it on our own, but expertise and resources are 
readily available.   
 
Platelet-rich Plasma 
• Predictable biomaterial-tissue Response  
o (2): it has been shown to produce regenerative healing in the equine epidermis 
and dermis without fibrosis or scar formation [98].   
• Practical for Use in Surgery 
o (2): it is injectable and is currently used in clinical applications [99].  
• Regenerative 
o (2):  it has been shown to produce regenerative healing in the equine epidermis 
and dermis without fibrosis or scar formation [98].   
• Contractile 
o (2): although no data was found regarding the elasticity of platelet-rich plasma, it 
received a score of 2 for contractile based on the fact that it is generally 
characterized as a highly compliant gel [100].   
• Marketable 
o (2): autologous platelet-rich plasma is used clinically [99],  
• Easy to produce 
o (0): the use of autologous materials would complicate the manufacturing process.   
 
Collagen Sponge 
• Predictable biomaterial-tissue Response 
o (2): for the same reasons as the injectable collagen scaffold [97].   
• Practical for Use in Surgery 
o (1): its shape could be customized by cutting to the correct size.   
• Regenerative 
o (2): seeded human heart cells have proliferated on a collagen matrices in a past 
study [53].   
• Marketable 
o (2): it is a currently approved biomaterial for clinical use [101].   
• Easy to produce 
o (1): collagen scaffold are available off-the-self, however producing our own 
collagen sponge would prove to be more difficult. 
 
Alginate Sponge 
• Predictable biomaterial-tissue Response 
o (2): thin lucent connective tissue enriched with blood vessels formed over it, 
integrated well with the infarcted area [28] 
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• Practical for use in surgery 
o (1): alginate sponge has to be prepared into certain sizes before implantation [28] 
• Regenerative 
o (2): human embryonic stem cells formed embroid bodies and populated the 
alginate scaffolds, two fold increase in cell number within first week in culture 
[102] 
• Contractile 
o (0): tested dry alginate sponges, elastic modulus between 385 and 1136kPa which 
translates to 0.0115 N/mm [103] 
• Marketable 
o (2): can be purchased commercially and is relatively inexpensive [103] 
• Easy to produce 
o (1): established protocols to make alginate with commercially available resources 
[104] 
 
Collagen Sponge 
• Predictable biomaterial-tissue Response 
o (1): injectable collagen from bovine dermis has caused high levels of anti bovine 
collagen antibodies in patients, collagen type IV is very strong in immunogenic 
character [105, 106] 
• Practical for use in surgery 
o (1): collagen sponge can be cut to size and sutured on to/in infarction [27, 31] 
• Regenerative 
o (2): collagen is readily available ECM component that allows cell infiltration and 
remodeling, excellent substrate for cell attachment and infiltration [27, 107] 
• Contractile 
o (1): no numbers but shown to allow contraction of myocytes on scaffold [27, 31] 
• Marketable 
o (2): commercially available [108] 
• Easy to produce 
o (2): buy off the shelf and cut to desired shape [27] 
 
Gelatin Sponge 
• Predictable biomaterial-tissue Response 
o (2): saw good biocompatibility, sponge filled with regenerated tissue, minimal 
inflammatory response and no multinucleated giant cells [109] 
• Practical for use in surgery 
o (1): commercially available, cut down to desired shape and suture in [29, 53] 
• Regenerative 
o (2): hMSCs proliferated and differentiated on the sponge [109] 
• Contractile 
o (2): tensile testing, modulus about 123 Pa, less than 7kPa [53] 
• Marketable 
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o (2): commercially available [110] 
• Easy to produce 
o (2): off the shelf commercially available material [53] 
 
Collagen Gel 
• Predictable biomaterial-tissue Response 
o  (1): injectable collagen from bovine dermis has caused high levels of anti bovine 
collagen antibodies in patients, collagen type IV is very strong in immunogenic 
character [105, 106] 
• Practical for use in surgery 
o (2): injectable [106] 
• Regenerative 
o (2): collagen is readily available ECM component that allows cell infiltration and 
remodeling, excellent substrate for cell attachment and infiltration [27, 107] 
• Contractile 
o (1): no numbers but shown to allow contraction of myocytes on scaffold [27, 31] 
• Marketable 
o (2): commercially available [108] 
• Easy to produce 
o (2): established manufacturing techniques [106, 111] 
 
Alginate Gel 
• Predictable biomaterial-tissue Response 
o (2): minimum immune response when purified, unpurified causes major 
encapsulation [104] 
• Practical for use in surgery 
o (2): injectable, can tailor viscosity to desired properties [104] 
• Regenerative 
o (2): cell migration and proliferation seen in the gel [112] 
• Contractile 
o (2): subjective, gel – high compression, low tensile 
• Marketable 
o (2): materials can be purchased commercially and is relatively inexpensive [103] 
• Easy to produce 
o (1): produced through established techniques [103, 104] 
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Appendix I: Strength Strain Testing Protocols 
 Strength/Strain-Preliminary Testing 
Objectives and 
Specifications 
Endocardial patch should withstand a force of at least 1.37N/mm 
(4.11 N or 419.1 g) 
Materials and 
Equipment 
• Instron In-Spec 2200 
• Camera with tripod 
• Computer with ImageJ 
• Dog bone shaped cutter 
• Sample size n = 2 
Procedure • Setup Instron according to ‘Setup and Test Basics for Instron’ 
• Set crosshead speed to 4 mm/s according to ‘Setting 
Crosshead Speed’ 
• Samples should be cut into 1cm by 10cm dogbone shapes as 
specified (lab notebook p 33) and hydrated in PBS for 30 
minutes before testing 
• Place two dots on gauge length of dog bone about 1 cm apart, 
to be used for stretch analysis 
• Secure material first in the upper grip then in the lower grip 
• Apply tare load by adjusting position of upper grip so the 
material is taught between the grips 
• Zero the displacement and tare according to ‘Setup and Test 
Basics for Instron’  
• Re-measure and record gage length 
• Start test and start camera (pictures at " second intervals) 
• Stop test after material fails 
Expected 
Results and 
Methods of 
Analysis 
Results 
• Force vs Displacement curve 
• Strain 
o Use ImageJ program to calculate actual strain between 
zero force and 1.37N/mm 
Analysis 
• Force vs Displacement 
o Pass: sample did not fail at 1.37N/mm (4.11 N or 
419.1 g) 
o Fail: sample failed below 1.37N/mm (4.11 N or 419.1 
g) 
• Strain 
o Should be 5 to 15% at specification 
References [10, 49-51] 
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Protocol  Cutting Dog Bone Samples for Strength/Strain Testing 
Objectives and 
Specifications 
To prepare ASTM standard samples for tensile testing 
 
Materials and 
Equipment 
• Steel punch made according to ASTM standard E8M – 04 
• Acrylic board 
• Clamp 
• Hammer 
• Petri dish 
• Saline solution 
• Sand paper 
• X-acto knife 
Procedure • Tightly secure the acrylic board on the bench top using the 
clamp 
• Place the material on the board, making sure there are no 
kinks or folds 
• Carefully place the metal punch over the material 
• Holding it securely with one hand, hammer at least 15 times 
to cut the material 
• Lift the punch and cut any uncut parts of the material using an 
x-acto knife. Do not drag knife on material, cut by simply 
applying downward pressure. 
• Immerse sample in PBS in a Petri dish for 30 minutes 
• Smooth out acrylic base and sharpen punch edges using the 
sand paper 
• Wipe the acrylic base before reuse 
 
Crosshead Speed:  
Sample width: 3mm 
NF
mmmmNF
11.4
3*/37.1
=
=
 
 
Crosshead Speed for Preliminary Testing: 
Average Heart Rate:  [10] 
 
  
Heart beats in one day = 100,000 Beats/Day
Beats per Minute, BPM =
100,000 Beats
Day
!
1 Day
24 Hrs
!
1 Hr
60 min
= 69.4 BPM
 
 
Stretch % of heart muscle: around 21% 
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)(
60
%
bpmteavgheartra
s
stretch
strainrate =  
 
Crosshead speed = gage length * strain rate 
Maximum possible crosshead speed = 4mm/s 
 
mmgagelength
gagelengthssmm
7.16
*/24.0/4
=
=
 
 
 Strength/Strain-Characterization Testing 
Objectives and 
Specifications 
Endocardial patch should withstand a force of at least 1.37N/mm 
(4.11 N or 419.1 g) 
Materials and 
Equipment 
• Instron In-Spec 2200 
• Camera with tripod 
• Computer with ImageJ 
• Dog bone shaped cutter 
• Sample size n = 3  
Procedure • Setup Instron according to ‘Setup and Test Basics for Instron’ 
• Set crosshead speed to 4 mm/s according to ‘Setting 
Crosshead Speed’ 
• Samples should be cut into 1cm by 10cm dogbone shapes as 
specified (lab notebook p 33) and hydrated in PBS for 30 
minutes before testing 
• Place two dots on gauge length of dog bone about 1 cm apart, 
to be used for stretch analysis 
• Secure material first in the upper grip then in the lower grip 
• Apply tare load by adjusting position of upper grip so the 
material is taught between the grips 
• Zero the displacement and tare according to ‘Setup and Test 
Basics for Instron’  
• Start test and start camera (pictures at " second intervals) 
• Stop test after material fails 
Expected 
Results and 
Methods of 
Analysis 
Results 
• Force vs Displacement curve 
• Strain 
o Use ImageJ program to calculate actual strain between 
zero force and 1.37N/mm (should be between 5 and 
15%) 
Analysis 
• Force vs Strain 
o Comparison of failure strength to specification 
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o Comparison of stretch at force specification 
• ANOVA: quantitative comparison of different materials to 
each other 
References [10, 49-51] 
 
 
Crosshead Speed for Characterization Testing 
Average heart rate: 69.4 bpm 
Stretch % of heart muscle: between 5 and 15% 
 
s
bpm
st
/12.0
4.69
60
1.0
==
!
!"
 
smmmmspeedCrossheads /4.220*/12.0 ==  
 
Setup and Test Basics for Instron (In-Spec 2200) 
1. Equipment setup 
a. Plug DAQ board into computer (National Instruments BNC 2120) 
i. Secure the cable labeled EXT into ACH1 
ii. Secure the cable labeled LOAD into ACH0 
iii. Ensure settings on DAQ board are set as follows 
1. ACH0 – GS 
2. ACH1 – FS 
b. Plug the power cord from the Instron into an outlet 
c. Turn machine on using power switch at the top 
2. Open Measurement and Automation 
a. Data Neighborhood – Traditional NI-DAQ Virtual Channels: Ch 0 and Ch 1 
b. Check that each channel (ch0 is load and ch1 is extension) is set up as seen in 
Figures 1 through 4 
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c. Right click over channel number and select test, a second window will open 
i. Load: apply force to load cell, observe green line, it should move upwards 
the more force that is applied 
ii. Extension: press start button on Instron, green line should move up if 
upper grip is moving up and down if upper grip is moving down 
3. Open 10lb.llb (must have LabVIEW version 7.1 or program will not work) 
a. Double click on red In-Spec 220 icon, LabView user interface will open in a new 
window 
b.  Using dropdown menus at top of screen, set load cell to ch_0 and extension to 
Ch_1 
c. Go to Window-Show Block Diagram, check that the slope and intercept on the 
load cell part of the diagram are correctly set (Page 39 in lab notebook) 
d. Press the arrow button on top left hand side of toolbar (run) 
e. Tare (Part 1) 
i. Put 0 in the Tare value box, press green arrow 
ii. record exact reading from grams box under Mass  
f. Set up sample in grips according to desired procedure 
g. Tare (Part 2) 
i. Take exact reading from grams box under Mass and subtract it from the 
reading recorded in step e part ii 
ii. Add 205.5 g to this value and put it in the Tare value box 
iii. Press enter 
iv. White line will not relocate to zero on the Load Cell graph until the green 
button on the Instron is pressed to start the test. After taring the value in 
the grams box should be around -4400ish grams. 
h. Zero Extension: 
i. Put 0 in the Zero Mark box and press enter 
ii. Take the number in the millimeters box to the right and put it in the zero 
mark box 
iii. A white line will relocate to the zero mark on the extension/time graph 
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i. Press Red stop sign button on the toolbar at the top of the screen (NOT the big 
button with the word STOP on it) 
j. Right click in the area of the extension chart, select data operations, then clear 
chart, white lines will disappear 
k. Repeat for load cell chart. This clears all the base setup data out so that it is not 
used in the data analysis 
l. Press the arrow button on the top left hand side of the toolbar again (run) 
m. Press green start button on front of Instron 
n. Allow test to run according to desired procedure 
Press square STOP button at end of test (press green button on face of Instron to stop the 
machine as well) 
A box will pop up,  choose saving location, press ok 
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Appendix J: Drawings of Dog Bone and Suturability Base 
Dimensions all in inches 
 
 
Figure 43: Dog Bone Punch 
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Figure 44: Suturability Base 
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Appendix K: ImageJ Strain Measurement 
 
• Measure distance between markers 
o Open ImageJ – then open image 
o Convert the image to 8 bit format 
" In the Image menu select Type, then 8 bit 
o Set scale on image 
" Draw a line on a physical scale (e.g., 1 inch ruler) using the straight line 
sections tool from the button toolbar on and measure it (Ctrl+M) 
" In the Analyze menu, choose Set Scale – the number of pixels is given, 
type in the true length (e.g., 1.00 inch) 
" Re-measure (Ctrl+M) – this should now read the true length 
" Re-draw and re-measure the calibration line 5 to 10 times 
" Save: in the Results box, choose Save As from the file menu, this will save 
the measurements as a text file 
" Copy measurements to a spread sheet to determine the calibration error. 
o Measure marker positions 
" Make the image binary:  
• Threshold image by pressing Ctrl+Shift+T  
• In the Threshold box move both sliders around until the dots are 
red 
• Press Apply then Ok  
" In the Analyze menu choose Set measurements  
• Check the boxes next to centroid, area, invert y coordinates, and 
limit to threshold, press Ok 
" Use the wand tool on the button menu to select one marker, then measure 
it (Ctrl+M), repeat for other markers 
" Save: In the Results box, choose Save As from the file menu, this will 
save the measurements as a text file 
o Calculate distance 
" Copy x and y centroid positions to a spreadsheet and calculate distance.  d2 
= (x2-x1)
2 + (y2-y1)
2 and strain. 
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Appendix L: Suture Retention Testing Protocols 
 
 Suture Retention-Preliminary Testing 
Objectives and 
Specifications 
Sutures should not pull out of scaffold under a force of 2.74 N/suture 
(279.4 g/suture)  
Materials and 
Equipment 
• Instron In-Spec 2200 
• 6-0 Prolene sutures 
• Camera with tripod 
• Sample size n = 2   
Procedure • Setup Instron according to ‘Setup and Test Basics for Instron’ 
• Set crosshead speed to about 100 mm/min (approx 2 mm/s) 
according to ‘Setting Crosshead Speed’ 
• Samples should be cut into 2cm by 1cm rectangles and 
hydrated in PBS for 30 minutes before testing 
• Put suture through material to form a loop 2 mm in from the 
edge of the material. 
• Secure material first into bottom grip then grip both ends of 
the looped suture in the top grip 
• Apply tare load by adjust position of upper grip so the 
material and suture are taught between the grips 
• Zero the displacement and tare according to ‘Setup and Test 
Basics for Instron’  
• Re-measure and record gage length 
• Start test, allow it to run until suture pulls free of the material 
Expected 
Results and 
Methods of 
Analysis 
Results 
• Force vs Displacement curve 
Analysis 
• Pass: maximum force is greater than 2.74 N (279.4 g) 
• Fail: maximum force is equal to or less than 2.74 N (279.4 g) 
References [113] 
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 Suture Retention-Characterization Testing 
Objectives and 
Specifications 
Sutures should not pull out of scaffold under a force of 2.74 N/suture 
(279.4 g/suture)  
Materials and 
Equipment 
• Instron In-Spec 2200 
• 6-0 Prolene sutures 
• Camera with tripod 
• Sample size n = 2   
Procedure • Setup Instron according to ‘Setup and Test Basics for Instron’ 
• Set crosshead speed to about 100 mm/min (approx 2 mm/s) 
according to ‘Setting Crosshead Speed’ 
• Samples should be cut into 2cm by 1cm rectangles and 
hydrated in PBS for 30 minutes before testing 
• Put suture through material to form a loop 2 mm in from the 
edge of the material. 
• Knot ends of suture around metal ring using a square knot 
with seven total throws 
• Grip the ring in the top grip as seen in the following figure. 
Then secure material into bottom grip. 
 
• Apply tare load by adjust position of upper grip so the 
material and suture are taught between the grips 
• Zero the displacement and tare according to ‘Setup and Test 
Basics for Instron’  
• Re-measure and record gage length 
• Start test, allow it to run until suture pulls free of the material 
Expected 
Results and 
Methods of 
Analysis 
Results 
• Force vs Displacement curve: force at failure 
Analysis 
• ANOVA: quantitative comparison of different materials to 
each other 
• Visual inspection of material/suture at specification and 
failure 
References [113] 
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Appendix M: Suturability Testing Protocol 
 Suturability-Characterization Testing 
Objectives and 
Specifications 
Force required to penetrate scaffold with a needle should be less than 
5N (816.5 g) 
Materials and 
Equipment 
• Instron In-Spec 2200 
• Base material holder* 
• 6-0 Prolene suture needles 
• Sample size n = 3 
Procedure • Setup Instron according to ‘Setup and Test Basics for Instron’ 
• Set crosshead speed to about 100mm/min (about 2 mm/s) 
according to ‘Setting Crosshead Speed’ 
• Samples should be cut into 2cm by 2cm squares and hydrated 
in PBS 30 minutes before testing 
• Place material between washers of base holder so face of 
material is perpendicular to the top grip. 
• Anchor suturing needle into the top grip pointing down at the 
base. 
• Move top grip to position so that needle head is 1cm from 
material 
• Zero displacement and tare according to ‘Setup and Test 
Basics for Instron’ 
• Start the test, allow it to run until needle has punctured 
through the opposite side of the material 
Expected 
Results and 
Methods of 
Analysis 
Results 
• Force vs. Displacement curve: maximum force 
Analysis 
• ANOVA: quantitative comparison of different materials to 
each other 
References [58] 
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Appendix N: Manufacturing of Fibrin Gel 
Protocol  Preparation of Fibrin Gel, revised 12/14/2006 00:18 
Objectives 
and 
Specifications 
Resuspend fibrinogen in H2O for stock solution.  Prepare other components to 
make fibrin adhesive. 
Materials and 
Equipment 
Materials 
• Bovine fibrinogen 
• Bovine thrombin 
• Sterile phosphate buffered saline (PBS) 
• Sterile calcium chloride, anhydrous 
• Deionized (DI) water 
Equipment 
• 0.22 !m filters 
• Sterile 1 ml tubes 
• -20ºC freezer 
• Micromedics FibriJect applicator 
Procedure Resuspend fibrinogen in H2O [63] 
1. Add bovine fibrinogen to DI H2O at a concentration of 30 mg/ml (refer 
to fibrinogen content on bottle to calculate quantities). 
2. Warm solution to 37ºC and mix every 10 minutes until all fibrinogen 
has dissolved (could take approx. 3-10 hours). 
3. Filter through 0.22 !m cell culture filter and aliquot into sterile 1 ml 
tubes. 
4. Store at -20ºC or colder. 
 
Resuspend thrombin in H2O 
1. Add bovine thrombin to a clean tube. 
2. Add DI H2O to bring thrombin to a concentration of 2 U/ml [64]. 
3. Procedure? (should be easier than fibrinogen). 
4. Filter through 0.22 !m cell culture filter and aliquot into sterile 1 ml 
tubes. 
5. Store at -20ºC. 
 
Application of adhesive 
1. Thaw concentrated fibrinogen and thrombin at RT or 37ºC. 
2. Dilute fibrinogen to the desired concentration (refer to Table 29 for 
basis of concentrations and references). 
a. Dilute fibrinogen solutions to 6 mg/ml in PBS for seeded fibrin 
gels and add cell suspension (106 cells/ml, see ‘Migration’ 
protocol) 1:10 to fibrinogen solution. 
b. Dilute fibrinogen solutions to 6, 10, or 18 mg/ml for migration 
substrate. 
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Table 29: Fibrinogen concentrations 
Fibrinogen sol. 
conc. 
Final fibrin 
conc. 
Reference 
0.6 mg/ml 0.3 mg/ml Migration was the same as at 
physiological 3 mg/ml (data wasn’t 
shown)[71] 
3-6 mg/ml 1.5-3 mg/ml Migration was no affected by 
fibrinogen concentration in this 
range (abstract only) [114] 
6 mg/ml 3 mg/ml Physiological fibrinogen 
concentration is 2.64±0.807 in 
healthy volunteers and 3.43±2.040 
in patients with angina pectoris 
[67].  Fibroblasts migrated 
optimally at 3 mg/ml (abstract 
only) [68] 
7-11 mg/ml 3.5-5.5 
mg/ml 
Induced site directed angiogenesis 
through delivery of #-endothelial 
cell growth factor [115] 
10 mg/ml 5 mg/ml Mesenchymal stem cell 
proliferation within a 3D clot was 
maximum (lowest concentration 
tested) [52]. 
18 mg/ml 9 mg/ml Optimized for proliferation of 
seeded mesenchymal stem cells 
[69]. 
 
3. Add CaCl2 (111 g/mol) to thrombin solution to give 20 mM 
concentration (basis: 5-20 mM [64], or 35 mM [116]). 
4. Draw the desired volumes of the fibrinogen and thrombin solution into 
the two separate syringes of the Micromedics FibriJect fibrin adhesive 
applicator. 
5. Attach the blending connector applicator tip. 
6. Dispense equal parts concentrated fibrinogen and thrombin solution 
[64]. 
7. Allow to polymerize in situ. 
 
 
 128 
Appendix O: Migration Testing Protocols 
Protocol Name Thawing hMSCs 
Objectives and 
Specifications 
Thaw human mesenchymal stem cells (hMSCs) so that they can be used 
for experiments 
Materials and 
Equipment 
1. DMEM (Dulbecco’s Modified Eagle’s Medium), 10% FBS, 1% 
P/S with all supplements (serum = FBS, L-glutamine, antibiotics 
= P/S), 37C. Stored at -20C. 
2. Pipets: 25mL, 10mL, 5mL Serological Pipets. 
3. Miscellaneous items: Sterile culture flasks, 15mL conical tubes, 
70% Isopropyl Alcohol (IPA), Pipet Aid, Lab marker for 
labeling. 
Procedure 1. Spray inside surface of hood with 70% IPA.  Spray all exterior 
surfaces of containers to be brought into hood with 70% IPA.  
Set up all necessary items in hood.   
2. Remove stored cryovial(s) containing cells from Liquid Nitrogen 
cryotank/Dry ice. Optional: Wipe cryovial(s) with 70% IPA and 
in sterile field, brefly twist cap a quarter turn to relieve pressure, 
then retighten.  
3. Thaw cells rapidly by immediately immersing vial(s) into 37° C 
water bath.  Do not submerge them completely and watch them 
closely. Gently agitate for approx. 2 min (no longer than 3 min). 
Note: Most cell death occurs between –50° C and 0° C when 
thawing. 
4. When fully thawed (all ice crystals melted), remove vial(s) 
immediately, wipe dry then spray outside of vial(s) thoroughly 
with 70% IPA before bringing cells into the hood. Transfer 
thawed cell suspension into 15mL tube containing 5mL pre-
warmed media to dilute.   
5. Centrifuge cells at 1000rpm for 5 minutes to remove any residual 
DMSO. While cells are being spun down, set up new T75 flasks 
and add 13mL of DMEM to each. Allow temperature to 
equilibrate to 37° C. 
6. Decant supernatant; Resuspend cell pellet in minimum volume of 
fresh pre-warmed media. Perform CELL COUNTING. Seed cells 
by transferring the appropriate amount of cell suspension into 
new culture flask(s) with fresh medium.  Note: Amount of 
suspension transferred will depend on the density at which cells 
were frozen and desired cell density for new seed. 
7. Place cells in incubator, and replace with equal volume of fresh 
medium after 24 hrs to remove any (floating) dead cells. Observe 
cells daily for growth (confluency reached by ~1 week) and 
freedom from contamination. Media to be changed every 3-4 
days. 
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8. Clean up hood and spray down surface with 70% IPA. Close it 
and turn on UV light. 
References Protocol obtained from Gaudette laboratory  
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Protocol Name Subculturing hMSCs 
Objectives and 
Specifications 
Culture hMSCs so that they can be used for experiments 
Materials and 
Equipment 
1. DMEM (Dulbecco’s Modified Eagle’s Medium), 10% FBS, 
1% P/S with all supplements (serum = FBS, L-glutamine, 
antibiotics = P/S), 37C. Stored at 4C. 
2. 0.25% Trypsin, 37C. Stored at -20C.  (Not to be left in water 
bath for extended period of time.) 
3. Pipets: 25mL, 10mL, 5mL Serological Pipets, 5mL aspirating 
Pasteur Pipets.  
4. Miscellaneous items: Sterile culture flasks for seeding, 70% 
Isopropyl Alcohol (IPA), Pipet Aid, Lab marker for labeling. 
Procedure 1. Spray inside surface of hood with 70% IPA.  Spray all 
exterior surfaces of containers to be brought into hood with 
70% IPA.  Set up all necessary items in hood.   
2. Remove all media from T75 flasks with hMSCs (P# donor #) 
previously cultured at high density. Remember: Handle flasks 
vertically as to not allow media to enter neck of dish, 
specially designed for CO2 exchange.  
3. Add 5mL Trypsin gently to bottom edge/corner of flask (as to 
not shock/dislodge cells). Rock flask gently to ensure full 
coating of bottom surface. Check cells under microscope to 
make sure they are detaching from flask and have “rounded-
up” morphology and are “flying around”. (Trypsin is a 
protease that acts to degrade protein.) 
4. When all cells appear round, add 5 mL fresh media (DMEM, 
10%FBS), and thoroughly wash flask to gather up all cells 
from the bottom of the flask by gently triturating up and down 
while tilting the flask. Note: No need to aspirate trypsin since 
DMEM will inactivate its proteolytic action. 
5. Centrifuge cells at 1000rpm for 5 minutes.  
6. Decant supernatant and resuspend cell pellet in minimum 
volume of fresh pre-warmed media. Determine number cells 
according to CELL COUNTING protocol.  
7. Add appropriate volume (depending on % confluency) of cell 
suspension to fresh flasks.  Gently rock/swirl flask to spread 
out cells.   
8. Place cells in incubator and observe daily for growth (toward 
confluency) and freedom from contamination. Media to be 
changed every 3-4 days. 
9. Clean up hood and spray down surface with 70% IPA. Close 
it and turn on UV light. 
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References Protocol obtained from Gaudette laboratory 
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Protocol Name Cell Counting 
Objectives and 
Specifications 
Determine concentration of cells in suspension 
Materials and 
Equipment 
1. Hemacytometer 
2. Trypan Blue 
3. PBS 
4. Cell counter; 10!L pipettes 
Procedure 1. Prepare a 1:10 dilution (thus dilution factor = 10) of cell 
suspension to be counted as follows: Place 50 µL Trypan Blue 
+ 40$µL non-sterile PBS + 10$µL cell suspension in a small 
Eppendorf tube. Triturate gently as to increase accuracy of 
count. Note: Trypan Blue is toxic and a potential carcinogen 
so extra care should be taken with its use. 
2. Prepare the hemacytometer by placing a clean coverslip onto 
its center grid section (mirror-like polished surface with 
wells).  Both should be cleaned with ethanol prior to use.  
3. Carefully load a small amount (~10!L) of cell suspension into 
the wells underneath and on each end of the coverslip. Note: A 
hemacytometer is a specialized glass slide with a 3x3 grid 
pattern etched upon it whose volume is known. When covered 
by a coverslip, cells spread out due to capillary action. 
4. Using a microscope, cells are counted within each of squares 
of the hemacytometer grid to obtain a measure of cell 
concentration as follows: 
 
        
 
Count all viable cells in each of the 4 corner fields adjacent 
to the center square (i.e. squares that lie along a diagonal, 
here 1, 3, 7 & 9) for each side of hemacytometer for a total of 
8 fields.  Adopt a rule for counting cells that fall on grid lines 
to eliminate duplicate counts (i.e. count cells on left or top 
lines of a square, but not those on bottom or right lines). 
Note: Dead cells appear blue as stained by Trypan Blue and 
should be excluded from the count, while viable cells appear 
bright and do not take up the dye unless exposed to it for an 
extended period of time after which they may absorb it and 
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appear non-viable.   
5. Use the following equations with numbers attained from 
count to calculate cell concentrations. Final count or actual 
cell density in cells/mL !  Eqn:  C1V1 = C2V2 
 
              average count per field 
# viable cells / mL  = [# viable cells / total # fields] X dilution factor (10) X 104 
          
Total # viable cells = # viable cells/mL X original vol from which sample removed  
           =  C1          X          V1 
 
Final resuspension volume (# mL of cells to add)  = total # cells/target cell density 
           V2 = C1V1                 /          C2 
 
% viability  =  total # viable cells / total # cells   X   100  
Note: Must perform dead count for total # cells. 
References Protocol obtained from Gaudette laboratory 
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Protocol Name MTS Assay 
Objectives and 
Specifications 
Determine concentration of cells in suspension 
Materials and 
Equipment 
1. CellTiter 96® AQueous One Solution 
2. 96 well plates 
3. Pipettes; pipette tips; lab marker;  
Procedure 1. Thaw the CellTiter 96® AQueous One Solution Reagent. It 
should take approximately 90 minutes at room temperature on 
the bench top, or 10 minutes in a water bath at 37°C, to 
completely thaw the 20ml size. 
2. Pipet 20!l of CellTiter 96® AQueous One Solution Reagent 
into each well of the 96-well assay plate containing the 
samples in 100!l of culture medium. If culture volume is 
larger than 100!l, add solution to obtain total ratio of 1:5. 
3. Incubate the plate for 2 hours at 37°C in a humidified, 5% 
CO2 atmosphere.  
4. Record the absorbance at 490nm using a 96-well plate reader. 
References Protocol modified from manufacturers instructions. 
 
 
 
 
 
 
Protocol  Cellular Migration Plate Handling, revised 3/1/2007 11:17 AM 
Objectives and 
Specifications 
Measure the migration of cells into a fibrin gel. 
Materials and 
Equipment 
Materials 
• Unseeded and seeded fibrinogen solution and thrombin/CaCl2 
solution from fibrin gel preparation protocol 
• 70% ethanol solution 
• Sterile deionized H2O (0.22 !m filtered) 
Equipment 
• Sterile 12-well tissue culture plates (16 mm well diameter) 
• Sterile scoring tool (autoclaved) 
• Sterile score-marking guide (8 mm diameter, autoclaved) 
• Sterile Micromedics FibriJect applicator (soaked in 70% ethanol, 
rinsed with sterile H2O), 3 ml syringes, and needles (22 gauge, 1”). 
• Nikon Eclipse TS100 inverted microscope 
• RT Color Spot camera system and Spot imaging software  
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(Diagnostic Instruments, Inc.) 
Procedure Scoring the plate 
Under sterile conditions: 
1. Place the score-marking guide into the well. 
2. Use the scoring tool to score the bottom of the well around the 
inside of the marking guide. 
3. Ensure that the score mark goes all the way around the 
circumference. 
4. Wash each well with 70% ethanol to ensure sterility and that all 
plastic particles are removed. 
5. Wash thoroughly with sterile H2O. 
 
Application of fibrin gels 
6. Flush the blending applicator tip with sterile H2O. 
7. Fill 3 ml syringes with an equal amount of unseeded fibrinogen 
solution and thrombin solution. 
8. Remove as much air as possible from syringes. 
9. Screw the syringe containing fibrinogen onto the side of the 
blending applicator tip marked with an O. 
10. Screw the syringe containing thrombin onto the othr side of the 
blending applicator. 
11. Snap syringes into the FibriJect housing and attach the connecting 
plunger cap. 
12. Screw a needle onto the tip of the blending applicator. 
13. Uncap the needle and place the tip between the score mark and the 
outer edge of the plate. 
14. Depressed the plungers simultaneously via the connecting plunger 
cap to dispense 800 !l of unseeded fibrin gel into the outer ring. 
15. Flush the blending tip thoroughly with 70% ethanol and leave to 
soak. 
16. Allow ~10 min for the unseeded gel to polymerize. 
17. Repeat steps 1-7 for the seeded fibrinogen solution. 
18. Uncap the needle and place the tip in the center of the inner ring at 
the bottom of the well. 
19. Depressed the plungers simultaneously via the connecting plunger 
cap to dispense 300 !l of seeded fibrin gel into the inner ring. 
20. Allow ~10 min for seeded gel to polymerize. 
21. Add media before taking initial images of the gels. 
22. Store plate in incubator at 37ºC. 
 
Imaging of gels 
1. Place plate on microscope, ensure that 10X objective is in place and 
turn light on to full brightness. 
2. Power camera on and start Spot imaging software. 
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3. Focus microscope using the bottom of the score mark for reference. 
4. Focus 184 !m (300 tic marks or 1.5 revolutions on the microscope 
dial) up into the gel. 
5. Acquire images at 4 locations surrounding the score mark using the 
‘Cardiac Patch MQP Bright Field’ image setup (auto brightness). 
6. Save images in a different folder for each day of the experiment with 
appropriate filenames. 
7. Repeat steps 3-6 for each well. 
 
 
 
Calibration of Focal Depth for Cellular Migration Plate Handling 
 
The thickness of a standard glass microscope slide was measured using digital calipers.  
The number of tic marks was that this corresponded to was then measured by focusing first on a 
fingerprint on the bottom of the slide, then focusing up to a fingerprint on the top surface of the 
slide. The calculated conversion factor is given below: 
 
  
645 tic marks = 1.05 mm = 1050 µm
Conversion factor =
645 tic marks
1050 µm
= 0.614 tic marks/µm
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Appendix P: Calculations for Migration Assay 
 
How thick should the gels be? 
 
Greiling et al: 0.6ml of final solution poured into 24-well plates, d=16mm (Fisher 
Scientific Costar Cell Culture Plates) 
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How big should the seeded and unseeded gels be? 
 
The cell seeded gels used by Greiling et al. were made by pouring collagen gels that covered 
the well and allowing them to contract before pouring the outer gel. Liu et al. observed the 
contraction of collagen gels seeded in 24-well plates (16mm diameter) with corneal 
fibroblasts at the following concentrations: 
• Collagen: 1.8 mg/ml 
• Cells: 2x105 cells/ml 
The average gel contraction was ~2.5mm, therefore the average final diameter was: 16mm – 
2.5 mm = 13mm % 13/18*100 = 81.25% ~ 80% of original diameter 
 
The average diameters of the cell seeded collagen gels used by Greiling et al. were probably 
about 80% of the well diameter (i.e. ~13mm). This was sufficient for observing migration 
after 24 hours. Since we are interested in observing cell spreading over a longer time period 
we should have a larger unseeded region for them to migrate into % 50/50 ratio between 
diameters is a reasonable start. 
 
Dseeded = 50% well diameter % Rseeded = 25% well diameter 
Dunseeded = 50% well diameter % Runseeded = 25% well diameter 
12-well plates: A=3.8cm2 = &r2 % cmdcm
cmA
r 2.21.1
8.3
=!===
""
 
Total Volume (d=22mm; r=11mm): 
V=At where A=&r2=&(11mm)2(1cm/10mm)2=3.80cm2 
V=(3.80cm2)(0.298cm)=1.13cm3 ~ 1.10ml of total fibrin gel 
 
Volume of seeded fibrin gel (d=11m; r=5.5mm): 
V=At where  A=&r2=&(5.5mm)2(1cm/10mm)2 = 0.95cm2 
V=(0.95cm2)(0.298cm) = 0.283cm3 ~ 0.280ml of cell seeded fibrin gel 
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Volume of unseeded fibrin gel=1.10ml-0.28ml = 0.820ml of unseeded fibrin gel 
 
What proportion of the final solution do other people use as cell suspension? 
 
• Pins Labratory: 1/6 cell suspension, 1/6 thrombin solution, 2/3 fibrinogen solution  
• Jockenhoevel et al.: “The Fibrinogen solution was serial Filtered and sterilized. 10% 50 
mMCaCl2, 20% Thrombin (20 units/ml) and 70% resuspended cells in Tris buffered 
saline were mixed gently. The Fibrinogen was added in a ratio 1:1 and mixed by gently 
shaking.” " Thrombin/cell solution (~1/3 thrombin solution, ~2/3 cell suspension), " 
fibrinogen solution to give final ratios of 1/6 thrombin solution, 1/3 cell suspension, " 
fibrinogen solution 
 
What concentrations of cell suspensions are required for the following ratios of cell 
suspension in the fibrin gel for the migration tests? (Note: Greiling et al. used 60,000 
cells/600µl gel = 100,000 cells/ml). 
• 12-well tissue culture plates: We want 28,000 cells/280µL gel (final concentration = 
100,000 cells/mL) = 28,000 cells/140µL fibrinogen solution. Any of these concentrations 
would work well.  
o 1/2: 70µl of cell suspension (28,000 cells/0.070ml = 400,000 cells/ml)  
o 1/3: 47µl of cell suspension (28,000 cells/0.047ml = 595,744 cells/ml ~ 600,000 
cells/mL)  
o 1/4: 35µl of cell suspension (28,000 cells/0.035ml = 800,000 cells/ml)  
 
 
REFERENCES: [71, 117, 118] 
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 Appendix Q: Transformation of Strength/Strain Preliminary 
Data 
 
Strength-Stretch Preliminary 
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Figure 45: Raw Strength/Strain Preliminary Data 
 
• Initial toe region, need to zero out this portion so that strain and modulus can be 
calculated 
o Find point in bounce of force where the values stop fluctuating and begin rising 
o Use this point as zero load 
o Use corresponding extension at this point to zero the extension 
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Strength/Strain Preliminary
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Figure 46: Zeroed Strength/Strain Preliminary Data 
 
• Figure 46 shows corrected data, eliminates discrepancies in beginning region 
• Use corrected data to validate strain rate, see Figure 47, strain rate validation 
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Figure 47: Strength/Strain Strain Rate Validation 
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o 4mm/s crosshead speed = 20mm gage length x strain rate 
o Strain rate = 0.2/s 
o Data intersects at 1s and 20% strain: VALIDATED 
 
• With the procedure validated: can now examine the difference between crosshead strain 
and local strain measured through image analysis 
o Graph crosshead strain and calculated local strain against each other, find 
relationship 
y = 0.68x - 0.0082
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Figure 48: Crosshead Strain vs Local Strain 
o R squared value fairly high (close to 1 indicates high linear correlation between 
data sets) 
o Use relationship (slope/intercept equation) to predict ImageJ strain from the 
crosshead strain, plot the predicted strain vs the actual ImageJ strain and compare 
to perfect relationship (points are equal R2 = 1) 
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Figure 49: Predicted vs. Actual Image J Strain 
 
o Use equation: Local Strain = 0.68 (Crosshead Strain) -0.0082 to convert 
crosshead strain to local strain 
• With the data now graphed against corrected local strain, the strain at the specification 
can be calculated 
o Isolate three or four points around the specification line for each material 
o Draw a line of best fit through these points and display equation 
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y = 49.64x + 2.2241
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Figure 50: Calculation of Strain at Specification – Line of Best Fit and Equation 
o Equations are grouped, from right to left, as Veritas, UBM, then Hemashield 
o Take these equations and plug in 4.11N for y, solve for x 
o X= strain at specification 
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Appendix R: Suture Retention Statistical Analysis   
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Appendix S: Transformation of Strength/Strain 
Characterization Data 
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Figure 51: Raw Strength/Strain Preliminary Data 
 
• Initial toe region, need to zero out this portion so that strain and modulus can be 
calculated 
o Find point in bounce of force where the values stop fluctuating and begin rising 
o Use this point as zero load 
o Use corresponding extension at this point to zero the extension 
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Zeroed Load vs Zeroed Extension
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Figure 52: Zeroed Strength/Strain Preliminary Data 
 
• Figure 52 shows corrected data, eliminates discrepancies in beginning region 
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• Use corrected data to validate strain rate, see Figure 53, strain rate validation 
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Figure 53: Strength/Strain Strain Rate Validation 
o 4mm/s crosshead speed = 25.4mm gage length (overall average) x strain rate 
o Strain rate = 0.16/s 
o Data intersects at 1s and 16% strain: VALIDATED 
 
• With the procedure validated: can now examine the difference between crosshead strain 
and local strain measured through image analysis 
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o Graph crosshead strain and calculated local strain against each other, find 
relationship 
y = 0.7608x - 0.0138
R2 = 0.9387
R2 = 1
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Figure 54: Crosshead Strain vs. Local Strain 
o R squared value fairly high (close to 1 indicates high linear correlation between 
data sets) 
o Use relationship (slope/intercept equation) to predict ImageJ strain from the 
crosshead strain, plot the predicted strain vs the actual ImageJ strain and compare 
to perfect relationship (points are equal R2 = 1) 
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Figure 55: Predicted vs. Actual Image J Strain 
 
o Use equation: Local Strain = 0.76 (Crosshead Strain) -0.0138 to convert 
crosshead strain to local strain 
• With the data now graphed against corrected local strain, the strain at the specification 
can be calculated 
o Isolate three or four points around the specification line for each material 
o Draw a line of best fit through these points and display equation 
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Figure 56: Calculation of Strain at Specification – Line of Best Fit 
o Equations are shown in the following table: 
Table 30: Calculation of Strain at Specification - Equations 
Sample Equation 
Veritas 1 75.231x + 1.4568 
Veritas 2 89.913x - 2.6398 
Veritas 3 76.837x - 3.259 
Veritas 4 70.537x - 2.8469 
Veritas 5 69.64x + 1.0445 
Veritas 6 97.159x - 0.1106 
UBM 1 60.843x - 1.3975 
UBM 2 53.093x - 1.3725 
UBM 3 52.073x - 2.8554 
UBM 4 43.507x - 1.0727 
UBM 5 37.704x + 0.6841 
UBM 6 39.47x - 0.7775 
Hemashield 1 73.953x - 0.2834 
Hemashield 2 86.003x - 1.0905 
Hemashield 3 53.053x + 0.2536 
 
o Take these equations and plug in 4.11N for y, solve for x 
o X= strain at specification 
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Strain ANOVA (SPSS) 
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Appendix T: Analysis of Suturability Data 
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Appendix U: Statistical Analysis of MTS Viability 
Table 31: Comparison between % increase at Day 1 Experiment 1 
Dependent 
Variable (I) Material2 (J) Material2 
Mean 
Difference (I-J) Std. Error Sig. 95% Confidence Interval 
            Lower Bound Upper Bound 
Day1 3mg/ml 5mg/ml -33.66386 15.05910 .677 -88.6128 21.2851 
    9mg/ml 23.31764 15.05910 1.000 -31.6313 78.2666 
    Veritas 36.92166 15.05910 .457 -18.0273 91.8706 
    UBM -118.58052(*) 15.05910 .000 -173.5295 -63.6315 
    Plastic -87.68294(*) 15.05910 .001 -142.6319 -32.7340 
  5mg/ml 3mg/ml 33.66386 15.05910 .677 -21.2851 88.6128 
    9mg/ml 56.98150(*) 15.05910 .039 2.0325 111.9305 
    Veritas 70.58552(*) 15.05910 .008 15.6365 125.5345 
    UBM -84.91667(*) 15.05910 .002 -139.8656 -29.9677 
    Plastic -54.01908 15.05910 .056 -108.9681 .9299 
  9mg/ml 3mg/ml -23.31764 15.05910 1.000 -78.2666 31.6313 
    5mg/ml -56.98150(*) 15.05910 .039 -111.9305 -2.0325 
    Veritas 13.60402 15.05910 1.000 -41.3450 68.5530 
    UBM -141.89816(*) 15.05910 .000 -196.8471 -86.9492 
    Plastic -111.00058(*) 15.05910 .000 -165.9496 -56.0516 
  Veritas 3mg/ml -36.92166 15.05910 .457 -91.8706 18.0273 
    5mg/ml -70.58552(*) 15.05910 .008 -125.5345 -15.6365 
    9mg/ml -13.60402 15.05910 1.000 -68.5530 41.3450 
    UBM -155.50218(*) 15.05910 .000 -210.4512 -100.5532 
    Plastic -124.60460(*) 15.05910 .000 -179.5536 -69.6556 
  UBM 3mg/ml 118.58052(*) 15.05910 .000 63.6315 173.5295 
    5mg/ml 84.91667(*) 15.05910 .002 29.9677 139.8656 
    9mg/ml 141.89816(*) 15.05910 .000 86.9492 196.8471 
    Veritas 155.50218(*) 15.05910 .000 100.5532 210.4512 
    Plastic 30.89759 15.05910 .940 -24.0514 85.8466 
  Plastic 3mg/ml 87.68294(*) 15.05910 .001 32.7340 142.6319 
    5mg/ml 54.01908 15.05910 .056 -.9299 108.9681 
    9mg/ml 111.00058(*) 15.05910 .000 56.0516 165.9496 
    Veritas 124.60460(*) 15.05910 .000 69.6556 179.5536 
    UBM -30.89759 15.05910 .940 -85.8466 24.0514 
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Table 32: Comparison between % increase at Day 4 Experiment 1 
Dependent 
Variable (I) Material2 (J) Material2 
Mean 
Difference (I-J) Std. Error Sig. 95% Confidence Interval 
            
Lower 
Bound 
Upper 
Bound 
Day4 3mg/ml 5mg/ml -24.87976 54.85163 1.000 -225.0273 175.2678 
    9mg/ml 22.20931 54.85163 1.000 -177.9382 222.3569 
    Veritas -89.11757 54.85163 1.000 -289.2651 111.0300 
    UBM -349.28452(*) 54.85163 .001 -549.4321 -149.1370 
    Plastic -126.89704 54.85163 .588 -327.0446 73.2505 
  5mg/ml 3mg/ml 24.87976 54.85163 1.000 -175.2678 225.0273 
    9mg/ml 47.08907 54.85163 1.000 -153.0585 247.2366 
    Veritas -64.23781 54.85163 1.000 -264.3853 135.9097 
    UBM -324.40476(*) 54.85163 .001 -524.5523 -124.2572 
    Plastic -102.01729 54.85163 1.000 -302.1648 98.1303 
  9mg/ml 3mg/ml -22.20931 54.85163 1.000 -222.3569 177.9382 
    5mg/ml -47.08907 54.85163 1.000 -247.2366 153.0585 
    Veritas -111.32688 54.85163 .978 -311.4744 88.8207 
    UBM -371.49383(*) 54.85163 .000 -571.6414 -171.3463 
    Plastic -149.10636 54.85163 .280 -349.2539 51.0412 
  Veritas 3mg/ml 89.11757 54.85163 1.000 -111.0300 289.2651 
    5mg/ml 64.23781 54.85163 1.000 -135.9097 264.3853 
    9mg/ml 111.32688 54.85163 .978 -88.8207 311.4744 
    UBM -260.16695(*) 54.85163 .007 -460.3145 -60.0194 
    Plastic -37.77948 54.85163 1.000 -237.9270 162.3681 
  UBM 3mg/ml 349.28452(*) 54.85163 .001 149.1370 549.4321 
    5mg/ml 324.40476(*) 54.85163 .001 124.2572 524.5523 
    9mg/ml 371.49383(*) 54.85163 .000 171.3463 571.6414 
    Veritas 260.16695(*) 54.85163 .007 60.0194 460.3145 
    Plastic 222.38748(*) 54.85163 .024 22.2399 422.5350 
  Plastic 3mg/ml 126.89704 54.85163 .588 -73.2505 327.0446 
    5mg/ml 102.01729 54.85163 1.000 -98.1303 302.1648 
    9mg/ml 149.10636 54.85163 .280 -51.0412 349.2539 
    Veritas 37.77948 54.85163 1.000 -162.3681 237.9270 
    UBM -222.38748(*) 54.85163 .024 -422.5350 -22.2399 
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Table 33: Comparison between increases at both time points for each material (Exp 1) 
   
Sum of 
Squares df Mean Square F Sig. 
Fibring3mg Between Groups 668.165 1 668.165 .421 .552 
  Within Groups 6346.978 4 1586.744     
  Total 7015.143 5       
Fibrin5mg Between Groups 227.726 1 227.726 .547 .501 
  Within Groups 1666.071 4 416.518     
  Total 1893.798 5       
Fibrin9mg Between Groups 740.183 1 740.183 2.188 .213 
  Within Groups 1352.972 4 338.243     
  Total 2093.155 5       
Veritas Between Groups 32477.368 1 32477.368 4.661 .097 
  Within Groups 27872.044 4 6968.011     
  Total 60349.412 5       
UBM Between Groups 95112.054 1 95112.054 36.463 .004 
  Within Groups 10433.741 4 2608.435     
  Total 105545.796 5       
Plastic Between Groups 5457.687 1 5457.687 2.066 .224 
  Within Groups 10566.798 4 2641.700     
  Total 16024.486 5       
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Table 34: Comparison of % increase between materials at each time point (Exp 2) 
Dependent 
Variable (I) Material (J) Material 
Mean Difference 
(I-J) Std. Error Sig. 
95% Confidence 
Interval 
            
Lower 
Bound 
Upper 
Bound 
Day1 3mg/mL 5mg/mL -.14220 .10381 1.000 -.4695 .1851 
    9mg/mL .08116 .10381 1.000 -.2461 .4084 
    Plastic -.24907 .10381 .201 -.5763 .0782 
  5mg/mL 3mg/mL .14220 .10381 1.000 -.1851 .4695 
    9mg/mL .22335 .10381 .315 -.1039 .5506 
    Plastic -.10687 .10381 1.000 -.4341 .2204 
  9mg/mL 3mg/mL -.08116 .10381 1.000 -.4084 .2461 
    5mg/mL -.22335 .10381 .315 -.5506 .1039 
    Plastic -.33023(*) .10381 .047 -.6575 -.0030 
  Plastic 3mg/mL .24907 .10381 .201 -.0782 .5763 
    5mg/mL .10687 .10381 1.000 -.2204 .4341 
    9mg/mL .33023(*) .10381 .047 .0030 .6575 
Day4 3mg/mL 5mg/mL -.01592 .31255 1.000 -1.0013 .9694 
    9mg/mL -1.47163(*) .31255 .003 -2.4570 -.4863 
    Plastic -.50024 .31255 .813 -1.4856 .4851 
  5mg/mL 3mg/mL .01592 .31255 1.000 -.9694 1.0013 
    9mg/mL -1.45570(*) .31255 .003 -2.4411 -.4703 
    Plastic -.48432 .31255 .883 -1.4697 .5010 
  9mg/mL 3mg/mL 1.47163(*) .31255 .003 .4863 2.4570 
    5mg/mL 1.45570(*) .31255 .003 .4703 2.4411 
    Plastic .97138 .31255 .054 -.0140 1.9567 
  Plastic 3mg/mL .50024 .31255 .813 -.4851 1.4856 
    5mg/mL .48432 .31255 .883 -.5010 1.4697 
    9mg/mL -.97138 .31255 .054 -1.9567 .0140 
Day7 3mg/mL 5mg/mL -.47956 .44842 1.000 -1.8933 .9342 
    9mg/mL -3.56151(*) .44842 .000 -4.9752 -2.1478 
    Plastic 1.10601 .44842 .178 -.3077 2.5197 
  5mg/mL 3mg/mL .47956 .44842 1.000 -.9342 1.8933 
    9mg/mL -3.08195(*) .44842 .000 -4.4957 -1.6682 
    Plastic 1.58556(*) .44842 .025 .1718 2.9993 
  9mg/mL 3mg/mL 3.56151(*) .44842 .000 2.1478 4.9752 
    5mg/mL 3.08195(*) .44842 .000 1.6682 4.4957 
    Plastic 4.66751(*) .44842 .000 3.2538 6.0812 
  Plastic 3mg/mL -1.10601 .44842 .178 -2.5197 .3077 
    5mg/mL -1.58556(*) .44842 .025 -2.9993 -.1718 
    9mg/mL -4.66751(*) .44842 .000 -6.0812 -3.2538 
Day14 3mg/mL 5mg/mL -.61164 .93019 1.000 -3.5442 2.3210 
    9mg/mL -2.50754 .93019 .117 -5.4402 .4251 
    Plastic 2.27702 .93019 .184 -.6556 5.2096 
  5mg/mL 3mg/mL .61164 .93019 1.000 -2.3210 3.5442 
    9mg/mL -1.89590 .93019 .385 -4.8285 1.0367 
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    Plastic 2.88867 .93019 .055 -.0439 5.8213 
  9mg/mL 3mg/mL 2.50754 .93019 .117 -.4251 5.4402 
    5mg/mL 1.89590 .93019 .385 -1.0367 4.8285 
    Plastic 4.78457(*) .93019 .001 1.8520 7.7172 
  Plastic 3mg/mL -2.27702 .93019 .184 -5.2096 .6556 
    5mg/mL -2.88867 .93019 .055 -5.8213 .0439 
    9mg/mL -4.78457(*) .93019 .001 -7.7172 -1.8520 
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Table 35: Comparison of % increase between time points for each material (Exp 2) 
Dependent 
Variable (I) Time (J) Time 
Mean 
Difference 
(I-J) Std. Error Sig. 95% Confidence Interval 
            Lower Bound Upper Bound 
Fibrin3mg Day 1 Day 4 -.18829 .59561 1.000 -2.0661 1.6895 
    Day 7 -2.52698(*) .59561 .007 -4.4047 -.6492 
    Day 14 -3.58094(*) .59561 .000 -5.4587 -1.7032 
  Day 4 Day 1 .18829 .59561 1.000 -1.6895 2.0661 
    Day 7 -2.33869(*) .59561 .012 -4.2165 -.4609 
    Day 14 -3.39265(*) .59561 .001 -5.2704 -1.5149 
  Day 7 Day 1 2.52698(*) .59561 .007 .6492 4.4047 
    Day 4 2.33869(*) .59561 .012 .4609 4.2165 
    Day 14 -1.05396 .59561 .613 -2.9317 .8238 
  Day 14 Day 1 3.58094(*) .59561 .000 1.7032 5.4587 
    Day 4 3.39265(*) .59561 .001 1.5149 5.2704 
    Day 7 1.05396 .59561 .613 -.8238 2.9317 
Fibrin5mg Day 1 Day 4 -.06202 .70816 1.000 -2.2946 2.1706 
    Day 7 -2.86434(*) .70816 .010 -5.0969 -.6317 
    Day 14 -4.05039(*) .70816 .001 -6.2830 -1.8178 
  Day 4 Day 1 .06202 .70816 1.000 -2.1706 2.2946 
    Day 7 -2.80233(*) .70816 .011 -5.0349 -.5697 
    Day 14 -3.98837(*) .70816 .001 -6.2210 -1.7558 
  Day 7 Day 1 2.86434(*) .70816 .010 .6317 5.0969 
    Day 4 2.80233(*) .70816 .011 .5697 5.0349 
    Day 14 -1.18605 .70816 .719 -3.4186 1.0465 
  Day 14 Day 1 4.05039(*) .70816 .001 1.8178 6.2830 
    Day 4 3.98837(*) .70816 .001 1.7558 6.2210 
    Day 7 1.18605 .70816 .719 -1.0465 3.4186 
Fibrin9mg Day 1 Day 4 -1.74107(*) .53047 .039 -3.4135 -.0687 
    Day 7 -6.16964(*) .53047 .000 -7.8420 -4.4972 
    Day 14 -6.16964(*) .53047 .000 -7.8420 -4.4972 
  Day 4 Day 1 1.74107(*) .53047 .039 .0687 3.4135 
    Day 7 -4.42857(*) .53047 .000 -6.1010 -2.7562 
    Day 14 -4.42857(*) .53047 .000 -6.1010 -2.7562 
  Day 7 Day 1 6.16964(*) .53047 .000 4.4972 7.8420 
    Day 4 4.42857(*) .53047 .000 2.7562 6.1010 
    Day 14 .00000 .53047 1.000 -1.6724 1.6724 
  Day 14 Day 1 6.16964(*) .53047 .000 4.4972 7.8420 
    Day 4 4.42857(*) .53047 .000 2.7562 6.1010 
    Day 7 .00000 .53047 1.000 -1.6724 1.6724 
Plastic Day 1 Day 4 -.43946 .19279 .250 -1.0473 .1684 
    Day 7 -1.17191(*) .19279 .000 -1.7797 -.5641 
    Day 14 -1.05485(*) .19279 .001 -1.6627 -.4470 
  Day 4 Day 1 .43946 .19279 .250 -.1684 1.0473 
    Day 7 -.73244(*) .19279 .015 -1.3403 -.1246 
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    Day 14 -.61538(*) .19279 .046 -1.2232 -.0076 
  Day 7 Day 1 1.17191(*) .19279 .000 .5641 1.7797 
    Day 4 .73244(*) .19279 .015 .1246 1.3403 
    Day 14 .11706 .19279 1.000 -.4908 .7249 
  Day 14 Day 1 1.05485(*) .19279 .001 .4470 1.6627 
    Day 4 .61538(*) .19279 .046 .0076 1.2232 
    Day 7 -.11706 .19279 1.000 -.7249 .4908 
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Appendix V: Information About Harvesting Bovine Blood 
Phone interview with Maureen Brown, a technician at the University of Massachusetts Medical 
School Medical School blood bank. 
 
12:46 pm, November 30, 2006 
Notes: 
• Surgeons sometimes like to use whole blood, especially for cardiac applications 
• Whole blood can be store for 28 days under 1-6ºC refrigeration with EDTA for 
anticoagulation and CPD for nourishment.  Should get colder than 1ºC or cells will be 
damaged, but should be under 6ºC to keep bacteria from growing. 
• Anticoagulants vary, the one they use for collecting blood is Absol, it come in the blood 
collection bags.  Absol comes in different mixture and must be added to blood within 8 
hours. 
• Seperated red cells can be stored for 42 days in 1-6ºC depending on anticoagulant 
(Absol) 
• Plasma can be frozen at temperatures below -18ºC 
• Plasma with platelets should probably be stored at 1-6ºC for 28 days 
• ABB website will have specific information about anticoagulants 
 
Phone conversation of Richard Blood of Blood Farm, Groton, Ma. 
 
• Bovine whole blood is sold for $20/gallon. 
• Beef is killed on Wednesday mornings. 
• To collect blood a wide-mouth container must be brought to slaughter, along with the 
desired anticoagulant. 
• A government release form must be signed.  This form simply states that the blood will 
not be used as part of any food products and that Blood Farm takes no responsibility for 
the way in which it is used. 
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Appendix W: Power Analysis 
Power of t-test to Detect a Difference with alpha = 0.05
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Table 36: Power of t-test to detect a difference between sample groups 
Sample Size (n) Difference 
(# of SD) 3 4 5 6 7 8 
0.05 0.055 0.044 0.039 0.036 0.034 0.033 
0.25 0.074 0.066 0.063 0.063 0.064 0.066 
0.50 0.105 0.106 0.113 0.123 0.133 0.145 
1.00 0.215 0.259 0.309 0.360 0.411 0.460 
1.25 0.300 0.375 0.452 0.525 0.592 0.652 
1.50 0.402 0.492 0.603 0.685 0.753 0.808 
1.75 0.516 0.639 0.738 0.813 0.868 0.908 
2.00 0.627 0.753 0.840 0.899 0.937 0.961 
2.25 0.726 0.839 0.908 0.949 0.972 0.985 
2.50 0.804 0.899 0.949 0.975 0.988 0.994 
2.75 0.863 0.938 0.973 0.988 0.995 0.998 
3.00 0.905 0.962 0.985 0.994 0.998 0.999 
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Power of ANOVA to Detect a Difference 
Between 3 Groups with alpha = 0.05
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Table 37: Power of ANOVA to detect a difference between 3 groups 
Sample Size (n) Difference 
(# of SD) 3 4 5 6 7 8 9 10 11 12 
1.00 0.00 0.00 0.00 0.00 0.30 0.30 0.35 0.45 0.50 0.55 
1.25 0.00 0.20 0.30 0.35 0.45 0.55 0.57 0.65 0.70 0.73 
1.50 0.20 0.30 0.46 0.55 0.62 0.67 0.72 0.76 0.84 0.88 
1.75 0.25 0.42 0.60 0.70 0.78 0.82 0.88 0.93 0.95 0.97 
2,00 0.50 0.52 0.70 0.82 0.90 0.92 0.94 0.97 0.98 0.99 
2.50 0.48 0.72 0.88 0.94 0.98 0.99 0.99 0.99 0.99 0.99 
3.00 0.70 0.90 0.98 0.99 0.99 0.99 0.99 0.99 0.99 0.99 
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Power of ANOVA to Detect a Difference 
Between 5 Groups with alpha = 0.05
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Table 38: Power of ANOVA to detect a difference between 5 groups 
Sample Size (n) Difference 
(# of SD) 3 4 5 6 7 8 9 10 11 12 
1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.35 0.40 0.45 
1.50 0.00 0.00 0.35 0.45 0.60 0.65 0.70 0.73 0.80 0.84 
2.00 0.35 0.50 0.62 0.68 0.80 0.88 0.90 0.95 0.96 0.98 
2.50 0.60 0.74 0.84 0.90 0.94 0.97 0.99 0.99 0.99 0.99 
3.00 0.65 0.85 0.93 0.97 0.99 0.99 0.99 0.99 0.99 0.99 
 
Calculating power for unpaired t-test [119] 
 
DEFINITIONS 
H0 = there is no difference between the means of the two groups 
HA = there is a difference between the means of the two groups 
 
ASSUMPTIONS 
• n1 = n2 
• '1 = '2 
• i.e. variances are equal 
 
STEPS 
1. Compute t statistics for H0 and HA 
2. Compute difference between t statistics for H0 and HA 
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3. Power is probability of difference in t statistics (determined from one-tailed critical values of 
t table) 
2
2
2
1
2
21'
n
nn
t
!
"
!!
µµ
=
+
#
=   
Where: 
• µ = population mean 
• ' = population standard deviation 
• n = sample size 
• ( = difference in population means 
 
Calculating power for ANOVA [119] 
 
DEFINITIONS 
H0 = there is no difference between the migration in the different groups 
HA = migration is different for at least one of the groups 
 
STEPS 
1. Compute the non-centrality parameter (size of the treatment we wish to detect) 
k
n
2!
"
# =   
where  ( = minimum difference between treatment groups 
            ' = standard deviation within the underlying population 
  k = number of treatment groups 
  n = sample size of each treatment group 
2. Compute degrees of freedom 
)n = k -1 
)d = k(n – 1) 
3. Obtain power from power chart 
 
REFERENCES 
[119] 
 
Mechanical Testing Sample Size:  
 
SD
stdev
ionspecificataverage
#=
!
 
Calculate #SD, go to chart, find sample size with 0.9 or better 
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Appendix X: Project Budget 
Vendor Contents PO # Total Cost  
Micromedics FibriJect applicators  $8.16 Donation (shipping charge) 
Boston Scientific Hemashield Platinum  $0.00 Donation 
Bio Stockroom Filters, syringes  $20.00 (Est.) 
Sigma-Aldrich Fibrinogen, thrombin BME7-165 $67.02  
Cambrex Trypsin BME7-185 $57.40  
Sigma-Aldrich Fibrinogen BME7-187 $103.62  
Sigma-Aldrich Thrombin BME7-223 $38.62  
Promega MTS assay BME7-228 $101.00  
Promega MTS assay BME7-239 $101.00  
  Total $496.82  
  Budget $624.00  
  Remaining $127.18  
 
 
 
 
